Nothing Special   »   [go: up one dir, main page]

WO2004056773A1 - Novel piperidine derivatives as modulators of chemokine receptor ccr5 - Google Patents

Novel piperidine derivatives as modulators of chemokine receptor ccr5 Download PDF

Info

Publication number
WO2004056773A1
WO2004056773A1 PCT/SE2003/002008 SE0302008W WO2004056773A1 WO 2004056773 A1 WO2004056773 A1 WO 2004056773A1 SE 0302008 W SE0302008 W SE 0302008W WO 2004056773 A1 WO2004056773 A1 WO 2004056773A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
heteroaryl
optionally substituted
compound
Prior art date
Application number
PCT/SE2003/002008
Other languages
French (fr)
Inventor
John Cumming
Alan Faull
Colin Fielding
John Oldfield
Howard Tucker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203821A external-priority patent/SE0203821D0/en
Priority claimed from SE0300499A external-priority patent/SE0300499D0/en
Priority claimed from SE0301425A external-priority patent/SE0301425D0/en
Priority to BR0317459-0A priority Critical patent/BR0317459A/en
Priority to NZ540780A priority patent/NZ540780A/en
Priority to EP03781235A priority patent/EP1572650A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to US10/539,859 priority patent/US20060189650A1/en
Priority to CA002508624A priority patent/CA2508624A1/en
Priority to JP2005502630A priority patent/JP2006514107A/en
Priority to MXPA05006381A priority patent/MXPA05006381A/en
Priority to AU2003288856A priority patent/AU2003288856B2/en
Publication of WO2004056773A1 publication Critical patent/WO2004056773A1/en
Priority to IS7942A priority patent/IS7942A/en
Priority to NO20053539A priority patent/NO20053539L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to heterocyclic derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.
  • Pharmaceutically active piperidine derivatives are disclosed in WO01/87839, EP-A1- 1013276, WO00/08013, WO99/38514, WO99/04794, WO00 76511, WO00/76512, O00/76513, O00/76514, " WOOO/76972, US 2002/0094989 andBioorg. Med. Chem. Lett. 13 (2003) 119-123.
  • Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a role in the maturation of cells of the immune system. Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif.
  • the chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or ⁇ ) and Cys-Cys (C-C, or ⁇ ) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
  • the C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
  • IL-8 interleukin-8
  • NAP-2 neutrophil-activating peptide 2
  • the C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l ⁇ and l ⁇ (MlP-l ⁇ and MlP-l ⁇ ).
  • chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCRl, CXCR2, CXCR3 and CXCR4.
  • CCR5 receptor is expressed on T-lymphocytes, monocytes, macrophages, dendritic cells, microglia and other cell types.
  • chemokines principally "regulated on activation normal T-cell expressed and secreted” (RANTES), macrophage inflammatory proteins (M1P) MlP-l ⁇ and MlP-l ⁇ and monocyte chemoattractant protein-2 (MCP-2).
  • RANTES normal T-cell expressed and secreted
  • M1P macrophage inflammatory proteins
  • MlP-l ⁇ MlP-l ⁇
  • MlP-l ⁇ monocyte chemoattractant protein-2
  • CCR5 is also a co-receptor for HIV-1 and other viruses, allowing these viruses to enter cells. Blocking the receptor with a CCR5 antagonist or inducing receptor intemalisation with a CCR5 agonist protects cells from viral infection.
  • the present invention provides a compound of formula (I):
  • A is absent or is (CH 2 ) 2 ;
  • R 1 is C ⁇ .8 alkyl, C(O)NR 10 R ⁇ , C(O) 2 R 12 , NR 13 C(O)R 14 , NR 15 C(O)NR 16 R 17 , NR 18 C(O) 2 R 19 , heterocyclyl, aryl or heteroaryl;
  • R 10 , R 13 , R 15 , R 16 and R 18 are hydrogen or C 1-6 alkyl;
  • R n , R 12 , R 14 , R 17 and R 19 are C 1-8 alkyl (optionally substituted by halo, hydroxy, C 1-6 alkoxy,
  • C ⁇ .6 haloalkoxy C 3-6 cycloalkyl (optionally substituted by halo), Cs -6 cycloalkenyl, S(C 1-4 alkyl), S(O)(C 1- alkyl), S(O) 2 (C 1-4 alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C 3 .
  • R 11 , R 12 , R 14 and R 17 can also be hydrogen; or R 10 and R 11 , and/or R 16 and R 17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C 1-6 alkyl, S(O) ⁇ (C 1-6 alkyl) or C(O)(C 1-6 alkyl); R 2 is C 1-6 alkyl, phenyl, heteroaryl or C 3 . 7 cycloalkyl;
  • R 3 is H or C 1-4 alkyl;
  • R 4 is aryl, heteroaryl, C ⁇ -6 alkyl or C 3-7 cycloalkyl;
  • X is O or S(O) p ;
  • m and n are, independently, 0, 1, 2 or 3, provided m 4- n is 1 or more;
  • aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR 20 R 21 , NR 22 R 23 , NR 24 C(O)R 25 , NR 26 C(O)NR 7 R 28 , S(O) 2 NR 29 R 30 , NR 31 S(O) 2 R 32 , C(O)NR 33 R 34 , CO 2 R 36 , NR 37 CO 2 R 38 , S(O) q R 39 , OS(O) 2 R 49 , Cj.
  • R 20 , R 22 , R 24 , R 26 , R 27 , R 29 , R 31 , R 33 , R 37 , R 40 , R 51 and R 54 are, independently, hydrogen or C 1-6 alkyl;
  • R 21 , R 23 , R 25 , R 28 , R 30 , R 32 , R 34 , R 36 , R 38 , R 39 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 52 , R 53 , R 55 , R 56 and R 57 are, independently, C 1-6 alkyl (optionally substituted by halo, hydroxy, C 1-6 alkoxy, C 1-6 haloalkoxy, C 3 .
  • Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers).
  • the present invention covers all such isomers and mixtures thereof in all proportions.
  • Suitable salts include acid addition salts such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate orp- toluenesulphonate.
  • acid addition salts are succinate, glutarate or malonate.
  • the compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.
  • Alkyl groups and moieties are straight or branched chain and, for example, comprise one to six (such as one to four) carbon atoms.
  • Alkyl is, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or tert-butyl. Methyl is sometimes abbreviated to Me hereinbelow.
  • Haloalkyl includes CF 3
  • haloalkoxy includes CF 3 .
  • Fluoroalkyl includes, for example, one to six, such as one to three, fluorine atoms, and comprises, for example, a CF 3 group. Fluoroalkyl is, for example, CF 3 or CH 2 CF 3 . Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl (such as cyclohexyl). Cycloalkenyl includes cyclopentenyl.
  • Heterocyclyl is, for example, piperidine, piperazine, pyrrolidine, azetidine, tetrahydrofuran, morpholine or thiomorpholine. Further examples of heterocyclyl are tetrahydropyran and tetrahydrothiopyran.
  • Aryl includes phenyl and naph hyl. In one aspect of the invention aryl is phenyl.
  • Heteroaryl is, for example, an aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof.
  • Heteroaryl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, [l,2,4]-triazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl, 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[l,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl, 1,2,3-
  • Aryloxy includes phenoxy.
  • Heteroaryloxy includes pyridinyloxy and pyrimidinyloxy.
  • Phenyl(C 1-4 alkyl)alkyl is, for example, benzyl, l-(phenyl)eth-l-yl or l-(phenyl)eth-2- yl.
  • Heteroaryl(C 1- alkyl)alkyl is, for example, pyridinylmethyl, pyrimidinylmethyl or 1- (pyridinyl)eth-2-yl.
  • Phenyl(C ⁇ . 4 alkoxy) is, for example, benzyloxy or phenylCH(CH 3 )O.
  • Heteroaryl(C 1-4 alkoxy) is, for example, pyridinylCH 2 O, pyrimidinylCH 2 O or pyridinylCH(CH 3 )O.
  • Heteroaryl rings can carry various substituents including sulphonyl groups.
  • a sulphonyl group on a heteroaryl ring can be a good leaving group (susceptible to nucleophilic displacement) and examples of such situation are: 2-methanesulphonyl-pyridine and 2- or 4- methanesulphonyl-pyrimidine.
  • the present invention covers compounds including a heteroaryl ring carrying a sulphonyl group which are sufficiently stable (non-reactive) to be isolated using the experimental procedures described.
  • the present invention provides a compound of formula (I) wherein: A is absent or is (CH 2 ) 2 ; R 1 is C 1-8 alkyl, C(O)NR 10 R ⁇ , C(O) 2 R 12 , NR 13 C(O)R 14 , NR 15 C(O)NR 16 R 17 , NR 18 C(O) 2 R 19 , heterocyclyl, aryl or heteroaryl; R 10 , R 13 , R 15 , R l ⁇ and R 18 are hydrogen or C 1-6 alkyl; R 11 , R 12 , R 14 , R 17 and R 19 are C 1-8 alkyl (optionally substituted by halo, hydroxy, C 1-6 alkoxy, C 1-6 haloalkoxy, C -6 cycloalkyl (optionally substituted by halo), C 5-6 cycloalkenyl, S(C 1-4 alkyl), S(O)(C 1-4 alkyl), S(O) 2 (C 1-4 al
  • R 3 is H or CM alkyl
  • R 4 is aryl, heteroaryl, C 1-6 alkyl or C 3-7 cycloalkyl
  • X is O or S(O) p
  • m and n are, independently, 0, 1, 2 or 3, provided m + n is 1 or more
  • aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR 20 R 21 , NR 22 R 23 , NR 2 C(O)R 25 , NR 26 C(O)NR 27 R 28 , S(O) 2 NR 29 R 30 , NR 31 S(O) 2 R 32 , C(O)NR 33 R 34 , CO 2 R 36 , NR 37 CO 2 R 38 ,
  • the present invention provides a compound of formula (I) wherein: A is absent or is (CH 2 ) 2 ; R 1 is C 1-8 alkyl, C(O)NR 10 R n , C(O) 2 R 12 , NR 13 C(O)R 14 , NR 15 C(O)NR 16 R 17 , NR 18 C(O) 2 R 19 , heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl or heteroaryl; R 10 , R 13 , R 15 , R 16 and R 18 are hydrogen or C 1-6 alkyl; R 11 , R 12 , R 14 , R 17 and R 19 are C 1-8 alkyl (optionally substituted by halo, hydroxy, C 1-6 alkoxy, C 1-6 haloalkoxy, C 3-6 cycloalkyl (optionally substituted by halo), C 5 .
  • A is absent or is (CH 2 ) 2 ;
  • R 1 is C 1
  • R ⁇ , R 12 , R 14 and R 17 can also be hydrogen; or R 10 and R ⁇ , and/or R 16 and R 17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C 1-6 alkyl, S(O) ⁇ (C 1-6 alkyl) or C(O)(C 1-6 alkyl);
  • R 2 is C 1-6 alkyl, phenyl, heteroaryl or C 3-7 cycloalkyl;
  • R 3 is H or CM alkyl;
  • R 4 is aryl, heteroaryl, C 1-6 alkyl or C 3 .
  • X is O or S(O) p ;
  • m and n are, independently, 0, 1, 2 or 3, provided m + n is 1 or more;
  • aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR 20 R 21 , NR 22 R 23 , NR 24 C(O)R 25 , NR 26 C(O)NR 27 R 28 , S(O) 2 NR 29 R 30 , NR 31 S(O) 2 R 32 , C(O)NR 33 R 34 , CO 2 R 36 , NR 37 CO 2 R 38 , S(O) q R 39 , OS(O) 2 R 49 , C ⁇ -6 alkyl (optionally mono-substituted by S(O) 2 R 50 or C(O)NR 51 R 52 ), C 2-6 alkenyl, C 2-6 alkynyl, C 3 .
  • the present invention provides a compound of formula (I) wherein A is absent or is (CH 2 ) 2 ;
  • R 1 is C alkyl, C(O)NR 10 R ⁇ , C(O) 2 R 12 , NR 13 C(O)R 14 , NR 15 C(O)NR 16 R 17 , NR 18 C(O) 2 R 19 , heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl or heteroaryl;
  • R 10 , R 13 , R 15 , R 16 and R 18 are hydrogen or C 1-6 alkyl;
  • R ⁇ , R 12 , R 14 , R 17 and R 19 are C 1-8 alkyl (optionally substituted by halo, hydroxy, C 1-6 alkoxy, C ⁇ -6 haloalkoxy, C 3-6 cycloalkyl (optionally substituted by halo), C5-6 cycloalkenyl, S(C 1- alkyl), S(
  • R 1 R 12 , R 14 and R 17 can also be hydrogen; or R 10 and R n , and/or R 16 and R 17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C 1-6 alkyl, S(O) ⁇ (C 1-6 alkyl) or C(O)(C 1-6 alkyl); R 2 C 1-6 alkyl, phenyl, heteroaryl or C 3-7 cycloalkyl; R 3 is H or CM alkyl; R 4 is aryl or heteroaryl; X is O or S(O) p
  • the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C 1-6 alkyl), S(O)(C ⁇ -6 alkyl), S(O) 2 (C 1-6 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-6 alkyl), S(O) 2 N(C 1-6 alkyl) 2 , cyano, C 1-6 alkyl, C 1-6 alkoxy, CH 2 S(O) 2 (C 1-6 alkyl), OS(O) 2 (C 1-6 alkyl), OCH 2 heteroaryl (such as OCH 2 tetrazolyl), OCH 2 CO 2 H, OCH 2 CO 2 (C 1-6 alkyl), OCH 2 C(O)NH 2 , OCH 2 C(O)NH(C 1-6 alkyl), OCH 2
  • the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C ⁇ -6 alkyl), S(O)(C 1-6 alkyl), S(O) 2 (C 1-6 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-6 alkyl), S(O) 2 N(C 1-6 alkyl) 2 , cyano, C 1-6 alkyl, C 1-6 alkoxy, NH 2 , NH(C 1-6 alkyl), N(C W alkyl) 2 , C(O)NH 2 , C(O)NH(C ⁇ -6 alkyl), C(O)N(C 1-6 alkyl) 2 , C(O)[N-linked heterocyclyl], CO 2 H, CO 2 (C 1-6 alkyl), NHC(O)(C 1-6
  • the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C 1-6 alkyl), S(O)(C ⁇ -6 alkyl), S(O) (C ⁇ -6 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-6 alkyl), S(O) 2 N(C 1-6 alkyl) 2 , cyano, C 1-6 alkyl, C 1-6 alkoxy, CH2S(O) 2 (C 1-6 alkyl), OS(O) 2 (C 1-6 alkyl), OCH 2 heteroaryl (such as OCH 2 tetrazolyl),
  • the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C 1-4 alkyl), S(O)(C 1- alkyl), S(O) 2 (C 1- alkyl), S(O) 2 NH 2 , S(O) 2 NH(C ⁇ -4 alkyl), S(O) 2 N(C ⁇ -4 alkyl) 2 , cyano, C M alkyl, C 1-4 alkoxy, C(O)NH 2 , C(O)NH(C alkyl), CO 2 H, CO 2 (C ⁇ -4 alkyl), NHC(O)(C 1-4 alkyl), NHS(O) 2 (C 1-4 alkyl), CF 3 , CHF 2 , CH 2 F, CH 2 CF 3 or OCF 3 .
  • heteroaryl is tetrazolyl, pyrrolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or quinolinyl.
  • heteroaryl is pyrrolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or quinolinyl.
  • R , R , R , R and R are hydrogen or C 1-4 alkyl (for example methyl).
  • R 10 , R 13 , R 15 , R 16 and R 18 are hydrogen.
  • R 11 , R 12 , R 14 , R 17 , R 18 and R 19 are C 1-8 alkyl
  • R 11 , R 12 , R 14 , R 17 and R 19 are C 1-8 alkyl (optionally substituted by halo (such as fluoro)), phenyl (optionally substituted as recited above), C 3-6 cycloalkyl (optionally substituted by halo (such as fluoro)) or C-linked nitrogen containing heterocyclyl (optionally substituted on the ring nitrogen).
  • R 1 is NHC(O)R 14 , phenyl or heterocyclyl, wherein R 14 is as defined above, and phenyl and heterocyclyl are optionally substituted as described above.
  • R 1 is NR 13 C(O)R 14 , wherein R 13 and R 14 are as defined above.
  • R 13 is hydrogen.
  • R 14 is C 1-8 alkyl (optionally substituted by halo (such as fluoro, for example to form CF 3 CH 2 )), phenyl (optionally substituted as recited above), C 3-6 cycloalkyl (optionally substituted by halo (such as fluoro, for example to form l,l-difluorocyclohex-4-yl)) or C-linked nitrogen containing heterocyclyl (such as tetrahydropyran or piperidine, optionally substituted on the ring nitrogen).
  • halo such as fluoro, for example to form CF 3 CH 2
  • phenyl optionally substituted as recited above
  • C 3-6 cycloalkyl optionally substituted by halo (such as fluoro, for example to form l,l-difluorocyclohex-4-yl)) or C-linked nitrogen containing heterocyclyl (such as tetrahydropyran or piperidine, optionally substituted
  • the present invention provides a compound of the invention wherein R 14 is C 1-8 alkyl (optionally substituted by halo (such as fluoro, for example to form
  • phenyl optionally substituted by halo
  • Cs. 6 cycloalkyl (optionally substituted by halo (such as fluoro, for example to form l,l-difluorocyclohex-4-yl)).
  • heterocyclyl is optionally substituted (such as singly substituted for example on a ring nitrogen atom when present) by C 1-6 alkyl [optionally substituted by phenyl ⁇ which itself optionally substituted by halo, C M alkyl, C M alkoxy, cyano, nitro, CF 3 , OCF 3 , (C M alkyl)C(O)NH, S(O) 2 NH 2 , C M alkylthio or S(O) 2 (C ⁇ -4 alkyl) ⁇ or heteroaryl ⁇ which itself optionally substituted by halo, C - alkyl, C 1-4 alkoxy, cyano, nitro, CF 3 , (C alkyl)C(O)NH, S(O) 2 NH 2 , C M alkylthio or S(O) 2 (C 1-4 alkyl) ⁇ ], phenyl ⁇ optionally substituted by halo, C 1-4 alkyl, C alk
  • R 1 is optionally substituted aryl (such as optionally substituted phenyl) or optionally substituted heteroaryl, wherein the optional substituents are as recited above.
  • R 1 when R 1 is heterocyclyl it is, for example, tetrahydropyran, tetrahydrothiopyran, piperidine, piperazine, pyrrolidine or azetidine. In another aspect when R 1 is heterocyclyl it is, for example, piperidine, piperazine, pyrrolidine or azetidine.
  • R 1 is optionally substituted heterocyclyl, such as optionally substituted: piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, azetidin-1-yl or azetidin-3-yl.
  • the heterocyclyl of R 1 is mono-substituted by C 1-6 alkyl, C 3- cycloalkyl, phenyl ⁇ optionally substituted by halo (for example fluoro), C 1- alkyl (for example methyl), C 1-4 alkoxy (for example methoxy), CF 3 or OCF 3 ⁇ , S(O) 2 (C M alkyl) (for example S(O) 2 CH 3 , S(O) 2 CH 2 CH 3 or S(O) 2 CH(CH 3 ) 2 ), S(O) 2 (C M fluoroalkyl) (for example S(O) 2 CF 3 or S(O) 2 CH 2 CF 3 ), S(O) 2 phenyl ⁇ optionally substituted (such as mono- substituted) by halo (for example chloro), cyano, C 1- alkyl, C 1-4 alkoxy, CF 3 , OCF 3 , S(O) 2 (C 1- alkyl
  • Said heterocyclyl can also be mono-substituted by S(O) 2 N(C 1 . 4 alkyl) 2 .
  • said heterocyclyl is a 4-substituted piperidin-1-yl, a 1- substituted piperidin-4-yl, a 4-substituted piperazin-1-yl, a 3-substituted pyrrolidin-1-yl, a 1- substituted pyrrolidin-3-yl, a 3-substituted azetidin-1-yl or a 1 -substituted azetidin-3-yl (for example where said substituent is as recited earlier in this paragraph).
  • heterocyclyl is a 1 -substituted piperidin-4-yl or a 4-substituted piperazin-1-yl, wherein the substituent is S(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 haloalkyl), S(O) 2 (phenyl), S(O) 2 N(C 1-4 alkyl) 2 or phenyl.
  • R 1 is piperidinyl or piperazinyl (such as piperidin-4- yl or ⁇ iperazin-1-yl), either of which is N-substituted by phenyl, S(O) 2 R 39 (wherein R 39 is C 1-4 alkyl (such as methyl or ethyl), phenyl or CF 3 ) or S(O) 2 NR 29 R 30 (wherein R 29 and R 30 are, independently, C 1-4 alkyl (such as methyl)).
  • R 1 is NHC(O)R 14 wherein R 14 is C M haloalkyl
  • C 1- fluoroalkyl such as CH 2 CF 3 or CH 2 CH 2 CF 3
  • phenyl optionally substituted by halo
  • C 3-6 cycloalkyl substituted by one or two fluoros
  • R 1 is phenyl optionally substituted by S(O) 2 R 39 (wherein R 39 is C alkyl (such as methyl)).
  • R 1 is heteroaryl (such as pyridinyl) optionally substituted by CF 3 .
  • R 1 is heterocyclyl (such as tetrahydropyran or tetrahy drothiopyran) .
  • R 2 is phenyl or heteroaryl, either of which is optionally substituted by halo, C M alkyl, C M alkoxy, S(O) n (C 1-4 alkyl), nitro, cyano or CF 3 ; wherein n is 0, 1 or 2, for example 0 or 2.
  • R 2 is heteroaryl it is, for example an optionally substituted thiophenyl (that is, thienyl).
  • R 2 is phenyl or thienyl, either of which is optionally substituted by halo (such as chloro or fluoro) or CF 3 .
  • R 2 is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF 3 ), or optionally substituted (for example unsubstituted or mono-substituted) heteroaryl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF 3 ).
  • halo such as chloro or fluoro
  • cyano methyl, ethyl, methoxy, ethoxy or CF 3
  • the invention provides a compound of the invention wherein R 2 is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (for example chloro or fluoro)).
  • R 2 is phenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 3-chloro-5-fluorophenyl or 3,5- difluorophenyl.
  • the invention provides a compound of the invention wherein R 2 is phenyl, 3 -fluorophenyl, 3-chlorophenyl or 3,5-difluorophenyl.
  • R 3 is hydrogen or methyl.
  • R 3 is C M alkyl (such as methyl) and the carbon to which R 3 is attached has the R absolute configuration.
  • R 3 is hydrogen.
  • the present invention provides a compound of the invention wherein R 4 is optionally substituted phenyl (the optional substituents being selected from those recited above).
  • the present invention provides a compound of the invention wherein R 4 is optionally substituted aryl (such as phenyl) or optionally substituted heteroaryl (such as pyridyl, imidazolyl or 1,3,4-thiadiazolyl), (the optional substituents being selected from those recited above).
  • R 4 is optionally substituted aryl (such as phenyl) or optionally substituted heteroaryl (such as pyridyl, imidazolyl or 1,3,4-thiadiazolyl), (the optional substituents being selected from those recited above).
  • the present invention provides a compound of the invention wherein R 4 is phenyl optionally substituted by one or more of halo, hydroxy, nitro, S(C ⁇ -6 alkyl), S(O)(C 1-6 alkyl), S(O) 2 (C 1-6 alkyl), S(O) 2 NH 2 , S(O) 2 NH(d -6 alkyl), S(O) 2 N(C 1-6 alkyl) 2 , cyano, C 1-6 alkyl, C M alkoxy, CH 2 S(O) 2 (C 1-6 alkyl), OS(O) 2 (C 1-6 alkyl), OCH 2 heteroaryl (such as OCH 2 tetrazolyl), OCH 2 CO 2 H, OCH 2 CO 2 (C 1-6 alkyl), OCH 2 C(O)NH 2 , OCH 2 C(O)NH(C 1-6 alkyl), OCH 2 CN, NH 2 , NH(C 1-6 alkyl), N(C
  • the present invention provides a compound of the invention wherein R 4 is phenyl optionally substituted by halogen (such as chloro or fluoro), cyano, C 1- alkyl (mono-substituted by S(O) 2 (C 1-4 alkyl) or C(O)NH(C 1-4 alkyl), CM alkoxy, S(C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), OS(O) 2 (C 1-4 alkyl), OCH 2 COOH, OCH 2 -tetrazolyl (itself optionally substituted by C alkyl), carboxamide or tetrazolyl (itself optionally substituted by C alkyl).
  • halogen such as chloro or fluoro
  • cyano C 1- alkyl (mono-substituted by S(O) 2 (C 1-4 alkyl) or C(O)NH(C 1-4 alkyl)
  • CM alkoxy S(C 1-4 alkyl),
  • the present invention provides a compound of the invention wherein R 4 is aryl or heteroaryl each being optionally substituted by OS(O)2R 49 or C 1-6 alkyl (mono-substituted by S(O) 2 R 50 or C(O)NR 51 R 52 ); wherein R 49 , R 50 , R 51 and R 52 are as defined above.
  • the present invention provides a compound of the invention wherein R 4 is phenyl (optionally substituted by halogen (such as chloro or fluoro), cyano, C alkyl, C M alkoxy, S(C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), OS(O) 2 (CM alkyl) or carboxamide), C 3-7 cycloalkyl (such as cyclohexyl), pyridyl (optionally substituted by C M alkyl), imidazolyl (optionally substituted by C 1-4 alkyl) or 1,3,4-thiadiazolyl (optionally substituted by C alkyl).
  • halogen such as chloro or fluoro
  • cyano such as C alkyl, C M alkoxy, S(C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), OS(O) 2 (CM alkyl) or carboxamide
  • C 3-7 cycloalkyl such as cyclohex
  • the present invention provides a compound of the invention wherein R 4 is phenyl ⁇ optionally substituted by S(O) 2 (C 1- alkyl) (such as CH 3 S(O)2, for example in the 4-position), C 1-4 alkoxy (such as CH 3 O, for example in the 4-position), OS(O) 2 (C 1-4 alkyl) (such as OSO 2 CH 3 , for example in the 4-position), halogen (such as chloro or fluoro) or cyano ⁇ .
  • S(O) 2 (C 1- alkyl) such as CH 3 S(O)2, for example in the 4-position
  • C 1-4 alkoxy such as CH 3 O, for example in the 4-position
  • OS(O) 2 (C 1-4 alkyl) such as OSO 2 CH 3 , for example in the 4-position
  • halogen such as chloro or fluoro
  • the invention provides a compound of the invention wherein A is absent.
  • the invention provides a compound of the invention wherein X is O or S(O) 2 .
  • X is S(O) 2 .
  • the invention provides a compound of the invention wherein m is 2 and n is 0 or n is 2 and m is 0. In a still further aspect the invention provides a compound of the invention wherein p is O.
  • the invention provides a compound of the invention wherein X is O and m and n are not both 1. In yet another aspect the invention provides a compound of the invention wherein X is
  • the invention provides a compound of the invention wherein X is S(O) 2 , n is 2 and m is 0.
  • the invention provides a compound of the invention wherein X is S(O) 2 , n is 0 and m is 2.
  • the invention provides a compound of the invention wherein X is O and m and n are both 1.
  • X is as defined above; Y is CH or N; R >4a is as defined for optional substituents on optionally substituted phenyl (above); and R la is mono-substituted by C ⁇ -6 alkyl, C 3- cycloalkyl, phenyl ⁇ optionally substituted by halo (for example fluoro), C M alkyl (for example methyl), C 1-4 alkoxy (for example methoxy), CF 3 or OCF 3 ⁇ , S(O) 2 (C ⁇ -4 alkyl) (for example S(O) 2 CH 3 , S(O) 2 CH 2 CH 3 or S(O) 2 CH(CH 3 ) 2 ), S(O) 2 (C 1-4 fluoroalkyl) (for example S(O) 2 CF 3 or S(O) 2 CH 2 CF 3 ), S(O) 2 phenyl ⁇ optionally substituted (such as mono-substituted) by halo (for example chloro), cyano,
  • the present invention provides a compound of formula (Ic): r-
  • R 2a is hydrogen, one or two halogen atoms (for example selected from chlorine and fluorine) or CF 3 .
  • R 2a is hydrogen.
  • R 14 and R 4a are as defined above.
  • R 2 and R 4a are as defined above.
  • the present invention provides a compound of formula (Ig):
  • R 14 and R 4a are as defined above.
  • R 2a and R 4a are as defined above.
  • R 1 , R 2a and R 4a are as defined above.
  • R 2a and R 4 are as defined above.
  • R 1 , R a and R 4a are as defined above.
  • the present invention provides a compound of fo ⁇ nula (II):
  • R a and R a are as defined above.
  • the present invention provides a compound of formula (In):
  • R 1 , R 2a and R 4a are as defined above.
  • R 2a is hydrogen, one or two halo (such as one chloro, one fluoro, one chloro and one fluoro or two fluoro) or CF 3 .
  • R 2a is, for example in the 2-, 3-, or 3- and 5- positions on the phenyl ring.
  • R 4a is one or more of halo, hydroxy, nitro, S(C 1-6 alkyl), S(O)(C 1-6 alkyl), S(O) 2 (C 1-6 alkyl), S(O) 2 NH 2 , S(O) 2 NH(d.
  • R 4a is halogen (such as chloro or fluoro), cyano, C M alkyl, C M alkoxy, S(C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), OS(O) 2 (C 1- alkyl) or carboxamide.
  • Table I comprises compounds of formula (la)
  • Table II comprises compounds of formula (lb)
  • Table III comprises compounds of formula (Ic)
  • Table IV comprises compounds of formula (Id)
  • Table V comprises compounds of formula (le)
  • Table VI comprises compounds of formula (If)
  • Table VII comprises compounds of formula (Ig):
  • Table VIII comprises compounds of formula (Ih):
  • Table IX comprises compounds of formula (Ii):
  • Table X comprises compounds of formula (Ij):
  • Table XI comprises compounds of
  • Table XII comprises compounds of formula (II):
  • Table XIII comprises compounds of formula (Im):
  • Table XIV comprises compounds of fo ⁇ nula (In):
  • the invention provides each individual compound listed in the tables above.
  • a compound of the invention wherein R 1 is an N-linked optionally substituted heterocycle can be prepared by reacting a compound of formula (II):
  • R 2 , R 3 , R 4 , m, n, A and X are as defined above, with a compound R1H (wherein the H is on a heterocycle ring nitrogen atom) wherein R 1 is as defined above, in the presence of a suitable base (for example a tri(C 1-6 alkyl)amine such as triethylamine or Hunig's base), in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) and, for example, at a room temperature (for example 10-30°C), optionally in the presence of sodium iodide.
  • a suitable base for example a tri(C 1-6 alkyl)amine such as triethylamine or Hunig's base
  • a suitable solvent such as a chlorinated solvent, for example dichloromethane
  • room temperature for example 10-30°C
  • a compound of the invention, wherein R 3 is hydrogen, can be prepared by coupling a compound of formula (III) :
  • R 1 and R 2 are as defined above, in the presence of NaBH(OAc) 3 (wherein Ac is C(O)CH 3 ) in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) at room temperature (for example 10-30°C).
  • a suitable solvent such as a chlorinated solvent, for example dichloromethane
  • a compound of the invention, wherein R 3 is hydrogen, can be prepared by coupling a compound of formula (III):
  • R 4 , m, n, A and X are as defined above, with a compound of formula (V): wherein R 1 and R 2 are as defined above and L is a leaving group such as halogen, tosylate, mesylate or triflate, in the presence of a base, such as potassium carbonate, in a suitable solvent (such as dioxane, acetonitrile or isopropanol) at temperatures from 60°C up to the boiling point of the solvent.
  • a base such as potassium carbonate
  • compounds of the invention can be prepared by using or adapting methods described in WO01/87839, EP-A1-1013276, WO00/08013, WO99/38514, WO99/04794, WOOO/76511, WOOO/76512, WOOO/76513, WOOO/76514, WOOO/76972 or US 2002/0094989.
  • the starting materials for these processes are either commercially available or can be prepared by literature methods, adapting literature methods or by following or adapting Methods herein described.
  • the invention provides processes for preparing the compounds of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) and (In). Many of the intermediates in the processes are novel and these are provided as further features of the invention.
  • the compounds of the invention have activity as pharmaceuticals, in particular as modulators (such as agonists, partial agonists, inverse agonists or antagonists) of chemokine receptor (such as CCR5) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).
  • modulators such as agonists, partial agonists, inverse agonists or antagonists
  • CCR5 chemokine receptor
  • AIDS Acquired Immunodeficiency Syndrome
  • the compounds of the present invention are also of value in inhibiting the entry of viruses (such as human immunodeficiency virus (HTV)) into target calls and, therefore, are of value in the prevention of infection by viruses (such as HIV), the treatment of infection by viruses (such as HIV) and the prevention and/or treatment of acquired immune deficiency syndrome (AIDS).
  • viruses such as human immunodeficiency virus (HTV)
  • HTV human immunodeficiency virus
  • a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), m) or (In) for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).
  • a method for modulating chemokine receptor activity (such as CCR5 receptor activity) in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof or a solvate thereof.
  • the present invention also provides the use of a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, as a medicament, such as a medicament for the treatment of transplant rejection, respiratory disease, psoriasis or rheumatoid arthritis (such as rheumatoid arthritis).
  • a medicament such as a medicament for the treatment of transplant rejection, respiratory disease, psoriasis or rheumatoid arthritis (such as rheumatoid arthritis).
  • Respiratory disease is, for example, COPD, asthma ⁇ such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness) ⁇ or rhinitis ⁇ acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis ⁇ ; and is particularly asthma or rhinitis] .
  • the present invention provides the use of a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).
  • chemokine receptor activity such as CCR5 receptor activity (such as rheumatoid arthritis)
  • the invention also provides a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament, such as a medicament for the treatment of rheumatoid arthritis.
  • the present invention provides the use of a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).
  • chemokine receptor activity such as CCR5 receptor activity (such as rheumatoid arthritis)
  • the invention further provides the use of a compound of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:
  • obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma ⁇ such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness) ⁇ ; bronchitis ⁇ such as eosinophilic bronchitis ⁇ ; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer
  • COPD chronic
  • arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
  • Alzheimer's disease multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle; in a warm blooded animal, such as man.
  • AIDS Acquired Immunodeficiency Syndrome
  • Lupus disorders such as lupus erythematosus or systemic lupus
  • erythematosus Hashimoto's thyroiditis
  • myasthenia gravis myasthenia gravis
  • type I diabetes nephrotic syndrome
  • the present invention further provides a method of treating a chemokine mediated disease state (such as a CCR5 mediated disease state) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or solvate thereof.
  • a chemokine mediated disease state such as a CCR5 mediated disease state
  • a warm blooded animal such as man
  • a compound of the invention or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR5 receptor) activity
  • said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Hi), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition will, for example, comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 to 70 %w, such as from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
  • compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration.
  • topical such as to the lung and/or airways or to the skin
  • the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.
  • a suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1 mg and 1 g of active ingredient.
  • composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.
  • Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of O.Olmgkg *1 to lOOmgkg '1 of the compound, for example in the range of O.lmgkg "1 to 20mgkg "1 of this invention, the composition being administered 1 to 4 times per day.
  • the intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection.
  • the intravenous dose may be given by continuous infusion over a period of time.
  • each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
  • Buffers such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl ⁇ - cyclodextrin may be used to aid formulation.
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
  • the invention further relates to combination therapies or compositions wherein a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, is administered concurrently (possibly in the same composition) or sequentially with an agent for the treatment of any one of the above disease states.
  • a compound of the invention can be combined with a TNF- ⁇ inhibitor (such as an anti-TNF monoclonal antibody (such as Remicade, CDP-870 and D.sub2.E.sub7.), or a TNF receptor immunoglobulin molecule (such as Enbrel.reg.)), a non-selective COX-1 / COX-2 inhibitor (such as piroxicam or diclofenac; a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen; a fenamate such as mefenamic acid, indomethacin, sulindac or apazone; a pyrazolone such as phenylbutazone; or a salicylate such as aspirin), a COX-1 / COX-2 inhibitor
  • a non-selective COX-1 / COX-2 inhibitor such as piroxicam or diclofenac
  • the present invention still further relates to the combination of a compound of the invention together with:
  • a leukotriene biosynthesis inhibitor a 5-li ⁇ oxygenase (5-LO) inhibitor or a 5- lipoxygenase activating protein (FLAP) antagonist
  • a leukotriene biosynthesis inhibitor such as zileuton, ABT-761, fenleuton, tepoxalin, Abbott-79175, Abbott-85761 , an N-(5-substituted)-thiophene-2- alkylsulfonamide, a 2,6-di-tert-butylphenol hydrazones, a methoxytetrahydropyran such as Zeneca ZD-2138, SB-210661, a pyridinyl-substiruted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; an indole or quinoline compound such as MK-591, MK-886 or BAY x 1005; • a receptor antagonist for
  • LTE.sub4. selected from the group consisting of a phenothiazin-3-one such as L- 651,392; an amidino compound such as CGS-25019c; a benzoxalamine such as ontazolast; a benzenecarboximidamide such as BIIL 284/260; or a compound such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro- 245913, iralukast (CGP 45715A) or BAY x 7195;
  • a phenothiazin-3-one such as L- 651,392
  • an amidino compound such as CGS-25019c
  • a benzoxalamine such as ontazolast
  • a benzenecarboximidamide such as BIIL 284/260
  • a compound such as zafirlukast,
  • a PDE4 inhibitor including an inhibitor of the isoform PDE4D
  • an antihistaminic H.subl. receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine or chlorpheniramine;
  • vasoconstrictor sympathomimetic agent such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride or ethylnorepinephrine hydrochloride;
  • an anticholinergic agent such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
  • a ⁇ .subl.- to ⁇ .sub4.-adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate or pirbuterol, or a methylxanthanine including theophylline and aminophylline; sodium cromoglycate; or a muscarinic receptor (Ml, M2, and M3) antagonist;
  • Ml, M2, and M3 muscarinic receptor
  • IGF-1 insulin-like growth factor type 1
  • an inhaled glucocorticoid with reduced systemic side effects such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate or mometasone furoate; • an inhibitor of a matrix metalloprotease (MMP), such as a stromelysin, a collagenase, or a gelatinase or aggrecanase; such as collagenase-1 (MMP-1), collagenase-2 (MMP- 8), collagenase-3 (MMP- 13), stromelysin- 1 (MMP-3), stromelysin-2 (MMP- 10), and stromelysin-3 (MMP-11) or MMP-12; • a modulator of chemokine receptor function such as CCR1 , CCR2, CCR2 A, CCR2B, CCR3, CCR4, CCR5, C
  • an immunosuppressant agent such as FK-506, rapamycin, cyclosporine, azathioprine or methotrexate;
  • a compound useful in the treatment of AIDS and/or HIV infection for example: an agent which prevents or inhibits the viral protein gpl20 from engaging host cell CD4 ⁇ such as soluble CD4 (recombinant); an anti-CD4 antibody (or modified / recombinant antibody) for example PRO 542; an anti-group 120 antibody (or modified / recombinant antibody); or another agent which interferes with the binding of groupl20 to CD4 for example BMS806 ⁇ ; an agent which prevents binding to a chemokine receptor, other than CCR5, used by the HTV virus ⁇ such as a CXCR4 agonist or antagonist or an anti-CXCR4 antibody ⁇ ; a compound which interferes in the fusion between the HIV viral envelope and a cell membrane ⁇ such as an anti- group 41 antibody; enfuvirtide (T-20) or T-1249 ⁇ ; an inhibitor of DC-SIGN (also known as CD209) ⁇ such as an anti-DC-SIGN antibody or an inhibitor of DC-
  • an existing therapeutic agent for the treatment of osteoarthritis for example a non- steroidal anti-inflammatory agent (hereinafter NSAID's) such as piroxicam or diclofenac, a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen, a fenamate such as mefenamic acid, indomethacin, sulindac or apazone, a pyrazolone such as phenylbutazone, a salicylate such as aspirin, a COX-2 inhibitor such as celecoxib, valdecoxib, rofecoxib or etoricoxib, an analgesic or intra-articular therapy such as a corticosteroid or a hyamronic acid such as hyalgan or synvisc, or a P2X7 receptor antagonist.
  • NSAID's such as piroxicam or diclofenac
  • the present invention still further relates to the combination of a compound of the invention together with: (i) a tryptase inhibitor; (ii) a platelet activating factor (PAF) antagonist; (iii) an interleukin converting enzyme (ICE) inhibitor; (iv) an IMPDH inhibitor; (v) an adhesion molecule inhibitor including a VLA-4 antagonist; (vi) a cathepsin; (vii) a MAP kinase inhibitor; (viii) a glucose-6 phosphate dehydrogenase inhibitor; (ix) a kinin- B.subl. - and B.sub2.
  • a -receptor antagonist comprising: (x) an anti-gout agent, e.g., colchicine; (xi) a xanthine oxidase inhibitor, e.g., allopurinol; (xii) an uricosuric agent, e.g., probenecid, sulfinpyrazone or benzbromarone; (xiii) a growth hormone secretagogue; (xiv) a transforming growth factor (TGF ⁇ ); (xv) a platelet-derived growth factor (PDGF); (xvi) a fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) a granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) a capsaicin cream; (xix) a TachykininNK.subl.
  • an anti-gout agent e.g., colchicine
  • NK.sub3. receptor antagonist selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) an elastase inhibitors selected from the group consisting of UT- 77 and ZD-0892; (xxi) a TNF ⁇ converting enzyme inhibitor (TACE); (xxii) an induced nitric oxide synthase inhibitor (iNOS); or (xxiii) a chemoattractant receptor-homologous molecule expressed on TH2 cells (a CRTH2 antagonist).
  • TACE TNF ⁇ converting enzyme inhibitor
  • iNOS induced nitric oxide synthase inhibitor
  • a chemoattractant receptor-homologous molecule expressed on TH2 cells a CRTH2 antagonist.
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
  • organic solutions were dried over anhydrous magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
  • chromatography unless otherwise stated means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column is referred to, this means a column containing lOg or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI".
  • IsoluteTM SCX column a column containing benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK.
  • ArgonautTM PS-trz ' s-amine scavenger resin is refe ⁇ ed to, this means a t -(2-aminoethyl)amine polystyrene resin obtained from Argonaut Technologies Inc., 887 Industrial Road, Suite G, San Carlos, California, USA.
  • the LC comprised water symmetry 4.6x50 column C18 with 5 micron particle size.
  • the eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid.
  • the eluent gradient went from 95% A to 95% B in 6 minutes.
  • the sample was spun at 30 revolutions per minute (to improve counting statistics) and irradiated with X-rays generated by a copper long-fine focus tube operated at 40kV and 40mA with a wavelength of 1.5406 angstroms.
  • the collimated X-ray source was passed through an automatic variable divergence slit set at V20 and the reflected radiation directed through a 2mm antiscatter slit and a 0.2mm detector slit.
  • the sample was exposed for 1 second per 0.02 degree 2-theta increment (continuous scan mode) over the range 2 degrees to 40 degrees 2-theta in theta- theta mode.
  • the running time was 31 minutes and 41 seconds.
  • the instrument was equipped with a scintillation counter as detector.
  • Control and data capture was by means of a Dell Optiplex 686 NT 4.0 Workstation operating with Diffract+ software.
  • the relative intensity of peaks can be affected by, for example, grains above 30 microns in size and non-unitary aspect ratios which may affect analysis of samples.
  • the skilled person will also realise that the position of reflections can be affected by the precise height at which the sample sits in the diffractometer and the zero calibration of the diffractometer. The surface planarity of the sample may also have a small effect.; and,
  • N-(3-Phenyl-3-chloropropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]- piperidine (prepared according to Method D; 180mg) was added to a solution of N- methanesulphonylpiperazine (61mg) and triethylamine (0.102ml) in dichloromethane (10ml) and the mixture was allowed to stand at room temperature for 16 hours. The reaction mixture was poured onto a 20g silica Bond Elut eluted with a solvent gradient (ethyl acetate - 25% methanol/ethyl acetate). The title compound was obtained, yield 67mg, MH 1" 612.
  • Example 3 This Example illustrates the preparation of (S) N-(3-phenyl-3-[4-chlorobenzoyl- amino]propyl-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]piperidine (Compound No. 2, Table TV).
  • Example 4 This Example illustrates the preparation of l- ⁇ (3i-)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl ⁇ -4-(2- ⁇ [4-(methylsulfonyl)phenyl]sulfonyl ⁇ ethyl)piperidine (Compound No. 7, Table V).
  • Example 5 This Example illustrates the preparation of (R or S) N-(3-[4- methanesulphonylpiperazinyl]-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]- piperidine (Compound 14, Table III).
  • MP-triacetoxyborohydride (where MP stands for "macroporous”; 585 mg) was added to a solution of (R) 3-(l-methanesulphonylpiperidin-4-yl)-3-[3,5- difluorophenyl]propionaldehyde (199 mg) (Method G) and 4-(2-[4- methanesulphonylphenylsulphonyl]ethyl)piperidine (194 mg) (Method B) in 20 ml of dichloromethane and the mixture was stirred at room temperature for 16 hours.
  • Example 7 This Example illustrates the preparation of (R) N-(3-phenyl-3-[l- methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-methanesulphonyloxyphenylsulphonyl)- ethyl]piperidine (Compound 29 in Table III).
  • Methanesulphonyl chloride (60.3 mg) was added to a solution of (R) N-(3-phenyl-3- [l-methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-hydroxyphenylsulphonyl)ethyl]piperidine (Compound 28 in Table III; 290 mg) and triethylamine (53 mg) in dichloromethane (10 ml) and the mixture was stirred for 16 hours, then washed with saturated aqueous sodium bicarbonate (2x20 ml) and dried.
  • Example 9 Preparation of (4- ⁇ [2-(l- ⁇ (3i?)-3-(3,5-difiuorophenyl)-3-[4- (methylsulfonyl) ⁇ henyl]propyl ⁇ piperidin-4-yl)ethyl]sulfonyl ⁇ phenoxy)acetonitrile (Compound 15 of Table V ) and 2-(4- ⁇ [2-(l- ⁇ (3i?)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl ⁇ piperidin-4-yl)ethyl]sulfonyl ⁇ phenoxy)acetamide (Compound 16 of Table V ).
  • Example 12 in a mixture of ethanol (20 ml) and THF (20 ml) and the mixture was stirred for 2 hours. The reaction mixture was evaporated to dryness and water (10 ml) was added. The solution was acidified to pH 3 with 2M HCI, the pH was adjusted to ⁇ 5 with sodium acetate and the mixture was extracted with dichloromethame (4x25 ml). The combined extracts were dried and evaporated to give the title compound, yield 0.9g. M1H 636.
  • EDCI was added to a solution of (4- ⁇ [2-(l- ⁇ (3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl ⁇ piperidin-4-yl)ethyl]sulfonyl ⁇ phenoxy)acetic acid (400 mg), methanesulphonamide (59 mg) and dimethylaminipyridine (163 mg) in dichloromethane and the mixture was stirred for 20 hours. The mixture was washed with water (2x25 ml), dried and evaporated to dryness.
  • succinate, malonate and fumarate salts of l- ⁇ (3J?)-3-(3,5-difluoro ⁇ henyl)-3-[4- (memylsulfonyl)phenyl]propyl ⁇ -4-(2- ⁇ [4-(methylsulfonyl)phenyl]sulfonyl ⁇ ethyl)piperidine were prepared using the method of Example 18.
  • the fumarate salt of l- ⁇ (3R)-3-(3,5- difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl ⁇ -4-(2- ⁇ [4- (methylsulfonyl) ⁇ henyl]sulfonyl ⁇ ethyl) ⁇ iperidine was formed as a crystalline solid.
  • the tartrate salt was formed as a gum.
  • PXRD of the succinate salt of l- ⁇ (3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl ⁇ -4-(2- ⁇ [4-(methylsulfonyl)phenyl]sulfonyl ⁇ ethyl)piperidine is presented in Figure 3.
  • Step 1 Preparation of (4S, 5R)-l-[(S)-3-(4-methanesulfonyl-phenyl)-3-phenyl-propionyl]-3,4- dimethyl-5-phenyl-imidazolidin-2-one
  • Step 2 Preparation of (S)-3-phenyl-3-(4-methanesulphonylphenyl)propan-l-ol
  • Step 4 Preparation of E-(4S, 5R)-l-(3-[4-Methanesulphonylphenyl]acryloyl)-3,4-dimethyl-5- phenyl-imidazolidin-2-one
  • Step 2 Preparation of N-tert-butoxycarbonyl-4-[2-(4-methylsulphonylphenylsulphonyl)ethyl]- piperidine.
  • m-Chloroperbenzoic acid (5.64g) was added to a solution of N-tert-butoxycarbonyl-4- [2-(4-methylthiophenylthio)ethyl]piperidine (2.1g) in dichloromethane (90 ml) at 0°C.
  • the reaction mixture was allowed to warm to room temperature and was stirred for 16 hours.
  • the reaction mixture was washed with saturated aqueous sodium bicarbonate solution (20 ml), water (20 ml) and brine (20 ml) then dried and evaporated to dryness.
  • the product was chromatographed on a 50g silica Bond Elut column eluting with a solvent gradient of 20% ethyl acetate/isohexane - ethyl acetate to give the product, yield 1.82g, MH 1" 375.9.
  • Trifluoroacetic acid (5 ml) was added to a solution of N-fert-butoxycarbonyl-4-[2-(4- methylsulphonylphenylsulphonyl)ethyl]piperidine (1.94g) in dichloromethane (20 ml) and was allowed to stand at room temperature for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in 2M sodium hydroxide (15 ml) and extracted with dichloromethane (3x20 ml). The combined dichloromethane extracts were dried and evaporated to dryness to give the title compound, yield 1.3g, ⁇ 331.9.
  • Variant B A solution of 4M hydrochloric acid in dioxane (15 ml) was added to a stirred solution of -tert-butoxycarbonyl-4-[2-(4-methylsulphonylphenylsulphonyl)ethyl]piperidine (5.62g) in dichloromethane (15 ml) and stirring was continued for 1 hour. The reaction mixture was triturated with diethyl ether and the solid formed was filtered, washed with diethyl ether and dried under high vacuum. The title compound was obtained as its hydrochloride salt, yield 4.88g, M1H 331.9.
  • Methanesulphonyl chloride was added to a stirred slurry of 4-benzoylpiperidine hydrochloride (4.51g) and triethylamine (8.35ml) in dichloromethane (100ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The mixture was diluted with dichloromethane (50ml) and washed with ammonium chloride solution (2x25ml) and brine (25ml), dried and evaporated to dryness to give 4-benzoyl-l - methanesulphonylpiperidine as a white solid, yield 3.98g.
  • Lithium bis(trimethylsilyl)amide (16.3ml of a IM solution in THF) was added dropwise to a solution of triethylphosphonoacetate (2.93ml) in THF at 0°C under an argon atmosphere and the mixture was stirred for 30 minutes.
  • a slurry of 4-benzoyl-l - methanesulphonylpiperidine (3.96g) in THF (30ml) was added, the reaction mixture was allowed to warm to room temperature and stirring was continued for 24 hours.
  • the reaction mixture was diluted with dichloromethane (80ml) and water (80ml). The organic layer was washed with water and the combined aqueous extracts were in turn extracted with dichloromethane (50ml).
  • Step 4 3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propan-l-ol.
  • Triethylamine (0.73 ml) was added to a solution of N-(3-hydroxy-3-phenylpro ⁇ yl)-4- [2-(4-methanesulphonylphenylsulphonyl)ethyl]-piperidine (1.22g) in dichloromethane (20 ml) followed by methanesulphonyl chloride (0.33g) and the mixture was stirred for 18 hours at room temperature. The reaction mixture was washed successively with water (25 ml) and brine (25 ml) and dried.
  • 3-Chloropro ⁇ iophenone (0.726g) was added to a mixture of 4-[2-(4- methanesulphonylphenylsulphonyl)ethyl]-piperidine (1.3g) (prepared as described in Method B) and potassium carbonate (1.09g) in DMF (20ml) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in dichloromethane (30ml). The dichloromethane solution was washed with water (25ml), brine (25ml) and dried.
  • Step 1 (R or S) N-(3-chloro-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]- piperidine
  • Methanesulphonyl chloride (158 ⁇ l) was added to a solution of (S)N-(3-hydroxy-3- phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]-piperidine (600 mg) and triethylamine (417 ⁇ l) in dichloromethane (10 ml) maintained at 0°C under an argon atmosphere. The reaction mixture was allowed to warm to room temperature and was stirred for 18 hours. The reaction mixture was diluted with dichloromethane (50 ml) and washed with saturated amonium chloride solution (2x25 ml) and brine (25 ml) and dried.
  • Step 2 (S) N-(3-hydroxy-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]-piperidine
  • Dioxane (100 ml) was charged to a 500 ml three necked flask and purged with argon for 10 minutes.
  • Acetylacetonatobis[ethylene]rhodium (I) (620 mg) and R-BINAP were added and the mixture was stirred for 10 minutes.
  • 3,5-Difluorophenylboronic acid (19g) was added and the mixture was purged with argon for 10 minutes.
  • N-(benzyloxycarbonylpiperidin-4- yl)propenoic acid isopropyl ester (8 g) and ethanediol (20 ml) in dioxane (100 ml) were added and the mixture was purged with argon for 10 minutes.
  • the mixture was heated at 100°C for 18 hours, allowed to cool and was passed through activated alumina (200g) washed through with ethyl acetate (3x100 ml). The combined washings were evaporated to dryness and the residue obtained was dissolved in ethyl acetate (100 ml) and washed successively with saturated aqueous sodium bicarbonate (2x100 ml) and 2M HCI (2x100 ml), dried and evaporated to dryness.
  • the product obtained (12g) was shown to be 40% of the required material by NMR and was used without further purification in the subsequent reactions.
  • Step 5 Preparation of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)- propanoic acid isopropyl ester.
  • Lithium aluminium hydride 25 ml of a IM solution in THF was added dropwise over 15 minutes to a solution of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propanoic acid isopropyl ester (lOg) in THF (150 ml) at -10°C.
  • the reaction mixture was stirred at -10°C for 30 minutes, 2M NaOH (25 ml) was added, the mixture was filtered and the filtrate evaporated to dryness. The residue obtained was dissolved in ethyl acetate and washed with 2M HCI (2x100 ml) and dried.
  • Step 7 Preparation of (R) 3-( -methanesulphonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propionaldehyde.
  • Step 1 Preparation of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid acid chloride.
  • Step 2 Preparation of l-[3-(N-methanesulphonyl ⁇ iperidin-4-yl)propenyl]-(4S, 5R)-3,4- dimethyl-4-phenyl-imidazolidin-2-one.
  • Lithium bis(trimethylsilyl)amide (8 ml of a IM solution in THF) was added dropwise to a suspension of (4R,5S)-l,5-dimethyl-4-phenyl-2-imidazolidinone (1.52g) in THF (20 ml) under argon at -10°C.
  • the reaction mixture was stirred at -10°C for 10 minutes, allowed to warm to 0°C and maintained at this temperature for 10 minutes then cooled again to -10°C.
  • the solution of the acid chloride prepared in Step 1 was added dropwise and the reaction mixture was allowed to warm to room temperature and washed with water (100 ml).
  • the aqueous extract was extracted with ethyl acetate (3x50 ml) and the ethyl acetate extracts were dried and the residue passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane - 70% ethyl acetate/isohexane). Yield 1.89g.
  • Step 3 Preparation of (R) l-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]- (4S,5R)-3,4-dimethyl-5-phenyl-imidazolidin-2-one.
  • reaction mixture was concentrated and filtered through a pad of silica (50g) washed with ethyl acetate (2x50 ml) and the ethyl acetate washings were washed with 2M HCI (2x150 ml) and dried.
  • the residue obtained on removal of the solvent was passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane- 70% ethyl acetate/isohexane) to give the product as a yellow solid, yield 1.34g, MH* " 484.
  • reaction mixture was filtered and the filtrate was passed through a 40 g Biotage column eluted with a solvent gradient (50% ethyl acetate/isohexane - 70% ethyl acetate/isohexane) to give the title compound as a white solid, yield 338 mg.
  • Potassium thioacetate (1.857 g) was added to a solution of 4-tosyloxymethyl-N-Boc- piperidine (CAS 166815-96-9) (3 g) in DMF (40 ml) and the mixture was heated at 100°C for 4 hours. The reaction mixture was allowed to cool to room temperature and water (5 ml) was added. The reaction mixture was extracted with diethyl ether (3x50 ml). The diethyl ether extracts were washed with saturated aqueous sodium bicarbonate (50 ml), brine (50 ml) and were dried.
  • N-Boc-piperidin-4-ylmethylthiol (1.155 g) was added to a suspension of sodium hydride (200 mg of a 60% dispersion in mineral oil) in DMF at 0°C and the mixture was stirred for 30 minutes.
  • 4-Methanesulphonylbenzyl chloride (1.023 g) was added, the reaction mixture was allowed to warm to room temperature and was stirred for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in dichloromethane (30 ml) and washed with water (25 ml) and brine (25 ml) and dried.
  • Step 5 [(piperidin-4-yl)methyl]-(4-methanesulphonylphenylmethyl)sulphone This was carried out as described in Step 3 of Method I, MH + 332.
  • Lithium aluminium hydride (2.823 ml of a IM solution in THF) was added dropwise to a solution of ethyl 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzoate (1.2 g) [prepared according to Method B using ethyl-4-mercaptobenzoate (CAS 28276-32-6) as starting material] in THF (20 ml) at 0°C and the mixture was stirred for 30 minutes. Ethyl acetate (10 ml) was added followed by water (0.1 ml), 2M NaOH (0.1 ml) and water (1 ml) and Celite (2 g). The mixture was stirred for 5 minutes and filtered.
  • p-Toluenesulphonyl chloride (541 mg) was added to a solution of 4-(2-[N-Boc- piperidin-4-yl]ethylsulphonyl)benzyl alcohol (1.086 g) and triethylamine (0.473 ml) in dichloromethane (30 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The reaction mixture was washed with water (25 ml), dried and evaporated to dryness.
  • Step 4 Preparation of 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzyl methyl sulphone.
  • m-Chloroperbenzoic acid (720 mg) was added to a solution of the thioether (Step 3) in dichloromethane (20 ml) at 0°C.
  • the reaction mixture was allowed to warm to room temperature and was stirred for 16 hours then washed with 2M NaOH (20 ml) and brine (20 ml) and dried.
  • the residue obtained on evaporation of the solvent was passed through a 50g silica Bond Elut column eluting with a solvent gradient (isohexane-50% ethyl acetate/isohexane), yield 416 mg, MH* 390 (- tert-Butyl).
  • reaction mixture was evaporated to dryness and the residue obtained on evaporation of the solvent was passed through a 50g silica Bond Elut column eluting with a solvent gradient (isohexane-50% ethyl acetate/isohexane), yield 394 mg, MH 1" 297 (-Boc).
  • Step 2 4-(2- ⁇ [4-(Cyanomethoxy)phenyl]sulfonyl ⁇ ethyl)piperidine tert-Butyl 4-(2- ⁇ [4-(cy anomethoxy)phenyl] sulfonyl ⁇ ethyl)piperidine- 1 -carboxylate (1.4g ) was dissolved in dioxane (5 ml) and HCl/dioxane (20 ml of 4M solution) was added.
  • Step 1 Benzyl 4- ⁇ 2-[(4-cyanophenyl)sulfonyl]ethyl ⁇ piperidine-l-carboxylate.
  • Benzyl chloroformate 800 mg was added to a solution of 4-[(2-piperidin-4- ylethyl)sulfonyl]benzonitrile (1.4g, Method B) and triethylamine (1.3g) in dichloromethane (25 ml) at 0°C.
  • the reaction mixture was allowed to warm to room temperature and was stirred for 2 hours, washed with 2M HCI (2x20 ml) and 2M NaOH (2x20 ml) and dried.
  • the residue obtained on removal of the solvent was purified by chromatography on a Bond-Elut column using an eluant gradient of hexane - 50% ethyl acetate/hexane. Yield 1.4g. NMR
  • Step 2 Benzyl 4-(2- ⁇ [4-(lH-tetrazol-5-yl)phenyl]sulfonyl ⁇ ethyl)piperidine-l-carboxylate.
  • the product from step 1 was mixed with sodium azide (220 mg) and ammonium chloride (182 mg) in DMF (25 ml) and heated at 100 °C for 4 hours. The reaction mixture was allowed to cool and the solvent was evaporated. The residue was dissolved in dichloromethane (50 ml) and washed with 2M NaOH (2x20 ml) and dried. Removal of the solvent gave the product, yield 1.9g, M1H 456, which was used directly in the next stage.
  • Step 3 Preparation of benzyl 4-(2- ⁇ [4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl ⁇ ethyl)- piperidine-1 -carboxylate and benzyl 4-(2- ⁇ [4-(l-methyl-lH-tetrazol-5-yl)phenyl]sulfonyl ⁇ - ethyl)piperidine- 1 -carboxylate
  • Methyl iodide (710 mg) was added to a solution of the product from step 2 (1.9g) in ethanol (25 ml) containing 2M NaO ⁇ (5 ml) and the mixture was stirred for 16 hours. A second portion of methyl iodide (710 mg) and 2M NaO ⁇ (5 ml) was added and stirring was continued for 72 hours. The reaction mixture was concentrated and water (30 ml) added.
  • M1H 470 Benzyl 4-(2- ⁇ [4-(l-methyl-lH-tetrazol-5-yl)phenyl]sulfonyl ⁇ ethyl)piperidine-l-carboxylate, yield 200 mg, NMR (CDC1 3 ): l.l(m, 2H), 1.8 (m, 5H), 2.7 (m, 2H) 3 3.1 (m, 2H), 4.1 (m, 2H), 4.15 (s, 3H), 5.1 (s, 2H), 7.4 (m, 5H), 7.95 (d, 2H), 8.15 (d, 2H). M1H 470.
  • Step 4 Preparation of 4-(2- ⁇ [4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl ⁇ ethyl)piperidine. 20% Palladium hydroxide on charcoal was added to a solution of benzyl 4-(2- ⁇ [4-(2- methyl-2H-tetrazol-5-yl)phenyl]sulfonyl ⁇ ethyl)piperidine-l -carboxylate (700 mg) in a mixture of ethyl acetate (50 ml) and ethanol (150 ml) and the mixture was hydrogenated under a hydrogen filled balloon. The catalyst was filtered and the filtrate evaporated to dryness to give the title compound as a white solid, yield 600 mg.
  • Nickel (II) acetate tetrahydrate 45 mg was added to borohydride exchange resin (borohydride on Amberlite® IRA- 140 [available from Aldrich]) (3.61 g) in methanol (35 ml) and after the reaction had subsided was allowed to stand for 1 minute.
  • the reaction mixture was filtered through Celite® and the resin was washed with methanol (3x10 ml). The combined filtrate and washings were evaporated to dryness and the product was used without further purification.
  • step 1 The product from step 1 (450mg) was dissolved in 4M HCI in dioxane (10 ml) and allowed to stand for 30 minutes. Diethyl ether (20 ml) was added and a solid was obtained on trituration, yield 597 mg, M+H 269.
  • Step 1 Preparation of tert-butyl 4-[2-( ⁇ 4-[(methylsulfonyl)amino] ⁇ henyl ⁇ thio)ethyl]- piperidine- 1 -carboxylate.
  • Methanesulphonyl chloride (0.63 ml) was added to a solution of tert-butyl 4- ⁇ 2-[(4- aminophenyl)thio] ethyl ⁇ piperidine- 1 -carboxylate (1.61g, Method B) in pyridine (40 ml) at 0°C and allowed to warm to room temperature. The reaction mixture was stirred for 5 hours then evaporated to dryness. The residue was dissolved in dichloromethane (40 ml) washed with water (2x20 ml) and dried.
  • Step 2 Preparation of tert-butyl 4-[2-( ⁇ 4-[(methylsulfonyl)amino]phenyl ⁇ sulfonyl)ethyl]- piperidine- 1 -carboxylate.
  • m-Chloroperbenzoic acid 375 mg was added to a solution of the product from step 1
  • Phenylisocyanate (86 ⁇ l) was added to a solution of tert-butyl 4- ⁇ 2-[(4- aminophenyl)sulfonyl]ethyl ⁇ piperidine-l-carboxylate (300 mg, Method O) in dichloromethane (10 ml) and the mixture was stirred for 16 hours. A further equivalent of phenylisocyanate was added and stirring continued for 24 hours. The reaction mixture was poured onto a 20g silica Bond-elut column and eluted with a solvent gradient of hexane-70% ethyl acetate/hexane. M1H 388 (M- Boc). The tert-butoxycarbonyl group was removed using the procedure described in step 2 of Method O to give the title compound as the hydrochloride salt, yield 124 mg, M+H 388.
  • the Boc protected compound (1.59g) was dissolved in 4M HCl/dioxane (10ml) and allowed to stand at room temperature for 1 hour. The reaction mixture was evaporated to dryness, redissolved in 2M sodium hydroxide (10ml) and extracted with dichloromethane (2x20ml) and dried. Removal of the solvent gave the title compound, yield 0.56g, MH + 465.
  • Example 19 The ability of compounds to inhibit the binding of RANTES was assessed by an in vitro radioligand binding assay.
  • Membranes were prepared from Chinese hamster ovary cells . which expressed the recombinant human CCR5 receptor. These membranes were incubated with O.lnM iodinated RANTES, scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated RANTES bound to the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated RANTES was calculated (IC 50 ). Certain compounds of formula (I) have an IC50 of less than 50 ⁇ M.
  • Example 20 The ability of compounds to inhibit the binding of MlP-l ⁇ was assessed by an in vitro radioligand binding assay.
  • Membranes were prepared from Chinese hamster ovary cells which expressed the recombinant human CCR5 receptor. These membranes were incubated with O.lnM iodinated MlP-l ⁇ , scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated MlP-l ⁇ bound to. the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated MlP-l ⁇ was calculated (IC 50 ). Certain compounds of formula (I) have an IC 5 0 of less than 50 ⁇ M.
  • Results from this test for certain compounds of the invention are presented in Table XV.
  • Table XV the results are presented as Pic50 values.
  • a Pic50 value is the negative log (to base 10) of the IC 50 result, so an IC50 of l ⁇ M (that is 1 x 10 "6 M) gives a Pic50 of 6. If a compound was tested more than once then the data below is an average of the probative tests results.
  • L is an activated group, such as halogen, mesylate, tosylate or triflate.
  • i reductive amination if R 3 is H can use sodium triacetoxyborohydride; if R 3 is alkyl can use titanium tetra-isopropoxide and sodium triacetoxyborohydride)
  • ii Deprotection eg TFA
  • iii amide bond formation eg acid chloride, active ester or carbodiimide mediated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compounds of formula (I) wherein R1, R2, R3, R4, A, X, m and n are as defined; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

Description

Novel piperidine derivatives as modulators of chemokine receptor CCR5
The present invention relates to heterocyclic derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents. Pharmaceutically active piperidine derivatives are disclosed in WO01/87839, EP-A1- 1013276, WO00/08013, WO99/38514, WO99/04794, WO00 76511, WO00/76512, O00/76513, O00/76514, "WOOO/76972, US 2002/0094989 andBioorg. Med. Chem. Lett. 13 (2003) 119-123. Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a role in the maturation of cells of the immune system. Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C-C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins lα and lβ (MlP-lα and MlP-lβ).
Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCRl, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above. The CCR5 receptor is expressed on T-lymphocytes, monocytes, macrophages, dendritic cells, microglia and other cell types. These detect and respond to several chemokines, principally "regulated on activation normal T-cell expressed and secreted" (RANTES), macrophage inflammatory proteins (M1P) MlP-lα and MlP-lβ and monocyte chemoattractant protein-2 (MCP-2).
This results in the recruitment of cells of the immune system to sites of disease. In many diseases it is the cells expressing CCR5 which contribute, directly or indirectly, to tissue damage. Consequently, inhibiting the recruitment of these cells is beneficial in a wide range of diseases. CCR5 is also a co-receptor for HIV-1 and other viruses, allowing these viruses to enter cells. Blocking the receptor with a CCR5 antagonist or inducing receptor intemalisation with a CCR5 agonist protects cells from viral infection.
The present invention provides a compound of formula (I):
Figure imgf000003_0001
wherein:
A is absent or is (CH2)2;
R1 is Cι.8 alkyl, C(O)NR10Rπ, C(O)2R12, NR13C(O)R14, NR15C(O)NR16R17, NR18C(O)2R19, heterocyclyl, aryl or heteroaryl;
R10, R13, R15, R16 and R18 are hydrogen or C1-6 alkyl; Rn , R12, R14, R17 and R19 are C1-8 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy,
Cι.6 haloalkoxy, C3-6 cycloalkyl (optionally substituted by halo), Cs-6 cycloalkenyl, S(C1-4 alkyl), S(O)(C1- alkyl), S(O)2(C1-4 alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C3.7 cycloalkyl (optionally substituted by halo or C1-4 alkyl), C4-7 cycloalkyl fused to a phenyl ring, C5-7 cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C1-6 alkyl), S(O)k(C1-6 alkyl), halo or C alkyl); or R11, R12, R14 and R17 can also be hydrogen; or R10 and R11, and/or R16 and R17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C1-6 alkyl, S(O)ι(C1-6 alkyl) or C(O)(C1-6 alkyl); R2 is C1-6 alkyl, phenyl, heteroaryl or C3.7 cycloalkyl;
R3 is H or C1-4 alkyl; R4 is aryl, heteroaryl, Cι-6 alkyl or C3-7 cycloalkyl; X is O or S(O)p; m and n are, independently, 0, 1, 2 or 3, provided m 4- n is 1 or more; aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR20R21, NR22R23, NR24C(O)R25, NR26C(O)NR 7R28, S(O)2NR29R30, NR31S(O)2R32, C(O)NR33R34, CO2R36, NR37CO2R38, S(O)qR39, OS(O)2R49, Cj. 6 alkyl (optionally mono-substituted by S(O)2R50 or C(O)NR51R52), C2-6 alkenyl, C2.6 alkynyl, C3-10 cycloalkyl, C1- haloalkyl, C1-6 alkoxy(Cι-6)alkyl, C1-6 alkoxy (optionally mono- substituted by CO2R53, C(O)NR5 R55, cyano, heteroaryl or C(O)NHS(O)2R56), NHC(O)NHR57, C1-6 haloalkoxy, phenyl, phenyl(Cι_ )alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)2, phenyl(C1-4)alkoxy, heteroaryl, heteroaryl(C1-4)alkyl, heteroaryloxy or heteroaryl(Cι-4)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(CM alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, C1-4 alkyl, CM alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(CM alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(Cι-4 alkyl), CF3 or OCF3; unless otherwise stated heterocyclyl is optionally substituted by C1-6 alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C alkyl, C alkoxy, cyano, nitro, CF3, OCF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(CM alkyl) or S(O)2(Cι- alkyl)} or heteroaryl {which itself optionally substituted by halo, C alkyl, C1- alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(CM alkyl) or S(O)2(C1-4 alkyl)}], phenyl {optionally substituted by halo, C1-4 alkyl, C1-4 alkoxy, cyano, nitro, CF3, OCF3, (CM alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(CM alkyl) or S(O)a(Cι. 4 alkyl)}, heteroaryl {optionally substituted by halo, C1-4 alkyl, C1-4 alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, C alkylthio, S(O)(C1-4 alkyl) or S(O)2(CM alkyl)} ,
S(O)2NR40R41, C(O)R42, C(O)2(C1-6 alkyl) (such as tert-butoxycarbonyl), C(O)2(ρhenyl(Cι.2 alkyl)) (such as benzyloxycarbonyl), C(O)NHR43, S(O)2R44, NHS(O)2NHR45, NHC(O)R46, NHC(O)NHR47 or NHS(O)2R48, provided none of these last four substituents is linked to a ring nitrogen; k, 1, p and q are, independently, 0, 1 or 2;
R20, R22, R24, R26, R27, R29, R31, R33, R37, R40, R51 and R54 are, independently, hydrogen or C1-6 alkyl; R21, R23, R25, R28, R30, R32, R34, R36, R38, R39, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R52, R53, R55, R56 and R57 are, independently, C1-6 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3.6 cycloalkyl, C5.6 cycloalkenyl, S(C1-4 alkyl), S(O)(C1- alkyl), S(O)2(C1-4 alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C3-7 cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C alkyl), S(O)2N(C1-4 alkyl)2, cyano, CM alkyl, C alkoxy, C(O)NH2, C(O)NH(Cι-4 alkyl), C(O)N(Cι-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3; R21, R23, R25, R28, R30, R34, R35, R36, R41, R42, R43, R45, R46, R47, R52, R53, R55 and R57 may additionally be hydrogen; or a pharmaceutically acceptable salt thereof or a solvate thereof.
Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.
Suitable salts include acid addition salts such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate orp- toluenesulphonate. In addition to these further examples of acid addition salts are succinate, glutarate or malonate. The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.
Alkyl groups and moieties are straight or branched chain and, for example, comprise one to six (such as one to four) carbon atoms. Alkyl is, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or tert-butyl. Methyl is sometimes abbreviated to Me hereinbelow.
Haloalkyl includes CF3, and haloalkoxy includes CF3.
Fluoroalkyl includes, for example, one to six, such as one to three, fluorine atoms, and comprises, for example, a CF3 group. Fluoroalkyl is, for example, CF3 or CH2CF3. Cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl (such as cyclohexyl). Cycloalkenyl includes cyclopentenyl.
Heterocyclyl is, for example, piperidine, piperazine, pyrrolidine, azetidine, tetrahydrofuran, morpholine or thiomorpholine. Further examples of heterocyclyl are tetrahydropyran and tetrahydrothiopyran. Aryl includes phenyl and naph hyl. In one aspect of the invention aryl is phenyl. Heteroaryl is, for example, an aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heteroaryl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, [l,2,4]-triazolyl, pyridinyl, pyrimidinyl, pyrazinyl, indolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl, 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[l,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl, 1,2,3-benzoxadiazolyl (also known as benzo[l,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3- benzoxadiazolyl), quinoxalinyl, a pyrazolopyridine (for example lH-pyrazolo[3,4- b]pyridinyl), quinolinyl, isoquinolinyl, a naphthyridinyl (for example [l,6]naphthyridinyl or [l,8]naphthyridinyl), a benzothiazinyl or dibenzothiophenyl (also known as dibenzothienyl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof. A further example of heteroaryl is tetrazolyl.
Aryloxy includes phenoxy.
Heteroaryloxy includes pyridinyloxy and pyrimidinyloxy.
Phenyl(C1-4 alkyl)alkyl is, for example, benzyl, l-(phenyl)eth-l-yl or l-(phenyl)eth-2- yl.
Heteroaryl(C1- alkyl)alkyl is, for example, pyridinylmethyl, pyrimidinylmethyl or 1- (pyridinyl)eth-2-yl.
Phenyl(Cι.4 alkoxy) is, for example, benzyloxy or phenylCH(CH3)O. Heteroaryl(C1-4 alkoxy) is, for example, pyridinylCH2O, pyrimidinylCH2O or pyridinylCH(CH3)O.
Heteroaryl rings can carry various substituents including sulphonyl groups. A sulphonyl group on a heteroaryl ring can be a good leaving group (susceptible to nucleophilic displacement) and examples of such situation are: 2-methanesulphonyl-pyridine and 2- or 4- methanesulphonyl-pyrimidine. The present invention covers compounds including a heteroaryl ring carrying a sulphonyl group which are sufficiently stable (non-reactive) to be isolated using the experimental procedures described.
In one particular aspect the present invention provides a compound of formula (I) wherein: A is absent or is (CH2)2; R1 is C1-8 alkyl, C(O)NR10Rπ, C(O)2R12, NR13C(O)R14, NR15C(O)NR16R17, NR18C(O)2R19, heterocyclyl, aryl or heteroaryl; R10, R13, R15, Rlδ and R18 are hydrogen or C1-6 alkyl; R11, R12, R14, R17 and R19 are C1-8 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C -6 cycloalkyl (optionally substituted by halo), C5-6 cycloalkenyl, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C3-7 cycloalkyl (optionally substituted by halo or C1-4 alkyl), C4- cycloalkyl fused to a phenyl ring, C5-7 cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C1-6 alkyl), S(O)k(C1-6 alkyl), halo or C1- alkyl); or R11, R12, R14 and R17 can also be hydrogen; or R10 and R11, and/or R16 and R17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by Cι-6 alkyl, S(O)ι(Cι-6 alkyl) or C(O)(C1-6 alkyl); R2 is C1-6 alkyl, phenyl, heteroaryl or C3. cycloalkyl; R3 is H or CM alkyl; R4 is aryl, heteroaryl, C1-6 alkyl or C3-7 cycloalkyl; X is O or S(O)p; m and n are, independently, 0, 1, 2 or 3, provided m + n is 1 or more; aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR20R21, NR22R23, NR2 C(O)R25, NR26C(O)NR27R28, S(O)2NR29R30, NR31S(O)2R32, C(O)NR33R34, CO2R36, NR37CO2R38,
S(O)qR39, OS(O)2R49, C1-6 alkyl (optionally mono-substituted by S(O)2R50 or C(O)NR51R52), C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-6 alkoxy(C1.6)alkyl, C1-6 alkoxy, Cι-6 haloalkoxy, phenyl, phenyl(CM)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)2, phenyl(CM)alkoxy, heteroaryl, heteroaryl(C1- )alkyl, heteroaryloxy or heteroaryl(CM)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(0)2(CM alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(CM alkyl)2, cyano, CM alkyl, C alkoxy, C(O)NH2, C(O)NH(CM alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(CM alkyl), NHS(O)2(C1-4 alkyl), CF3 or OCF3; unless otherwise stated heterocyclyl is optionally substituted by C1-6 alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, CM alkyl, CM alkoxy, cyano, nitro, CF3, OCF3, (CM alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(C1-4 alkyl) or S(O)2(C1-4 alkyl)} or heteroaryl {which itself optionally substituted by halo, C1-4 alkyl, C1- alkoxy, cyano, nitro, CF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, C alkylthio, S(O)(C1-4 alkyl) or S(O)2(CM alkyl)}], phenyl {optionally substituted by halo, CM alkyl, C1-4 alkoxy, cyano, nitro, CF3, OCF3, (CM alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(C1-4 alkyl) or S(O)2(C1-4 alkyl)}, heteroaryl {optionally substituted by halo, CM alkyl, C1- alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, C alkylthio, S(O)(CM alkyl) or S(O)2(Cι-4 alkyl)}, S(O)2NR 0R41, C(O)R42, C(O)2(C1-6 alkyl) (such as tert-butoxycarbonyl), C(O)2(phenyl(C1-2 alkyl)) (such as benzyloxycarbonyl), C(O)NHR43, S(O)2R44, NHS(O)2NHR45, NHC(O)R46, NHC(O)NHR47 or NHS(O)2R48, provided none of these last four substituents is linked to a ring nitrogen; k, 1, p and q are, independently, 0, 1 or 2; R20, R22, R24, R26, R27, R29, R31, R33, R37, R40 and R51 are, independently, hydrogen or Cι-6 alkyl; R21, R23, R25, R28, R30, R32, R34, R36, R38, R39, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R52 are, independently, C1-6 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, C5-6 cycloalkenyl, S(Cι- alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C3.7 cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1- alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(CM alkyl)2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(CM alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(Cι-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3; R21, R23, R25, R28, R30, R34, R35, R36, R41, R42, R43, R45, R46, R47 and R52 may additionally be hydrogen; or a pharmaceutically acceptable salt thereof or a solvate thereof.
In a further aspect the present invention provides a compound of formula (I) wherein: A is absent or is (CH2)2; R1 is C1-8 alkyl, C(O)NR10Rn, C(O)2R12, NR13C(O)R14, NR15C(O)NR16R17, NR18C(O)2R19, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl or heteroaryl; R10, R13, R15, R16 and R18 are hydrogen or C1-6 alkyl; R11, R12, R14, R17 and R19 are C1-8 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl (optionally substituted by halo), C5.6 cycloalkenyl, S(Ci alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C3-7 cycloalkyl (optionally substituted by halo or C alkyl), C4.7 cycloalkyl fused to a phenyl ring, C5.7 cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C1-6 alkyl), S(O)k(Cι-6 alkyl), halo or C1-4 alkyl); or Rπ, R12, R14 and R17 can also be hydrogen; or R10 and Rπ, and/or R16 and R17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C1-6 alkyl, S(O)ι(C1-6 alkyl) or C(O)(C1-6 alkyl); R2 is C1-6 alkyl, phenyl, heteroaryl or C3-7 cycloalkyl; R3 is H or CM alkyl; R4 is aryl, heteroaryl, C1-6 alkyl or C3.7 cycloalkyl; X is O or S(O)p; m and n are, independently, 0, 1, 2 or 3, provided m + n is 1 or more; aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR20R21, NR22R23, NR24C(O)R25, NR26C(O)NR27R28, S(O)2NR29R30, NR31S(O)2R32, C(O)NR33R34, CO2R36, NR37CO2R38, S(O)qR39, OS(O)2R49, Cι-6 alkyl (optionally mono-substituted by S(O)2R50 or C(O)NR51R52), C2-6 alkenyl, C2-6 alkynyl, C3.10 cycloalkyl, C1-6 haloalkyl, Cι-6 alkoxy(C1-6)alkyl, Cι-6 alkoxy, C1-6 haloalkoxy, phenyl, phenyl(C1-4)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)2, phenyl(C1-4)alkoxy, heteroaryl, heteroaryl(C1-4)alkyl, heteroaryloxy or heteroaryl(C1-4)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(CM alkyl), S(O)(C1- alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C alkyl), S(O)2N(CM alkyl)2, cyano, C1- alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), CF3 or OCF3; unless otherwise stated heterocyclyl is optionally substituted by C1-6 alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C1-4 alkyl, CM alkoxy, cyano, nitro, CF3, OCF3, (C1- alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(CM alkyl) or S(O)2(Cι-4 alkyl)} or heteroaryl {which itself optionally substituted by halo, C1-4 alkyl, CM alkoxy, cyano, nitro, CF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(Cι-4 alkyl) or S(O)2(C1-4 alkyl)}], phenyl {optionally substituted by halo, CM alkyl, C1-4 alkoxy, cyano, nitro, CF3, OCF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(CM alkyl) or S(O)2(C1-4 alkyl)}, heteroaryl {optionally substituted by halo, CM alkyl, CM alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(CM alkyl) or S(O)2(C1-4 alkyl)}, S(O)2NR40R41, C(O)R42, C(O)2(C1-6 alkyl) (such as tert-butoxycarbonyl), C(O)2(phenyl(C1-2 alkyl)) (such as benzyloxycarbonyl), C(O)NHR43, S(O)2R44, NHS(O)2NHR45, NHC(O)R46, NHC(O)NHR47 or NHS(O)2R48, provided none of these last four substituents is linked to a ring nitrogen; k, 1, p and q are, independently, 0, 1 or 2; R20, R22, R24, R26, R27, R29, R31, R33, R37, R40 and R51 are, independently, hydrogen or Cι-6 alkyl; R21, R23, R25, R28, R30, R32, R34, R36, R38, R39, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R52 are, independently, C1-6 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, C5-6 cycloalkenyl, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(CM alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C3-7 cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1- alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(CM alkyl)2, cyano, CM alkyl, C1- alkoxy, C(O)NH2, C(O)NH(CM alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3; R21, R23, R25, R28, R30, R34, R35, R36, R41, R42, R43, R44, R45, R46, R47 and R52 may additionally be hydrogen; or a pharmaceutically acceptable salt thereof or a solvate thereof. In another aspect the present invention provides a compound of formula (I) wherein A is absent or is (CH2)2; R1 is C alkyl, C(O)NR10Rπ, C(O)2R12, NR13C(O)R14, NR15C(O)NR16R17, NR18C(O)2R19, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl or heteroaryl; R10, R13, R15, R16 and R18 are hydrogen or C1-6 alkyl; Rπ, R12, R14, R17 and R19 are C1-8 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, Cι-6 haloalkoxy, C3-6 cycloalkyl (optionally substituted by halo), C5-6 cycloalkenyl, S(C1- alkyl), S(O)(C1-4 alkyl), S(O)2(Cι-4 alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C3-7 cycloalkyl (optionally substituted by halo or C1-4 alkyl), C4.7 cycloalkyl fused to a phenyl ring, C5-7 cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)( ,6 alkyl), S(O)k(C1-6 alkyl), halo or CM alkyl); or R1 R12, R14 and R17 can also be hydrogen; or R10 and Rn, and/or R16 and R17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C1-6 alkyl, S(O)ι(C1-6 alkyl) or C(O)(C1-6 alkyl); R2 C1-6 alkyl, phenyl, heteroaryl or C3-7 cycloalkyl; R3 is H or CM alkyl; R4 is aryl or heteroaryl; X is O or S(O)p; m and n are, independently, 0, 1, 2 or 3, provided m + n is 1 or more, and provided that when X is O then m and n are not both 1; unless specified otherwise aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR20R21, NR22R23, NR24C(O)R23, NR26C(O)NR27R28, S(O)2NR 9R30, NR31S(O)2R32, C(O)NR33R34, CO2R36, NR37CO2R38, S(O)qR39, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-6 haloalkyl, Cι-6 alkoxy(C1-6)alkyl, C1-6 alkoxy, C1-6 haloalkoxy, phenyl, phenyl(C1-4)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)2, phenyl(Cι. 4)alkoxy, heteroaryl, heteroaryl(C1-4)alkyl, heteroaryloxy or heteroaryl(CM)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, C1-4 alkyl, C1- alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(Cι- alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), CF3 or OCF3; unless otherwise stated heterocyclyl is optionally substituted by Cι-6 alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C1-4 alkyl, C1-4 alkoxy, cyano, nitro, CF3, OCF3, (Cι- alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(C1- alkyl) or S(O)2(C1-4 alkyl)} or heteroaryl {which itself optionally substituted by halo, C alkyl, C alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, C alkylthio, S(O)(C1-4 alkyl) or S(O)2(Cj-4 alkyl)}], phenyl {optionally substituted by halo, CM alkyl, CM alkoxy, cyano, nitro, CF3, OCF3, (CM alkyl)C(O)NH, S(O)2NH2, C1- alkylthio, S(O)(C1-4 alkyl) or S(O)2(C1-4 alkyl)}, heteroaryl {optionally substituted by halo, CM alkyl, C1-4 alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(CM alkyl) or S(O)2(C1-4 alkyl)}, S(O)2NR 0R41, C(O)R42, C(O)2(C1-6 alkyl) (such as tert-butoxycarbonyl), C(O)2(phenyl(Cι-2 alkyl)) (such as benzyloxycarbonyl), C(O)NHR43, S(O)2R44, NHS(O)2NHR45, NHC(O)R46, NHC(O)NHR47 or NHS(O)2R48, provided none of these last four substituents is linked to a ring nitrogen; k, 1, p and q are, independently, 0, 1 or 2; R20, R22i R24, R26, R27, R29, R31, R33, R37 and R40 are, independently, hydrogen or C1-6 alkyl; R21, R23, R25, R28, R30, R32, R34, R36, R38, R39, R41, R42, R43, R44, R45, R46, R47 and R48 are, independently, C1-6 alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, C5-6 cycloalkenyl, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(CM alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C3-7 cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(CM alkyl), S(O)2N(C1-4 alkyl)2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1- alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(Cι-4 alkyl), NHS(O)2(Cι-4 alkyl), C(O)(CM alkyl), CF3 or OCF3; R21, R23, R25, R28, R30, R34, R35, R36, R41, R42, R43, R44, R45, R46 and R47 may additionally be hydrogen; or a pharmaceutically acceptable salt thereof or a solvate thereof.
In a further aspect the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C1-6 alkyl), S(O)(Cι-6 alkyl), S(O)2(C1-6 alkyl), S(O)2NH2, S(O)2NH(C1-6 alkyl), S(O)2N(C1-6 alkyl)2, cyano, C1-6 alkyl, C1-6 alkoxy, CH2S(O)2(C1-6 alkyl), OS(O)2(C1-6 alkyl), OCH2heteroaryl (such as OCH2tetrazolyl), OCH2CO2H, OCH2CO2(C1-6 alkyl), OCH2C(O)NH2, OCH2C(O)NH(C1-6 alkyl), OCH2CN, NH2, NH(C1-6 alkyl), N(Cι-6 alkyl)2, C(O)NH2, C(O)NH(C!.6 alkyl), C(O)N(Cι-6 alkyl)2, C(O)[N-linked heterocyclyl], CO2H, CO2(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHC(O)O(C1-6 alkyl), NHS(O)2(C1-6 alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, phenyl, heteroaryl, phenyl(Q. 4 alkyl), heteroaryl(C1-4 alkyl), NHC(O)phenyl, NHC(O)heteroaryl, NHC(O)(C1-4 alkyl)phenyl, NHC(O)(C1-4 alkyl)heteroaryl, NHS(O)2ρhenyl, NHS(O)2heteroaryl, NHS(O)2(C1-4 alkyl)phenyl, NHS(O)2(CM alkyl)heteroaryl, NHC(O)NH(C1-6 alkyl),
NHC(O)NH(C3-7 cycloalkyl), NHC(O)NHphenyl, NHC(O)NHheteroaryl, NHC(O)NH(C1-4 alkyl)phenyl or NHC(O)NH(C1- alkyl)heteroaryl; wherein the foregoing phenyl and heteroaryl groups are optionally substituted by halo, hydroxy, nitro, S(C1- alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, C1-4 alkyl, CM alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(Cι-4 alkyl), NHS(O)2(C1-4 alkyl), CF3 or OCF3.
In yet another aspect the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(Cι-6 alkyl), S(O)(C1-6 alkyl), S(O)2(C1-6 alkyl), S(O)2NH2, S(O)2NH(C1-6 alkyl), S(O)2N(C1-6 alkyl)2, cyano, C1-6 alkyl, C1-6 alkoxy, NH2, NH(C1-6 alkyl), N(CW alkyl)2, C(O)NH2, C(O)NH(Cι-6 alkyl), C(O)N(C1-6 alkyl)2, C(O)[N-linked heterocyclyl], CO2H, CO2(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHC(O)O(C1-6 alkyl), NHS(O)2(C1-6 alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, phenyl, heteroaryl, phenyl(C1-4 alkyl), heteroaryl(C1- alkyl), NHC(O)phenyl, NHC(O)heteroaryl, NHC(O)(C1-4 alkyl)phenyl, NHC(O)(CM alkyl)heteroaryl, NHS(O)2phenyl, NHS(O)2heteroaryl, NHS(O)2(CM alkyl)phenyl, NHS(O)2(C1-4 alkyl)heteroaryl, NHC(O)NH(C1-6 alkyl), NHC(O)NH(C3-7 cycloalkyl), NHC(O)NHphenyl, NHC(O)NHheteroaryl, NHC(O)NH(C1-4 alkyl)phenyl or NHC(O)NH(C1-4 alkyl)heteroaryl; wherein the foregoing phenyl and heteroaryl groups are optionally substituted by halo, hydroxy, nitro, S(CM alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, Cι-4 alkyl, CM alkoxy, C(O)NH2, C(O)NH(Cι-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), CF3 or OCF3.
In a further aspect the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C1-6 alkyl), S(O)(Cι-6 alkyl), S(O) (Cι-6 alkyl), S(O)2NH2, S(O)2NH(C1-6 alkyl), S(O)2N(C1-6 alkyl)2, cyano, C1-6 alkyl, C1-6 alkoxy, CH2S(O)2(C1-6 alkyl), OS(O)2(C1-6 alkyl), OCH2heteroaryl (such as OCH2tetrazolyl),
OCH2CO2H, OCH2CO2(C1-6 alkyl), OCH2C(O)NH2, OCH2C(O)NH(Cι-6 alkyl), OCH2CN, NH2, NH(C1-6 alkyl), N(C1-6 alkyl)2, C(O)NH2, C(O)NH(C1-6 alkyl), C(O)N(C1-6 alkyl)2, CO2H, CO2(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHC(O)O(C1-6 alkyl), NHS(O)2(C1-6 alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, heteroaryl or heteroaryl(C1-4 alkyl); wherein the foregoing heteroaryl group (such as tetrazolyl) are optionally substituted by halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, C1-4 alkyl, CM alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(CM alkyl), CF3 or OCF3 {and in a further aspect of the invention the foregoing heteroaryl groups (such as tetrazolyl) are optionally substituted by CM alkyl}.
In another aspect the present invention provides a compound of formula (I) wherein, unless specified otherwise, aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1- alkyl), S(O)2(C1- alkyl), S(O)2NH2, S(O)2NH(Cι-4 alkyl), S(O)2N(Cι-4 alkyl)2, cyano, CM alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C alkyl), CO2H, CO2(Cι-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), CF3, CHF2, CH2F, CH2CF3 or OCF3.
In a further aspect of the invention heteroaryl is tetrazolyl, pyrrolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or quinolinyl. In a still further aspect heteroaryl is pyrrolyl, thienyl, imidazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl or quinolinyl.
In another aspect of the invention R , R , R , R and R are hydrogen or C1-4 alkyl (for example methyl). In yet another aspect R10, R13, R15, R16 and R18 are hydrogen. In a further aspect of the invention R11, R12, R14, R17, R18 and R19 are C1-8 alkyl
(optionally substituted by halo, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl (optionally substituted by halo), C5-6 cycloalkenyl, S(O)2(C1-4 alkyl), heteroaryl, phenyl, heteroaryloxy or aryloxy (for example phenoxy)), phenyl, heteroaryl, C3-7 cycloalkyl (optionally substituted by halo or C1- alkyl), C4-7 cycloalkyl fused to a phenyl ring, C5-7 cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(C1-6 alkyl), S(O)k(C1-4 alkyl), halo or C1-4 alkyl); k is 0, 1 or 2; or R10 and R11, and/or R16 and R17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C1-6 alkyl or C(O)(d.6 alkyl).
In yet another aspect of the invention R11, R12, R14, R17 and R19 are C1-8 alkyl (optionally substituted by halo (such as fluoro)), phenyl (optionally substituted as recited above), C3-6 cycloalkyl (optionally substituted by halo (such as fluoro)) or C-linked nitrogen containing heterocyclyl (optionally substituted on the ring nitrogen).
In a further aspect R1 is NHC(O)R14, phenyl or heterocyclyl, wherein R14 is as defined above, and phenyl and heterocyclyl are optionally substituted as described above. In another aspect of the invention R1 is NR13C(O)R14, wherein R13 and R14 are as defined above. For example R13 is hydrogen.
In yet another aspect of the invention R14 is C1-8 alkyl (optionally substituted by halo (such as fluoro, for example to form CF3CH2)), phenyl (optionally substituted as recited above), C3-6 cycloalkyl (optionally substituted by halo (such as fluoro, for example to form l,l-difluorocyclohex-4-yl)) or C-linked nitrogen containing heterocyclyl (such as tetrahydropyran or piperidine, optionally substituted on the ring nitrogen).
In another aspect the present invention provides a compound of the invention wherein R14 is C1-8 alkyl (optionally substituted by halo (such as fluoro, for example to form
CF3CH2)), phenyl (optionally substituted by halo) or Cs.6 cycloalkyl (optionally substituted by halo (such as fluoro, for example to form l,l-difluorocyclohex-4-yl)).
In a further aspect of the invention heterocyclyl is optionally substituted (such as singly substituted for example on a ring nitrogen atom when present) by C1-6 alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, CM alkyl, CM alkoxy, cyano, nitro, CF3, OCF3, (CM alkyl)C(O)NH, S(O)2NH2, CM alkylthio or S(O)2(Cι-4 alkyl)} or heteroaryl {which itself optionally substituted by halo, C - alkyl, C1-4 alkoxy, cyano, nitro, CF3, (C alkyl)C(O)NH, S(O)2NH2, CM alkylthio or S(O)2(C1-4 alkyl)}], phenyl {optionally substituted by halo, C1-4 alkyl, C alkoxy, cyano, nitro, CF3, OCF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio or S(O)2(CM alkyl)}, heteroaryl {optionally substituted by halo, C1- alkyl, C alkoxy, cyano, nitro, CF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio or S(O)2(C1-4 alkyl)}, S(O)2NR40R41, C(O)R42, C(O)NHR43 or S^R44; wherein R40, R41, R42, R43 and R44 are, independently, hydrogen or C1-6 alkyl.
In yet another aspect of the invention R1 is optionally substituted aryl (such as optionally substituted phenyl) or optionally substituted heteroaryl, wherein the optional substituents are as recited above.
In a further aspect of the invention when R1 is heterocyclyl it is, for example, tetrahydropyran, tetrahydrothiopyran, piperidine, piperazine, pyrrolidine or azetidine. In another aspect when R1 is heterocyclyl it is, for example, piperidine, piperazine, pyrrolidine or azetidine.
In a further aspect of the invention R1 is optionally substituted heterocyclyl, such as optionally substituted: piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, azetidin-1-yl or azetidin-3-yl.
In a still further aspect of the invention the heterocyclyl of R1 is mono-substituted by C1-6 alkyl, C3- cycloalkyl, phenyl {optionally substituted by halo (for example fluoro), C1- alkyl (for example methyl), C1-4 alkoxy (for example methoxy), CF3 or OCF3}, S(O)2(CM alkyl) (for example S(O)2CH3, S(O)2CH2CH3 or S(O)2CH(CH3)2), S(O)2(CM fluoroalkyl) (for example S(O)2CF3 or S(O)2CH2CF3), S(O)2phenyl {optionally substituted (such as mono- substituted) by halo (for example chloro), cyano, C1- alkyl, C1-4 alkoxy, CF3, OCF3, S(O)2(C1- alkyl) (for example S(O)2CH3 or S(O)2CH2CH2CH3) or S(O)2(Cι-4 fluoroalkyl) (for example S(O)2CH2CF3)}, benzyl {optionally substituted by halo (for example chloro or fluoro), CM alkyl, CM alkoxy (for example methoxy), CF3 or OCF3}, C(O)H, C(O)(C1-4 alkyl), benzoyl {optionally substituted by halo (for example chloro or fluoro), CM alkyl (for example methyl), CM alkoxy, CF3 or OCF3}, C(O)2(C1- alkyl), C(O)NH2, C(O)NH(CM alkyl) or C(O)NHphenyl {optionally substituted by halo (for example fluoro), C alkyl, C alkoxy, CF3 or OCF3} . Said heterocyclyl can also be mono-substituted by S(O)2N(C1.4 alkyl)2. In a still further aspect when said heterocyclyl is a 4-substituted piperidin-1-yl, a 1- substituted piperidin-4-yl, a 4-substituted piperazin-1-yl, a 3-substituted pyrrolidin-1-yl, a 1- substituted pyrrolidin-3-yl, a 3-substituted azetidin-1-yl or a 1 -substituted azetidin-3-yl (for example where said substituent is as recited earlier in this paragraph). In another aspect said heterocyclyl is a 1 -substituted piperidin-4-yl or a 4-substituted piperazin-1-yl, wherein the substituent is S(O)2(C1-4 alkyl), S(O)2(C1-4 haloalkyl), S(O)2(phenyl), S(O)2N(C1-4 alkyl)2 or phenyl.
In another aspect of the invention R1 is piperidinyl or piperazinyl (such as piperidin-4- yl or ρiperazin-1-yl), either of which is N-substituted by phenyl, S(O)2R39 (wherein R39 is C1-4 alkyl (such as methyl or ethyl), phenyl or CF3) or S(O)2NR29R30 (wherein R29 and R30 are, independently, C1-4 alkyl (such as methyl)). In yet another aspect of the invention R1 is NHC(O)R14 wherein R14 is CM haloalkyl
(for example C1- fluoroalkyl, such as CH2CF3 or CH2CH2CF3), phenyl (optionally substituted by halo) or C3-6 cycloalkyl (substituted by one or two fluoros).
In a further aspect of the invention R1 is phenyl optionally substituted by S(O)2R39 (wherein R39 is C alkyl (such as methyl)). In a still further aspect of the invention R1 is heteroaryl (such as pyridinyl) optionally substituted by CF3.
In another aspect of the invention R1 is heterocyclyl (such as tetrahydropyran or tetrahy drothiopyran) .
In yet another aspect of the invention R2 is phenyl or heteroaryl, either of which is optionally substituted by halo, CM alkyl, CM alkoxy, S(O)n(C1-4 alkyl), nitro, cyano or CF3; wherein n is 0, 1 or 2, for example 0 or 2. When R2 is heteroaryl it is, for example an optionally substituted thiophenyl (that is, thienyl). In another aspect R2 is phenyl or thienyl, either of which is optionally substituted by halo (such as chloro or fluoro) or CF3.
In a still further aspect R2 is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF3), or optionally substituted (for example unsubstituted or mono-substituted) heteroaryl (such as optionally substituted by halo (such as chloro or fluoro), cyano, methyl, ethyl, methoxy, ethoxy or CF3).
In another aspect the invention provides a compound of the invention wherein R2 is optionally substituted (for example unsubstituted or substituted in the 2-, 3-, or 3- and 5- positions) phenyl (such as optionally substituted by halo (for example chloro or fluoro)). In yet another aspect the invention provides a compound of the invention wherein R2 is phenyl, 3 -fluorophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 3-chloro-5-fluorophenyl or 3,5- difluorophenyl. In a further aspect the invention provides a compound of the invention wherein R2 is phenyl, 3 -fluorophenyl, 3-chlorophenyl or 3,5-difluorophenyl. In yet another aspect of the invention R3 is hydrogen or methyl. In a further aspect of the invention when R3 is CM alkyl (such as methyl) and the carbon to which R3 is attached has the R absolute configuration. In yet another aspect of the invention R3 is hydrogen.
In a still further aspect the present invention provides a compound of the invention wherein R4 is optionally substituted phenyl (the optional substituents being selected from those recited above).
In another aspect the present invention provides a compound of the invention wherein R4 is optionally substituted aryl (such as phenyl) or optionally substituted heteroaryl (such as pyridyl, imidazolyl or 1,3,4-thiadiazolyl), (the optional substituents being selected from those recited above). In yet another aspect the present invention provides a compound of the invention wherein R4 is phenyl optionally substituted by one or more of halo, hydroxy, nitro, S(Cι-6 alkyl), S(O)(C1-6 alkyl), S(O)2(C1-6 alkyl), S(O)2NH2, S(O)2NH(d-6 alkyl), S(O)2N(C1-6 alkyl)2, cyano, C1-6 alkyl, CM alkoxy, CH2S(O)2(C1-6 alkyl), OS(O)2(C1-6 alkyl), OCH2heteroaryl (such as OCH2tetrazolyl), OCH2CO2H, OCH2CO2(C1-6 alkyl), OCH2C(O)NH2, OCH2C(O)NH(C1-6 alkyl), OCH2CN, NH2, NH(C1-6 alkyl), N(C1-6 alkyl)2, C(O)NH2, C(O)NH(Cι-6 alkyl), C(O)N(C1-6 alkyl)2, CO2H, CO2(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHC(O)O(C1-6 alkyl), NHS(O)2(C1-6 alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, heteroaryl or heteroaryl(Cι-4 alkyl); wherein the foregoing heteroaryl groups (such as tetrazolyl) are optionally substituted by halo, hydroxy, nitro, S(CM alkyl), S(O)(C1- alkyl), S(O)2(CM alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(C1-4 alkyl)2, cyano, CM alkyl, CM alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(CM alkyl), NHS(O)2(CM alkyl), CF3 or OCF3 {and in a further aspect of the invention the foregoing heteroaryl groups (such as tetrazolyl) are optionally substituted by d. 4 alkyl}.
In a further aspect the present invention provides a compound of the invention wherein R4 is phenyl optionally substituted by halogen (such as chloro or fluoro), cyano, C1- alkyl (mono-substituted by S(O)2(C1-4 alkyl) or C(O)NH(C1-4 alkyl), CM alkoxy, S(C1-4 alkyl), S(O)2(C1-4 alkyl), OS(O)2(C1-4 alkyl), OCH2COOH, OCH2-tetrazolyl (itself optionally substituted by C alkyl), carboxamide or tetrazolyl (itself optionally substituted by C alkyl).
In yet another aspect the present invention provides a compound of the invention wherein R4 is aryl or heteroaryl each being optionally substituted by OS(O)2R49 or C1-6 alkyl (mono-substituted by S(O)2R50 or C(O)NR51R52); wherein R49, R50, R51 and R52 are as defined above.
In a further aspect the present invention provides a compound of the invention wherein R4 is phenyl (optionally substituted by halogen (such as chloro or fluoro), cyano, C alkyl, CM alkoxy, S(C1-4 alkyl), S(O)2(C1-4 alkyl), OS(O)2(CM alkyl) or carboxamide), C3-7 cycloalkyl (such as cyclohexyl), pyridyl (optionally substituted by CM alkyl), imidazolyl (optionally substituted by C1-4 alkyl) or 1,3,4-thiadiazolyl (optionally substituted by C alkyl).
In a further aspect the present invention provides a compound of the invention wherein R4 is phenyl {optionally substituted by S(O)2(C1- alkyl) (such as CH3S(O)2, for example in the 4-position), C1-4 alkoxy (such as CH3O, for example in the 4-position), OS(O)2(C1-4 alkyl) (such as OSO2CH3, for example in the 4-position), halogen (such as chloro or fluoro) or cyano}.
In a still further aspect the invention provides a compound of the invention wherein A is absent. In another aspect the invention provides a compound of the invention wherein X is O or S(O)2. In yet another aspect X is S(O)2.
In a further aspect the invention provides a compound of the invention wherein m is 2 and n is 0 or n is 2 and m is 0. In a still further aspect the invention provides a compound of the invention wherein p is O.
In another aspect the invention provides a compound of the invention wherein X is O and m and n are not both 1. In yet another aspect the invention provides a compound of the invention wherein X is
S(O)2 and m and n are both 1.
In a further aspect the invention provides a compound of the invention wherein X is S(O)2, n is 2 and m is 0.
In a still further aspect the invention provides a compound of the invention wherein X is S(O)2, n is 0 and m is 2.
In another aspect the invention provides a compound of the invention wherein X is O and m and n are both 1.
In a still further aspect the present invention provides a compound of formula (la):
Figure imgf000018_0001
wherein X is as defined above; Y is CH or N; R >4a is as defined for optional substituents on optionally substituted phenyl (above); and Rla is mono-substituted by Cι-6 alkyl, C3- cycloalkyl, phenyl {optionally substituted by halo (for example fluoro), CM alkyl (for example methyl), C1-4 alkoxy (for example methoxy), CF3 or OCF3}, S(O)2(Cι-4 alkyl) (for example S(O)2CH3, S(O)2CH2CH3 or S(O)2CH(CH3)2), S(O)2(C1-4 fluoroalkyl) (for example S(O)2CF3 or S(O)2CH2CF3), S(O)2phenyl {optionally substituted (such as mono-substituted) by halo (for example chloro), cyano, CM alkyl, C alkoxy, CF3, OCF3, S(O)2(C1-4 alkyl) (for example S(O)2CH3 or S(O)2CH2CH2CH3) or S(O)2(C1-4 fluoroalkyl) (for example S(O)2CH2CF3)}, benzyl {optionally substituted by halo (for example chloro or fluoro), CM alkyl, CM alkoxy (for example methoxy), CF3 or OCF3}, C(O)H, C(O)(C1-4 alkyl), benzoyl {optionally substituted by halo (for example chloro or fluoro), CM alkyl (for example methyl), CM alkoxy, CF3 or OCF3}, C(O)2(C1-4 alkyl), C(O)NH2, C(O)NH(C1-4 alkyl) or C(O)NHphenyl {optionally substituted by halo (for example fluoro), C alkyl, C1-4 alkoxy, CF3 or OCF3}. Rla can also be S(O)2N(C1-4 alkyl)2.
In another aspect the present invention provides a compound of formula (lb):
Figure imgf000019_0001
wherein X, Y, Rla and R4a are as defined above.
In yet another aspect the present invention provides a compound of formula (Ic): r-|1
Figure imgf000019_0002
wherein X, Y, Rla and R4a are as defined above, and R2a is hydrogen, one or two halogen atoms (for example selected from chlorine and fluorine) or CF3. In another aspect of the invention R2a is hydrogen.
In a further aspect the present invention provides a compound of formula (Id):
Figure imgf000019_0003
wherein R14 and R4a are as defined above.
In a still further aspect the present invention provides a compound of formula (Ie):
Figure imgf000020_0001
wherein R2 and R4a are as defined above.
In another aspect the present invention provides a compound of formula (If):
Figure imgf000020_0002
wherein Y, Rla, R2a and R4a are as defined above.
In yet another aspect the present invention provides a compound of formula (Ig):
Figure imgf000020_0003
wherein R14 and R4a are as defined above.
In a further aspect the present invention provides a compound of formula (Ih):
Figure imgf000020_0004
wherein R2a and R4a are as defined above.
In a still further aspect the present invention provides a compound of formula (Ii):
Figure imgf000021_0001
wherein R1, R2a and R4a are as defined above.
In another aspect the present invention provides a compound of formula (Ij):
Figure imgf000021_0002
wherein R2a and R4 are as defined above.
In yet another aspect the present invention provides a compound of formula (Ik):
Figure imgf000021_0003
wherein R1, R a and R4a are as defined above.
In a further aspect the present invention provides a compound of foπnula (II):
Figure imgf000021_0004
wherein R1, R2a and R4 are as defined above. In a still further aspect the present invention provides a compound of formula (Im):
Figure imgf000022_0001
wherein R a and R a are as defined above.
In another aspect the present invention provides a compound of formula (In):
Figure imgf000022_0002
wherein R1, R2a and R4a are as defined above.
In yet another aspect of the invention there is provided a compound of formula (la), (lb), (Ic) or (If) wherein Rla is S(O)2(C1-4 alkyl), S(O)2(CM haloalkyl), S(O)2(phenyl), S(O)2N(C1-4 alkyl)2 or phenyl. In yet another aspect of the invention there is provided a compound of formula (Ic),
(If), (Ih), (Ii), (Ij), (Ik), (Im) or (In) wherein R2a is hydrogen, one or two halo (such as one chloro, one fluoro, one chloro and one fluoro or two fluoro) or CF3. R2a is, for example in the 2-, 3-, or 3- and 5- positions on the phenyl ring.
In another aspect of the invention there is provided a compound of formula (la), (lb), (Ic), (Id), (If), (Ig), (Ih), (Ii), (Ik), (Im) or (In) wherein R4a is in the 4-position on the phenyl ring.
In a further aspect of the invention there is provided a compound of formula (la), (lb), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ik), (Im) or (In) wherein R4a is one or more of halo, hydroxy, nitro, S(C1-6 alkyl), S(O)(C1-6 alkyl), S(O)2(C1-6 alkyl), S(O)2NH2, S(O)2NH(d.6 alkyl), S(O)2N(Cι-6 alkyl)2, cyano, C1-6 alkyl, CM alkoxy, CH2S(O)2(C1-6 alkyl), OS(O)2(d.6 alkyl), OCH2heteroaryl (such as OCH2tetrazolyl), OCH2CO2H, OCH2CO2(d-6 alkyl), OCH2C(O)NH2, OCH2C(O)NH(C1-6 alkyl), OCH2CN, NH2, NH(C1-6 alkyl), N(C1-6 alkyl)2, C(O)NH2, C(O)NH(C1-6 alkyl), C(O)N(C1-6 alkyl)2, CO2H, CO2(d.6 alkyl), NHC(O)(C1-6 alkyl), NHC(O)O(C1.6 alkyl), NHS(O)2(C1-6 alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, heteroaryl or heteroaryl(Cι-4 alkyl); wherein the foregoing heteroaryl group (such as tetrazolyl) are optionally substituted by halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1- alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(CM alkyl)2, cyano, C alkyl, CM alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(CM alkyl), CF3 or OCF3 {and in a further aspect of the invention the foregoing heteroaryl groups (such as tetrazolyl) are optionally substituted by d. 4 alkyl}.
In a still further aspect of the invention there is provided a compound of formula (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im) or (In) wherein R4a is halogen (such as chloro or fluoro), cyano, CM alkyl, CM alkoxy, S(C1-4 alkyl), S(O)2(C1-4 alkyl), OS(O)2(C1- alkyl) or carboxamide.
The compounds listed in Tables I to XTV illustrate the invention.
Table I
Table I comprises compounds of formula (la)
,1
R'
Figure imgf000024_0001
Figure imgf000024_0002
Figure imgf000025_0002
Table II
Table II comprises compounds of formula (lb)
Figure imgf000025_0001
Figure imgf000026_0003
Figure imgf000026_0001
Table III
Table III comprises compounds of formula (Ic)
Figure imgf000026_0002
Figure imgf000026_0004
Figure imgf000027_0001
Figure imgf000027_0002
Figure imgf000028_0001
Figure imgf000028_0002
Table IV
Table IV comprises compounds of formula (Id)
Figure imgf000029_0001
Figure imgf000029_0002
Table V
Table V comprises compounds of formula (le)
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000031_0001
Figure imgf000031_0002
Table VI
Table VI comprises compounds of formula (If)
Figure imgf000032_0001
Figure imgf000032_0002
Table VII
Table VII comprises compounds of formula (Ig):
Figure imgf000033_0001
Figure imgf000033_0003
Table VIII
Table VIII comprises compounds of formula (Ih):
Figure imgf000033_0002
Figure imgf000033_0004
Figure imgf000034_0001
Figure imgf000034_0003
Table IX
Table IX comprises compounds of formula (Ii):
Figure imgf000034_0002
Figure imgf000034_0004
Table X
Table X comprises compounds of formula (Ij):
Figure imgf000035_0001
Figure imgf000035_0002
Table XI
Table XI comprises compounds of
Figure imgf000036_0001
Figure imgf000036_0002
Figure imgf000037_0001
Figure imgf000037_0003
Table XII
Table XII comprises compounds of formula (II):
Figure imgf000037_0002
Figure imgf000037_0004
Figure imgf000038_0001
Figure imgf000038_0003
Table XIII
Table XIII comprises compounds of formula (Im):
Figure imgf000038_0002
Figure imgf000038_0004
Table XIV
Table XIV comprises compounds of foπnula (In):
Figure imgf000039_0001
Figure imgf000039_0002
In yet another aspect the invention provides each individual compound listed in the tables above.
The compounds of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) and (In) are all compounds of the invention can be prepared as shown below.
A compound of the invention wherein R1 is an N-linked optionally substituted heterocycle can be prepared by reacting a compound of formula (II):
Figure imgf000040_0001
wherein R2, R3, R4, m, n, A and X are as defined above, with a compound R1H (wherein the H is on a heterocycle ring nitrogen atom) wherein R1 is as defined above, in the presence of a suitable base (for example a tri(C1-6 alkyl)amine such as triethylamine or Hunig's base), in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) and, for example, at a room temperature (for example 10-30°C), optionally in the presence of sodium iodide.
A compound of the invention, wherein R3 is hydrogen, can be prepared by coupling a compound of formula (III) :
Figure imgf000040_0002
wherein R >4 , m, n, A and X are as defined above, with a compound of formula (IV):
Figure imgf000040_0003
wherein R1 and R2 are as defined above, in the presence of NaBH(OAc)3 (wherein Ac is C(O)CH3) in a suitable solvent (such as a chlorinated solvent, for example dichloromethane) at room temperature (for example 10-30°C).
A compound of the invention, wherein R3 is hydrogen, can be prepared by coupling a compound of formula (III):
— (CH2) -X-(CH2)m-R4 ON)
wherein R4, m, n, A and X are as defined above, with a compound of formula (V):
Figure imgf000041_0001
wherein R1 and R2 are as defined above and L is a leaving group such as halogen, tosylate, mesylate or triflate, in the presence of a base, such as potassium carbonate, in a suitable solvent (such as dioxane, acetonitrile or isopropanol) at temperatures from 60°C up to the boiling point of the solvent.
Alternatively, compounds of the invention can be prepared according to Schemes 1-7 (below).
Alternatively, compounds of the invention can be prepared by using or adapting methods described in WO01/87839, EP-A1-1013276, WO00/08013, WO99/38514, WO99/04794, WOOO/76511, WOOO/76512, WOOO/76513, WOOO/76514, WOOO/76972 or US 2002/0094989.
The starting materials for these processes are either commercially available or can be prepared by literature methods, adapting literature methods or by following or adapting Methods herein described. In a still further aspect the invention provides processes for preparing the compounds of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) and (In). Many of the intermediates in the processes are novel and these are provided as further features of the invention.
The compounds of the invention have activity as pharmaceuticals, in particular as modulators (such as agonists, partial agonists, inverse agonists or antagonists) of chemokine receptor (such as CCR5) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)). The compounds of the present invention are also of value in inhibiting the entry of viruses (such as human immunodeficiency virus (HTV)) into target calls and, therefore, are of value in the prevention of infection by viruses (such as HIV), the treatment of infection by viruses (such as HIV) and the prevention and/or treatment of acquired immune deficiency syndrome (AIDS). According to a further feature of the invention there is provided a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), m) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).
According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (such as CCR5 receptor activity) in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof or a solvate thereof.
The present invention also provides the use of a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, as a medicament, such as a medicament for the treatment of transplant rejection, respiratory disease, psoriasis or rheumatoid arthritis (such as rheumatoid arthritis). [Respiratory disease is, for example, COPD, asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)} or rhinitis {acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis} ; and is particularly asthma or rhinitis] .
In another aspect the present invention provides the use of a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).
The invention also provides a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament, such as a medicament for the treatment of rheumatoid arthritis.
In another aspect the present invention provides the use of a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (such as CCR5 receptor activity (such as rheumatoid arthritis)) in a warm blooded animal, such as man).
The invention further provides the use of a compound of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:
(1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung or idiopathic interstitial pneumonia;
(2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
(3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis; (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
(5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
(6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle; in a warm blooded animal, such as man.
The present invention further provides a method of treating a chemokine mediated disease state (such as a CCR5 mediated disease state) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or solvate thereof.
In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR5 receptor) activity, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Hi), (Ii), (Ij), (Ik), (II), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will, for example, comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 to 70 %w, such as from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.
A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1 mg and 1 g of active ingredient.
In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.
Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of O.Olmgkg*1 to lOOmgkg'1 of the compound, for example in the range of O.lmgkg"1 to 20mgkg"1 of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (H), (Im) or (In) (for example a compound of formula (I), (la), (lb), (Ic), (Id) or (le)), or a pharmaceutically acceptable salt thereof or a solvent thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:
(a)
Figure imgf000046_0001
(e)
Figure imgf000047_0001
Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β- cyclodextrin may be used to aid formulation.
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
The invention further relates to combination therapies or compositions wherein a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, is administered concurrently (possibly in the same composition) or sequentially with an agent for the treatment of any one of the above disease states. In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis a compound of the invention can be combined with a TNF-α inhibitor (such as an anti-TNF monoclonal antibody (such as Remicade, CDP-870 and D.sub2.E.sub7.), or a TNF receptor immunoglobulin molecule (such as Enbrel.reg.)), a non-selective COX-1 / COX-2 inhibitor (such as piroxicam or diclofenac; a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen; a fenamate such as mefenamic acid, indomethacin, sulindac or apazone; a pyrazolone such as phenylbutazone; or a salicylate such as aspirin), a COX-2 inhibitor (such as meloxicam, celecoxib, rofecoxib, valdecoxib or etoricoxib) low dose methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine or auranofm, or parenteral or oral gold.
The present invention still further relates to the combination of a compound of the invention together with:
• a leukotriene biosynthesis inhibitor, a 5-liρoxygenase (5-LO) inhibitor or a 5- lipoxygenase activating protein (FLAP) antagonist, such as zileuton, ABT-761, fenleuton, tepoxalin, Abbott-79175, Abbott-85761 , an N-(5-substituted)-thiophene-2- alkylsulfonamide, a 2,6-di-tert-butylphenol hydrazones, a methoxytetrahydropyran such as Zeneca ZD-2138, SB-210661, a pyridinyl-substiruted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; an indole or quinoline compound such as MK-591, MK-886 or BAY x 1005; • a receptor antagonist for a leukotriene LTB.sub4., LTC.sub4., LTD.sub4. or
LTE.sub4. selected from the group consisting of a phenothiazin-3-one such as L- 651,392; an amidino compound such as CGS-25019c; a benzoxalamine such as ontazolast; a benzenecarboximidamide such as BIIL 284/260; or a compound such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro- 245913, iralukast (CGP 45715A) or BAY x 7195;
• a PDE4 inhibitor including an inhibitor of the isoform PDE4D;
• an antihistaminic H.subl. receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine or chlorpheniramine;
• a gastroprotective H.sub2. receptor antagonist; • an α.subl.- and α.sub2.-adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride or ethylnorepinephrine hydrochloride;
• an anticholinergic agent such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
• a β.subl.- to β.sub4.-adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate or pirbuterol, or a methylxanthanine including theophylline and aminophylline; sodium cromoglycate; or a muscarinic receptor (Ml, M2, and M3) antagonist;
• an insulin-like growth factor type I (IGF-1) mimetic;
• an inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate or mometasone furoate; • an inhibitor of a matrix metalloprotease (MMP), such as a stromelysin, a collagenase, or a gelatinase or aggrecanase; such as collagenase-1 (MMP-1), collagenase-2 (MMP- 8), collagenase-3 (MMP- 13), stromelysin- 1 (MMP-3), stromelysin-2 (MMP- 10), and stromelysin-3 (MMP-11) or MMP-12; • a modulator of chemokine receptor function such as CCR1 , CCR2, CCR2 A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX3CR1 for the C-X3-C family; • an osteoporosis agent such as roloxifene, droloxifene, lasofoxifene or fosomax;
• an immunosuppressant agent such as FK-506, rapamycin, cyclosporine, azathioprine or methotrexate;
• a compound useful in the treatment of AIDS and/or HIV infection for example: an agent which prevents or inhibits the viral protein gpl20 from engaging host cell CD4 {such as soluble CD4 (recombinant); an anti-CD4 antibody (or modified / recombinant antibody) for example PRO 542; an anti-group 120 antibody (or modified / recombinant antibody); or another agent which interferes with the binding of groupl20 to CD4 for example BMS806}; an agent which prevents binding to a chemokine receptor, other than CCR5, used by the HTV virus {such as a CXCR4 agonist or antagonist or an anti-CXCR4 antibody} ; a compound which interferes in the fusion between the HIV viral envelope and a cell membrane {such as an anti- group 41 antibody; enfuvirtide (T-20) or T-1249}; an inhibitor of DC-SIGN (also known as CD209) {such as an anti-DC-SIGN antibody or an inhibitor of DC-SIGN binding}; a nucleoside/nucleotide analogue reverse transciptase inhibitor {for example zidovudine (AZT), nevirapine, didanosine (ddl), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir, adefovir or tenofovir (for example as free base or as disoproxil fumarate)}; a non-nucleoside reverse transciptase inhibitor {for example nevirapine, delavirdine or efavirenz}; a protease inhibitor {for example ritonavir, indinavir, saquinavir (for example as free base or as mesylate salt), nelfinavir (for example as free base or as mesylate salt), amprenavir, lopinavir or atazanavir (for example as free base or as sulphate salt)}; a ribonucleotide reductase inhinbitor {for example hydroxyurea}; or an antiretroviral {for example emtricitabine}; or,
• an existing therapeutic agent for the treatment of osteoarthritis, for example a non- steroidal anti-inflammatory agent (hereinafter NSAID's) such as piroxicam or diclofenac, a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen, a fenamate such as mefenamic acid, indomethacin, sulindac or apazone, a pyrazolone such as phenylbutazone, a salicylate such as aspirin, a COX-2 inhibitor such as celecoxib, valdecoxib, rofecoxib or etoricoxib, an analgesic or intra-articular therapy such as a corticosteroid or a hyamronic acid such as hyalgan or synvisc, or a P2X7 receptor antagonist.
The present invention still further relates to the combination of a compound of the invention together with: (i) a tryptase inhibitor; (ii) a platelet activating factor (PAF) antagonist; (iii) an interleukin converting enzyme (ICE) inhibitor; (iv) an IMPDH inhibitor; (v) an adhesion molecule inhibitor including a VLA-4 antagonist; (vi) a cathepsin; (vii) a MAP kinase inhibitor; (viii) a glucose-6 phosphate dehydrogenase inhibitor; (ix) a kinin- B.subl. - and B.sub2. -receptor antagonist; (x) an anti-gout agent, e.g., colchicine; (xi) a xanthine oxidase inhibitor, e.g., allopurinol; (xii) an uricosuric agent, e.g., probenecid, sulfinpyrazone or benzbromarone; (xiii) a growth hormone secretagogue; (xiv) a transforming growth factor (TGFβ); (xv) a platelet-derived growth factor (PDGF); (xvi) a fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) a granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) a capsaicin cream; (xix) a TachykininNK.subl. and NK.sub3. receptor antagonist selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) an elastase inhibitors selected from the group consisting of UT- 77 and ZD-0892; (xxi) a TNFα converting enzyme inhibitor (TACE); (xxii) an induced nitric oxide synthase inhibitor (iNOS); or (xxiii) a chemoattractant receptor-homologous molecule expressed on TH2 cells (a CRTH2 antagonist).
The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C; (ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
(iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column is referred to, this means a column containing lOg or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI". Where an "Isolute™ SCX column" is referred to, this means a column containing benzenesulphonic acid (non-endcapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK. Where "Argonaut™ PS-trz's-amine scavenger resin" is refeπed to, this means a t -(2-aminoethyl)amine polystyrene resin obtained from Argonaut Technologies Inc., 887 Industrial Road, Suite G, San Carlos, California, USA.
(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
(v) yields, when given, are for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
(vi) when given, 1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio DMSO (CD3SOCD3) as the solvent unless otherwise stated; coupling constants (J) are given in Hz; (vii) chemical symbols have their usual meanings; SI units and symbols are used; (viii) solvent ratios are given in percentage by volume; (ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (APCI) mode using a direct exposure probe; where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)+; (x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)+; (xi) PS-NCO resin is an isocyanate resin and is available from Argonaut; (xii) Powder X-Ray Diffractometry (PXRD) analyses were performed using a Siemens D5000. The X-ray powder diffraction spectra were determined by mounting a sample of the crystalline salt on Siemens single silicon crystal (SSC) wafer mounts and spreading out the sample into a thin layer with the aid of a microscope slide. The sample was spun at 30 revolutions per minute (to improve counting statistics) and irradiated with X-rays generated by a copper long-fine focus tube operated at 40kV and 40mA with a wavelength of 1.5406 angstroms. The collimated X-ray source was passed through an automatic variable divergence slit set at V20 and the reflected radiation directed through a 2mm antiscatter slit and a 0.2mm detector slit. The sample was exposed for 1 second per 0.02 degree 2-theta increment (continuous scan mode) over the range 2 degrees to 40 degrees 2-theta in theta- theta mode. The running time was 31 minutes and 41 seconds. The instrument was equipped with a scintillation counter as detector. Control and data capture was by means of a Dell Optiplex 686 NT 4.0 Workstation operating with Diffract+ software. Persons skilled in the art of X-ray powder diffraction will realise that the relative intensity of peaks can be affected by, for example, grains above 30 microns in size and non-unitary aspect ratios which may affect analysis of samples. The skilled person will also realise that the position of reflections can be affected by the precise height at which the sample sits in the diffractometer and the zero calibration of the diffractometer. The surface planarity of the sample may also have a small effect.; and,
(xiii) the following abbreviations are used: THF tetrahydrofuran;
Boc tert-butoxycarbonyl
DMF N,N-dimethylformamide
DCM dichloromethane
DIPEA N,N-Diisopropylethylamine R-BINAP R 2,2'-Bis(diρhenylphosρhino)-l,l'-binaphthyl
HATU O-(7- Azabenzotriazol- 1 -yl)-N,NN',N-teframethyluronium hexafluorophosphate EDCI ethyl dimethylaminopropyl carbodiimide
HOBT 1 -hydroxybenzotriazole
Example 1
This Example illustrates the preparation of N-(3-phenyl-3-[4- methanesulphonylpiperazin-l-yl]propyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]- piperidine (Compound No. 8, Table I).
Figure imgf000053_0001
N-(3-Phenyl-3-chloropropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]- piperidine (prepared according to Method D; 180mg) was added to a solution of N- methanesulphonylpiperazine (61mg) and triethylamine (0.102ml) in dichloromethane (10ml) and the mixture was allowed to stand at room temperature for 16 hours. The reaction mixture was poured onto a 20g silica Bond Elut eluted with a solvent gradient (ethyl acetate - 25% methanol/ethyl acetate). The title compound was obtained, yield 67mg, MH1" 612.
NMR (CDC13): 1.6-1.8 (m, 7H), 2.2-2.6(m, 9H), 2.7(m, IH), 2.75 (s, 3H), 3.2 (m, 11H), 3.45 (m, IH), 7.2 (d, 2H), 7.3 (m, 3H), 8.2 (m, 4H).
Example 2
This Example illustrates the preparation of N-(3-phenyl-3-[l-methanesulphonyl- piperidin-4-yl]propyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]piperidine (Compound No. 10, Table I).
Figure imgf000053_0002
Sodium triacetoxyborohydride (267 mg) was added to a mixture of 3-(l- methanesulphonylpiperidin-4-yl)-3-phenylpropionaldehyde (247 mg) and 4-(2-[4- fluorophenylsulphonyl]ethyl)piperidine hydrochloride salt (288 mg) (CAS 313994-09-1) in dichloromethane (20 ml) and the mixture was stirred for 16 hours. The reaction mixture was washed successively with 2M sodium hydroxide (10 ml), water (10 ml) and brine (10 ml) and was dried. The residue obtained on removal of the solvent was chromatographed on a 20g silica Bond Elut column eluting with a solvent gradient (ethyl acetate - 20% methanol/ethyl acetate) to give the title compound, yield 250mg, MH+ 551. NMR (CDC13): 1.2 (m, 5H), 1.4 (m, 4H), 1.6-1.8 (m, 8H), 2.0 (m, 3H), 2.4 (m, IH),
2.5-2.6 (m, 2H), 2.8 (s, 3H), 2.85 (m, 2H), 3.1 (m, 2H), 3.7 (d, 1 H), 3.85 (d, IH), 7.1 (m, 2H), 7.3 (m, 5H), 7.9 (m, 2H).
Example 3 This Example illustrates the preparation of (S) N-(3-phenyl-3-[4-chlorobenzoyl- amino]propyl-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]piperidine (Compound No. 2, Table TV).
Figure imgf000054_0001
4-Chlorobenzoyl chloride (76μl) was added to a solution of (S) N-(3-amino-3- phenylpropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]piperidine (280mg) and triethylamine (157μl) in dichloromethane (15ml) and the mixture was stirred for 1 hour then washed with water (15ml) and brine (15ml) and dried. Removal of the solvent gave the title compound as a white solid, yield 320mg, MH1" 602.
NMR (do DMSO): 1.0 (m, 2H), 1.2 (m, IH), 1.5 (m, 2H), 1.6 (m, 2H), 1.8 (m, 2H), 1.9 (m, 2H), 2.25 (m, 2H), 2.8 (m, 2H), 3.3 (m,3H), 3.4 m, 2H), 5.0 (q, IH), 7.2 (m, IH), 7.3 (m,3H), 7.5 (d, 2H), 7.85 (d, 2H), 8.2 (m, 4H), 8.9 (d, IH).
Example 4 This Example illustrates the preparation of l-{(3i-)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl} -4-(2- {[4-(methylsulfonyl)phenyl]sulfonyl} ethyl)piperidine (Compound No. 7, Table V).
Figure imgf000055_0001
(i?)-3-(3,5-Difluorophenyl)-3-(4-methanesulfonylphenyl)propionaldehyde (0.357 g, 1.1 mmol; Method E) was dissolved in dichloromethane (3 ml) at room temperature and 4-[2- (4-methanesulphonylphenyl-sulphonyl)ethyl]piperidine hydrochloride (0.368 g, 1 mmol; Method B) was added as a single portion. After stirring for 0.5 h, sodium triacetoxyborohydride (0.211 g, 1 mmol) was added as a single portion and the reaction stirred for a further lh. The mixture was then washed with saturated aqueous sodium hydrogen carbonate, the organics were separated and poured directly onto an SCX column. Eluting with methanol followed by 20% 7M ammonia in methanol gave the product (0.319 g, 50%) as a white solid.
NMR: (d6-DMSO): 1.05 (m, 2H), 1.15 (m, IH), 1.6 (m, 4H), 1.8 (br t, 2H), 2.2 (m, 2H), 2.3 (m, 2H), 2.8 (br d, 2H), 3.4 (m, 6H), 3.5 (m, 2H), 4.3 (br t, IH), 7.1 (br t, IH), 7.2 (d, 2H), 7.7 (d, 2H), 7.9 (d, 2H), 8.3 (m, 4H).
LCMS: 640.2 (MH*).
Example 5 This Example illustrates the preparation of (R or S) N-(3-[4- methanesulphonylpiperazinyl]-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]- piperidine (Compound 14, Table III).
Figure imgf000055_0002
A solution of (R or S) N-(3-chloro-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)- ethyl] -piperidine (Method F; 310 mg) in dichloromethane (6 ml) was added to N- methanesulphonyl-piperazine hydrochloride (150 mg) followed by triethylamine (313 μl). The mixture was stirred for 48 hours, diluted with dichloromethane (5 ml) and MP-carbonate resin (1.34g), PS-isocyanate resin (682 mg) and PS-thiophenol resin (577 mg) were added. The mixture was stirred for 5 hours, filtered and the resins were washed with 10% methanol in dichloromethane (2x25 ml). The combined filtrates were evaporated to dryness and the residue was passed through a 20g Isolute column eluted with a solvent gradient of ethyl acetate-10% methanol/ethyl acetate to give the title compound, yield 81 mg; MH1" 552.
NMR (CDC13): 1.12-1.32 (m, 4H), 1.52-1.66 (m, 4H), 1.76-1.93 (m, 3H), 2.08 (m, IH), 2.21 (m, IH), 2.47-2.51 (m, 4H), 2.71 (s, 3H), 2.77-2.88 (m, 2H), 3.03-3.10 (m, 2H), 3.12-3.21 (m, 4H), 3.37 (m, IH), 7.14 (d, 2H), 7.15-7.32 (m, 5H), 7.88 (m, 2H).
Example 6
This Example illustrates the preparation of (R) N-(3-[3,5-difluorophenyl]-3-[l- methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-methanesulphonylphenylsulphonyl)- ethyl]piperidine (Compound 32 in Table III).
Figure imgf000056_0001
MP-triacetoxyborohydride (where MP stands for "macroporous"; 585 mg) was added to a solution of (R) 3-(l-methanesulphonylpiperidin-4-yl)-3-[3,5- difluorophenyl]propionaldehyde (199 mg) (Method G) and 4-(2-[4- methanesulphonylphenylsulphonyl]ethyl)piperidine (194 mg) (Method B) in 20 ml of dichloromethane and the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered and the solid washed with dichloromethane (3x10 ml) and the combined dichloromethane filtrate and washings were poured onto a 25g bond Elut cartridge and eluted with a solvent gradient (ethyl acetate - 20% methanol/ethyl acetate) to give the title compound, yield 168 mg; MH+ 647. NMR (DMSOdό) [note not all peaks are reported]: 2.78 (s, 3H), 6.87 (d, 2H), 6.99 (t, IH), 8.14 (q, 4H). Example 7 This Example illustrates the preparation of (R) N-(3-phenyl-3-[l- methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-methanesulphonyloxyphenylsulphonyl)- ethyl]piperidine (Compound 29 in Table III).
Figure imgf000057_0001
Methanesulphonyl chloride (60.3 mg) was added to a solution of (R) N-(3-phenyl-3- [l-methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-hydroxyphenylsulphonyl)ethyl]piperidine (Compound 28 in Table III; 290 mg) and triethylamine (53 mg) in dichloromethane (10 ml) and the mixture was stirred for 16 hours, then washed with saturated aqueous sodium bicarbonate (2x20 ml) and dried. The drying agent was filtered and the filtrate was poured onto a 20g Bond Elut cartridge and eluted with a solvent gradient (ethyl acetate - 20% methanol ethyl acetate) to give the product, yield 41.5 mg. NMR (DMSOdό) [note not all peaks are reported]: δ 2.77 (s, 3H), 7.11-7.23 (m, 3H), 7.30 (t, 2H), 7.60 (d, 2H), 8.0 (d, 2H).
Example 8
This Example illustrates the preparation of (R) N-(3 -phenyl-3 - [ 1 -methanesulphonyl- piperidin-4-yl]proρyl)-4-[2-(4-tetrazol-5-yl-phenylsulphonyl)ethyl]piperidine (Compound 30 in Table III).
Figure imgf000057_0002
Ammonium chloride (67 mg) and sodium azide (81.6 mg) were added to a solution of
(R) N-(3-phenyl-3-[l-methanesulphonylpiperidin-4-yl]propyl)-4-[2-(4-cyanophenyl- sulphonyl)ethyl]piperidine (350 mg; prepared by the method described in Example 6 using 4- (2-[4-cyanophenylsulphonyl]ethyl)piperidine [Method B] as reactant) in DMF (10 ml) and the mixture was heated at 100°C for 8 hours. Further equivalents of ammonium chloride (67 mg) and sodium azide (81.6 mg) were added and the mixture was heated at 100°C for a further 8 hours. The solvent was evaporated and the residue was stirred with water (10 ml). The water was decanted and the residue was dissolved in methanol (10 ml) and poured on to a 20g SCX2 cartridge eluted with methanol (4x20 ml) and IM ammonia/methanol. The ammonia/methanol washings were evaporated to dryness to give the title compound, yield 140mg, MH+ 601. NMR (DMSOd6) [note not all peaks are reported]: 52.77 (s, 3H), 7.04- 7.25 (m, 3H), 7.30 (t, 2H), 7.85 (d, 2H), 8.18 (d, 2H).
Example 9 Preparation of (4- {[2-(l- {(3i?)-3-(3,5-difiuorophenyl)-3-[4- (methylsulfonyl)ρhenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetonitrile (Compound 15 of Table V ) and 2-(4-{[2-(l-{(3i?)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetamide (Compound 16 of Table V ).
Figure imgf000058_0001
{4-[(2-Piperidin-4-ylethyl)sulfonyl]phenoxy} acetonitrile (0.9g, Method M) was dissolved in a solution of (R)-3-(3,5-difluorophenyl)-3-(4rmethanesulphonylphenyl)- propionaldehyde (0.85g) in dichloromethane (50 ml) and sodium triacetoxyborohydride (0.55g) was added. The reaction mixture was stirred for 16 hours, washed with 2M NaOH (2x50 ml), dried and evaporated to dryness. The residue obtained was purified by chromatography on a Bond-Elut column using an elution gradient of ethyl acetate - 30% methanol/ethyl acetate to give the title compound, yield 370 mg.
NMR (DMSOdό): 0.9-1.8 (m, 10H), 2-2.3 (m, 5H), 2.7 (m, 2H), 3.1 (s, 3H), 4.2 (t, IH), 5.3 (s, 2H), 6.9-7.2 (m, 5H), 7.5-7.9 (m, 6H); M1H 617.
A second fraction was collected and shown to be 2-(4-{[2-(l-{(3R)-3-(3,5- difluoroρhenyl)-3-[4-(methylsulfonyl)phenyl]propyl}ρiperidin-4- yl)ethyl]sulfonyl}phenoxy)acetamide (Compound 16 of Table V), yield 168 mg. NMR (DMSOd6): 0.9-1.8 (m, 10H), 2-2.3 (m, 5H), 2.7 (m, 2H), 3.1 (s, 3H), 4.2 (t, IH), 4.65 (s, 2H), 6.9-7.2 (m, 5H), 7.4-7.9 (m, 6H); M*H 635.
Example 10 Preparation of 1- {(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}-4-
(2-{[4-(lH-tetrazol-5-ylmethoxy)phenyl]sulfonyl}ethyl)piperidine (Compound 17 of Table V)
Figure imgf000059_0001
A mixture of (4-{[2-(l-{(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)ρhenyl]- propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetonitrile (300 mg), sodium azide (63 mg) and ammonium chloride (52 mg) in DMF (10 ml) was stirred and heated at 100°C for 4 hours. The solvent was evaporated and the residue was dissolved in water (10 ml). Water was decanted from the oil obtained and the residual oil was dissolved in methanol (10 ml) and poured onto a 20g SCX2 cartridge and eluted with methanol (4x20 ml) and IM ammonia/methanol (5x20 ml). The methanolic ammoma washings were evaporated to give the title compound, yield 0.15g. M"Η 660. NMR (DMSOd6) [note not all peaks are reported]: δ 5.3 (s, 2H), 7.04 (t, IH), 7.09-7.18 (m, 2H), 7.26 (d, 2H), 7.59 (d, 2H), 7.75 (d, 2H), 7.84 (d, 2H).
Example 11
Preparation of l-{(3i?)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}-4- (2-{[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine (Compound 19 of Table V)
Figure imgf000059_0002
4-(2-{[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine (300 mg,
Method N) was added to a solution of (R)-3-(3,5-difluorophenyl)-3-(4-methanesulphonyl- phenyl)propionaldehyde (290 mg) dissolved in dichloromethane (20 ml) followed by MP- triacetoxyborohydride (900mg) and the reaction mixture was stirred for 16 hours, filtered and evaporated to dryness. The residue was purified by chromatography on a Bond-elut column using an eluant gradient of ethyl acetate- 15% methanol/ethyl acetate to give the title compound, yield 167 mg.
NMR (CDC ): 1.2-1.4 (m, 3H), 1.6-1.9 (m, 7H), 2.8 (m, 2H), 3.05 (s, 3H), 3.1 (m, 2H), 4.1 (m, IH), 4.05 (s, 3H), 6.7 (m, 3H), 7.4 (m, 2H), 7.85 (d, 2H), 8 (d, 2H), 8.39 (d, 2H), M1H 644.
Using the procedure outlined above and using (R)-3-(l-methanesulphonylpiperidin-4- yl)-3-phenylpropionaldehyde (Method G) as starting material there was obtained 1- (methylsulfonyl)-4-{(lR)-3-[4-(2-{[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)- piperidin-l-yl]-l-phenylpropyl}piperidine (Compound 20 of Table V), M1H 615.
Example 12
Preparation of methyl (4-{[2-(l-{(3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetate (Compound 27 of Table V)
Figure imgf000060_0001
The product obtained on the reductive amination of (3R)-3-(3,5-difluorophenyl)-3-[4-
(methylsulfonyl)phenyl]propanal (0.85g) with benzyl {4-[(2-piperidin-4- ylethyl)sulfonyl]phenoxy} acetate (l.lg; prepared according to Method M steps 1 and 2, using benzyl bromoacetate as starting material), carried out according to the method described in Example 4, was poured onto a 20g SCX2 column and eluted with methanol (5x20 ml) and 10% ammonia in methanol (5x20 ml). The methanolic ammonia washings were concentrated and the product isolated had undergone ester exchange with the methanol eluant. The title compound was obtained, yield 1.3g; M1H 650. NMR (CDCI3): 1.2 (m, 4H), 1.6 (m, 6H), 1.8 (t, 2H), 2.8 (m, 2H), 3.01 (s, 3H), 3.1 (m, 2H), 3.8 (s, 3H), 4.1 (m, IH), 4.7 (s, 2H), 6.6-6.8 (m, 3H), 7 (d, 2H), 7.4 (d, 2H), 7.8-7.9 (m, 4H).
Example 13 Preparation of (4-{[2-(l-{(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)ρhenyl]- propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetic acid (Compound 28 of Table V).
Figure imgf000061_0001
2MNaOH was added to a solution of methyl (4-{[2-(l-{(3R)-3-(3,5-difluorophenyl)- 3-[4-(methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetate (1.2g)
(Example 12) in a mixture of ethanol (20 ml) and THF (20 ml) and the mixture was stirred for 2 hours. The reaction mixture was evaporated to dryness and water (10 ml) was added. The solution was acidified to pH 3 with 2M HCI, the pH was adjusted to ~5 with sodium acetate and the mixture was extracted with dichloromethame (4x25 ml). The combined extracts were dried and evaporated to give the title compound, yield 0.9g. M1H 636.
NMR (CDC13) [note that not all peaks are reported]: 3.03 (s, 3H), 4.01 (t, IH), 4.48 (bs, 2H), 6.67 (t, IH), 6.73 (d, 2H), 7.40 (d, 2H), 7.73 (d, 2H), 7.86 (d, 2H).
Example 14 Preparation of 2-(4-{[2-(l-{(3i?)-3-(3,5-difluorophenyl)-3-[4-
(methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)-N-
(methylsulfonyl)acetamide (Compound 29 Table V)
Figure imgf000061_0002
EDCI was added to a solution of (4-{[2-(l-{(3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)acetic acid (400 mg), methanesulphonamide (59 mg) and dimethylaminipyridine (163 mg) in dichloromethane and the mixture was stirred for 20 hours. The mixture was washed with water (2x25 ml), dried and evaporated to dryness. The residue was passed through a Bond- Elut column eluting with a solvent gradient of ethyl acetate - 25% methanol/ethyl acetate to give the title compound as a white solid, yield 8.3 mg. M1H 713.
NMR (DMSOdό): [note that not all peaks are reported]: 4.18 (t, IH), 4.42 (s, 2H), 6.97-7.12 (m, 3H), 7.15 (d, 2H), 7.59 (d, 2H), 7.74 (d, 2H), 7.85 (d, 2H).
Example 15 Preparation of 2-(4-{[2-(l-{(3R)-3-(3,5-difluorophenyl)-3-[4-
(methylsulfonyl)phenyl]propyl}piperidin-4-yl)ethyl]sulfonyl}phenoxy)-N-methylacetamide (Compound 30 Table V).
Figure imgf000062_0001
A mixture of (4-{[2-(l-{(3R)-3-(3,5-difluoroρhenyl)-3-[4-(methylsulfonyl)ρhenyl]- propyl}ρiperidin-4-yl)ethyl]sulfonyl}phenoxy)acetic acid (400 mg), HOBT (85 mg) and EDCI (245 mg) in dichloromethane (25 ml) was stirred at room temperature for 1.5 hours. Methanolic ammonia (10 ml) was added and stirring was continued for 16 hours. The reaction mixture was washed with water (2x20 ml), dried and evaporated to dryness and the residue obtained was dissolved in dichloromethane (20 ml) and stireed with MP carbonate (lg) for 2 hours. The product was chromatograhed on a Bond-Elut column eluting with a solvent gradient of ethyl acetate- 10% methanol/ethyl acetate to give the title compound, yield 144 ' mg. M1H 649.
ΝMR (CDC13): 1.2 (m, 4H), 1.6 (m, 6H), 1.8 (t, 2H), 2.8 (m, 2H), 2.95 (d, 3H), 3.01 (s, 3H), 3.1 (m, 2H), 4.1 (m, IH), 4.6 (s, 2H), 6.5 (broad peak, IH), 6.6-6.8 (m, 3H), 7.05 (d, 2H), 7.4(d, 2H), 7.9 (m, 4H). Example 16 Preparation of 1-{(1S,3(R or S)-3-(3,5-difluorophenyl)-l-methyl-3-[4- (methylsulfonyl)phenyl]propyl}-4-(2-{[4-(methylsulfonyl)phenyl]sulfonyl}ethyl)piperidine and 1-{(1S,3(S or R)-3-(3,5-difluorophenyl)-l-methyl-3-[4-(methylsulfonyl)phenyl]propyl}- 4-(2-{[4-(methylsulfonyl)phenyl]sulfonyl}ethyl)piperidine
Figure imgf000063_0001
To stirred solution of (4i?)-4-(3,5-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]butan- 2-one (500mg) in THF (50ml) was added 2 equivalents of 4-(2-{[4-
(methylsulfonyl)ρhenyl]sulfonyl}ethyl)piperidine and 5ml titanium isopropoxide, then stirred for 1 hour at 20-25°C. Sodium tris-acetoxyborohydride (2.5 g) was then added and stirring continued for 16 hours, then 2N NaOH (10ml) was added and the organic layer decanted from the white precipitate. The inorganic solids were slurried again with THF and the combined organic layers were dried and evaporated. The crude product was subjected to chromatography on silica, eluting with ethyl acetate to give a pure sample of one of the diastereomers (yield 30 mg).
NMR (CDC13): 0.91 (d, 3H), 1.1-2.6 (m, 13H), 2.77 (m, IH), 3.04 (s, 3H), 3.12 (s, 3H), 3.16 (m, 2H), 4.25 (m, IH), 6.66 (t, IH), 6.76 (d, 2H), 7.40 (d, 2H), 7.86 (d, 2H), 8.12 (d, 2H), 8.18 (d, 2H).
Example 17
Preparation of the hydrochloride salt of l-{(3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl} -4-(2- {[4-(methylsulfonyl)phenyl]sulfonyl} ethyl)piperidine.
4M HCI in dioxane (0.08 ml) was added to a hot solution of l-{(3R)-3-(3,5- difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl} -4-(2- { [4-(methylsulfonyl)phenyl]- sulfonyl} ethyl)piperidine (0.2g) in ethanol (25 ml) and the solution was allowed to cool and stand at room temperature for 16 hours. The hydrochloride salt obtained was filtered and dried, yield 197 mg. A sample of the salt obtained was crystallized from ethanol, filtered and dried. PXRD of this compound is presented in Figure 1.
Example 18 Preparation of the maleate salt of l-{(3R)-3-(3,5-difluorophenyl)-3-[4-
(methylsulfonyl)phenyl]propyl} -4-(2- {[4-(methylsulfonyl)phenyl]sulfonyl} ethyl)piperidine. l-{(3R)-3-(3,5-Difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}-4-(2-{[4- (methylsulfonyl)phenyl]sulfonyl}ethyl)piperidine (3g) was dissolved in a mixture of ethyl acetate (50ml) and ethanol (25ml) at 50°C. Meanwhile maleic acid (0.6g) was dissolved in ethanol (25ml) at 50°C and, when both solutions were ready, the solution of maleic acid was poured into the solution of free base. The resulting mixture was stirred while allowing to cool and then filtered after lhour and the residue (title compound) washed with ethyl acetate. The residue was dired in a vacuum oven to leave the title compound (about 3.5g, approximately 95% yield). PXRD of this maleate salt is presented in Figure 2.
The succinate, malonate and fumarate salts of l-{(3J?)-3-(3,5-difluoroρhenyl)-3-[4- (memylsulfonyl)phenyl]propyl}-4-(2-{[4-(methylsulfonyl)phenyl]sulfonyl}ethyl)piperidine were prepared using the method of Example 18. The fumarate salt of l-{(3R)-3-(3,5- difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl}-4-(2-{[4- (methylsulfonyl)ρhenyl]sulfonyl}ethyl)ρiperidine was formed as a crystalline solid. The tartrate salt was formed as a gum.
PXRD of the succinate salt of l-{(3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propyl} -4-(2- {[4-(methylsulfonyl)phenyl]sulfonyl} ethyl)piperidine is presented in Figure 3. PXRD of the malonate salt of l-{(3R)-3-(3,5-difluorophenyl)-3-[4-
(methylsulfonyl)pheny fjpropyl} -4-(2- { [4-(methylsulfonyl)phenyl] sulfonyl} ethyl)piperidine is presented in Figure 4.
Preparation of certain intermediates is now presented in Methods A to U. Method A
(.S -3-Phenyl-3-(4-methanesulfonylphenyl)propionaldehyde
Figure imgf000065_0001
Step 1: Preparation of (4S, 5R)-l-[(S)-3-(4-methanesulfonyl-phenyl)-3-phenyl-propionyl]-3,4- dimethyl-5-phenyl-imidazolidin-2-one
Figure imgf000065_0002
To a mixture of copper (I) iodide (960mg, 5.0mmol) and THF (20mL) was added NNN',N'-tetramethylethylenediamine (0.83mL, 5.5mmol) and the resulting mixture was stirred at room temperature for lOmin. then cooled to -78°C. Phenylmagnesium bromide (5.OmL, IM in THF, 5.0mmol) was added and the resulting mixture stirred at -78°C for 15min. A solution of di-n-butylboron triflate (3. OmL, IM in diethyl ether, 3.0mmol) and (E)- (4S, 5R)-l-(3-[4-methanesulfonylphenyl]acryloyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (step 4 below), l.Og, 2.51mmol) in THF (15mL) was added and the resulting mixture was stirred whilst allowing to warm to room temperature for 18h. The reaction mixture was washed with saturated aqueous ammonium chloride, water and brine, dried (MgSO4) and evaporated. The residue was purified by eluting through a 20g Bond Εlut with gradient of isohexane to ethyl acetate giving the sub-titled compound (1.49g, 100%); ΝMR (CDC13): 0.78 (d, 3H), 2.82 (s, 3H), 3.00 (s, 3H), 3.78 (dd, IH), 3.80 (m, IH), 3.98 (dd, IH), 4.72 (m, IH), 5.19 (d, IH), 6.99 (m, 2H), 7.22 (m, 8H), 7.48 (d, 2H), 7.79 (d, 2H); MS: 477 (MH+).
Step 2: Preparation of (S)-3-phenyl-3-(4-methanesulphonylphenyl)propan-l-ol
To a solution of (4S, 5R)-l-[(S)-3-(4-methanesulphonyl-phenyl)-3-phenyl-propionyl]- 3,4-dimethyl-5-phenyl-imidazolidin-2-one (846mg, 1.78mmol) in THF (20mL) at 0°C was added lithium aluminium hydride (3.6mL, IM in THF, 3.6mmol) and the resulting mixture was stirred for 15min. The reaction was quenched by the addition of 2M aqueous sodium hydroxide. The phases were separated and the organic phase pre-absorbed onto a Bond Elut and eluted with a gradient of isohexane to ethyl acetate giving the sub-titled compound as a white solid (285mg, 55%); NMR (CDC13): 1.63 (br s, IH), 2.33 (m, 2H), 3.00 (s, 3H), 3.59 (t, 2H), 4.28 (t, IH), 7.23 (m, 5H), 7.43 (d, 2H), 7.82 (d, 2H).
Step 3: Preparation of the title compound
To a solution of (S)-3-phenyl-3-(4-methanesulfonylphenyl)propan-l-ol (244mg, 0.84mmol) in DCM (5mL) was added Dess-Martin periodinane (392mg, 0.92mmol) and the resulting mixture was stirred at room temperature for 1.5h. The mixture was washed with 2M aqueous sodium hydroxide (2 x lOmL), dried and evaporated to give the title compound.
Step 4: Preparation of E-(4S, 5R)-l-(3-[4-Methanesulphonylphenyl]acryloyl)-3,4-dimethyl-5- phenyl-imidazolidin-2-one
Figure imgf000066_0001
To a stirred solution of 3-(4-methanesulphonylphenyl)acrylic acid (7.14g, 31.5mmol) in DCM (lOmL) was added thionyl chloride (3mL, 34.7mmol) dropwise and the resulting mixture was stirred at room temperature for 18h. To this solution was added DIPΕA (5.04mL, 28.9mmol) dropwise at room temperature. The resulting solution was added to a stirred solution of (4R, 5S)-l,5-dimethyl-4-phenyl-imidazolidin-2-one (5.0g, 26.3mmol) in DCM (20mL) and DIPΕA (4.58mL, 26.9mmol) and the resulting mixture stirred at room temperature for 4h. The mixture was washed with water and brine, pre-absorbed onto a Bond Εlut and eluted with a gradient of isohexane to ethyl acetate giving the title compound as a solid (7.61g, 73%); NMR (CDC13): 0.84 (d, 3H), 2.89 (s, 3H), 3.04 (s, 3H), 3.98 (m, IH), 5.42 (d, IH), 7.20 (m, 2H), 7.32 (m, 3H), 7.69 (d, IH), 7.74 (d, 2H), 7.93 (d, 2H), 8.31 (d, IH); MS: 399 (MH+).
Method B 4-[2-(4-Methanesulphonylphenylsulphonyl)ethyl]piperidine
Figure imgf000067_0001
Step 1 Preparation of N-tert-butoxycarbonyl-4-[2-(4-methylthiophenylthio)ethyl]piperidine
Figure imgf000067_0002
4-Methylthiobenzenethiol (1.16g) was added to a suspension of sodium hydride
(297mg of 60% dispersion in mineral oil) in DMF (20ml) at 0°C and stirred at this temperature for 30 minutes. N-tert-Butoxycarbonyl-4-[2-(4-toluenesulphonyloxy)ethyl]- piperidine (CAS No. 89151-45-1) (2.84g) was added, the reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The reaction mixture was evaporated to dryness and the residue obtained was dissolved in dichloromethane (30 ml) and the solution was washed with water (20 ml) and brine (20 ml) and dried. The residue obtained on removal of the solvent was chromatographed on a 50g silica Bond Elut column eluting with a solvent gradient of isohexane - 50% ethyl acetate/isohexane. Yield 2.5g, MH+ 268.
Step 2 Preparation of N-tert-butoxycarbonyl-4-[2-(4-methylsulphonylphenylsulphonyl)ethyl]- piperidine.
Figure imgf000067_0003
m-Chloroperbenzoic acid (5.64g) was added to a solution of N-tert-butoxycarbonyl-4- [2-(4-methylthiophenylthio)ethyl]piperidine (2.1g) in dichloromethane (90 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The reaction mixture was washed with saturated aqueous sodium bicarbonate solution (20 ml), water (20 ml) and brine (20 ml) then dried and evaporated to dryness. The product was chromatographed on a 50g silica Bond Elut column eluting with a solvent gradient of 20% ethyl acetate/isohexane - ethyl acetate to give the product, yield 1.82g, MH1" 375.9.
Step 3 Preparation of title compound Variant A
Trifluoroacetic acid (5 ml) was added to a solution of N-fert-butoxycarbonyl-4-[2-(4- methylsulphonylphenylsulphonyl)ethyl]piperidine (1.94g) in dichloromethane (20 ml) and was allowed to stand at room temperature for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in 2M sodium hydroxide (15 ml) and extracted with dichloromethane (3x20 ml). The combined dichloromethane extracts were dried and evaporated to dryness to give the title compound, yield 1.3g, ^^331.9.
Variant B A solution of 4M hydrochloric acid in dioxane (15 ml) was added to a stirred solution of -tert-butoxycarbonyl-4-[2-(4-methylsulphonylphenylsulphonyl)ethyl]piperidine (5.62g) in dichloromethane (15 ml) and stirring was continued for 1 hour. The reaction mixture was triturated with diethyl ether and the solid formed was filtered, washed with diethyl ether and dried under high vacuum. The title compound was obtained as its hydrochloride salt, yield 4.88g, M1H 331.9.
The following compounds were also prepared using a process analogous to Method B
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000069_0001
Figure imgf000069_0004
Method C
3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionaldehyde
Figure imgf000069_0002
Step 1 Preparation of 4-benzoyl-l -methanesulphonylpiperidine
Figure imgf000069_0003
Methanesulphonyl chloride was added to a stirred slurry of 4-benzoylpiperidine hydrochloride (4.51g) and triethylamine (8.35ml) in dichloromethane (100ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The mixture was diluted with dichloromethane (50ml) and washed with ammonium chloride solution (2x25ml) and brine (25ml), dried and evaporated to dryness to give 4-benzoyl-l - methanesulphonylpiperidine as a white solid, yield 3.98g. NMR (CDC13): 1.93 (m, 4H), 2.81 (s, 3H), 2.98 (d-t, 2H), 3.40 (m, IH), 3.77 ( , 2H), 7.43 (t, 2H), 7.57 (t, IH), 7.89 (d, 2H). Step 2 Preparation of ethyl 3-phenyl-3-(N-methanesulρhonylpiperidin-4-yl)acrylate.
Figure imgf000070_0001
Lithium bis(trimethylsilyl)amide (16.3ml of a IM solution in THF) was added dropwise to a solution of triethylphosphonoacetate (2.93ml) in THF at 0°C under an argon atmosphere and the mixture was stirred for 30 minutes. A slurry of 4-benzoyl-l - methanesulphonylpiperidine (3.96g) in THF (30ml) was added, the reaction mixture was allowed to warm to room temperature and stirring was continued for 24 hours. The reaction mixture was diluted with dichloromethane (80ml) and water (80ml). The organic layer was washed with water and the combined aqueous extracts were in turn extracted with dichloromethane (50ml). The combined dichloromethane extracts were washed with brine (25ml), dried and evaporated to dryness. The residue was chromatographed on a 90g Biotage column eluted with a solvent gradient (30-5% ethyl acetate/isohexane to give a less polar fraction (1.62g) and a more polar fraction (0.53g). Both fractions (cis/trans isomers) were combined and used for the next step. Less polar NMR (CDC13): 1.27 (t, 3H), 1.69 (m, 2H), 1.81 (d, 2H), 2.72 (s, 3H), 2.72
(t, 2H), 3.81 (d, 2H), 3.88 (m, IH), 4.21 (q, 2H), 5.78 (s, IH), 7.11 (m, 2H), 7.27 (m, 3H).
More polar NMR (CDCI3): 1.01 (t, 3H), 1.56 (m, 2H), 1.85 (d, 2H), 2.31 (m, IH), 2.63 (t, 2H), 2.74 (s, 3H), 3.83 (d, 2H), 3.92 (q, 3H), 5.82 (s, IH), 7.04 (d, 2H), 7.30 (m, 3H).
Step 3 Preparation of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionate
Figure imgf000070_0002
A solution of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)acrylate (2.06g) in ethanol (30ml) was hydrogenated over 24 hours under a hydrogen filled balloon using 20% palladium hydroxide as catalyst. The reaction mixture was filtered through Celite and the filtrate evaporated to dryness. The product obtained was used for the next step without further purification. MH+340.
Step 4 3-Phenyl-3-(N-methanesulphonylpiperidin-4-yl)propan-l-ol.
Figure imgf000071_0001
A solution of ethyl 3-phenyl-3-(N-methanesulphonylpiperidin-4-yl)propionate (2g) in THF (10ml) was added to a suspension of lithium aluminium hydride (232mg) in THF (20ml) at 0°C under argon over 30 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 2 hours. Water (10ml) was added followed by magnesium sulphate (lOg). The reaction mixture was filtered and the filtrate evaporated to dryness to give the product as a white foam, yield 1.57g. NMR (CDC13): 1.40 (m, 4H), 1.57 (m, IH), 1.78 (m, IH), 2.01 (m, 2H), 2.45 (m, 2H), 2.58 (t, IH), 2.70 (m, 3H), 3.31 (m, IH), 3.42 (m, IH), 3.67 (d, IH), 3.80 (d, IH), 7.04 (d, IH), 7.19 (t, IH), 7.29 (q, 2H).
Step 5 Preparation of the title compound
Figure imgf000071_0002
Dess-Martin periodinane (739mg) was added to a stirred solution of 3-phenyl-3-(N- methanesulphonylpiperidin-4-yl)propan-l-ol (454mg) in dichloromethane (8ml) and stirring was continued for 2 hours. The reaction mixture was diluted with dichloromethane (100ml) and washed with 2M sodium hydroxide (2x50ml), brine (50ml) and dried. The product obtained on removal of the solvent was used in subsequent steps without purification. Method D
N-(3-Phenyl-3-chloropropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]-piperidine
Figure imgf000072_0001
Triethylamine (0.73 ml) was added to a solution of N-(3-hydroxy-3-phenylproρyl)-4- [2-(4-methanesulphonylphenylsulphonyl)ethyl]-piperidine (1.22g) in dichloromethane (20 ml) followed by methanesulphonyl chloride (0.33g) and the mixture was stirred for 18 hours at room temperature. The reaction mixture was washed successively with water (25 ml) and brine (25 ml) and dried. The residue obtained after removal of the solvent was chromatographed on a 20g silica Bond Elut column eluted with a solvent gradient of ethyl acetate - 20% methanol ethyl acetate to give the title compound, yield 0.73g, MH1" 483.99. NMR(CDC13) : 1.3 (m, 3H), 1.6 (m, 4H), 1.9 (m, 2H), 2.1-2.3 (m, 2H), 2.4 (m, 2H), 2.8-2.9 (m, 2H), 3.1 (s, 3H), 3.2 (m, 2H), 5.0 (m, IH), 7.3 (m, 5H), 8.2 (m, 4H).
N-(3-Hydroxy-3-phenylpropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]-piperidine
Figure imgf000072_0002
Sodium borohydride (lOOmg) was added in portions to a solution of N-(3-oxo-3- phenylpropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]-piperidine (1.22g) in ethanol (20ml) at room temperature and was stirred for 18 hours. The reaction mixture was evaporated to dryness and the residue was dissolved in dichloromethane (30ml) and this solution was washed with water (25ml), brine (25ml) and dried. Removal of the solvent gave the title compound as white solid, yield 1.21g, MH1" 465.98.
N-(3-Oxo-3-phenylpropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]-piperidine
Figure imgf000073_0001
3-Chloroproρiophenone (0.726g) was added to a mixture of 4-[2-(4- methanesulphonylphenylsulphonyl)ethyl]-piperidine (1.3g) (prepared as described in Method B) and potassium carbonate (1.09g) in DMF (20ml) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in dichloromethane (30ml). The dichloromethane solution was washed with water (25ml), brine (25ml) and dried. The residue obtained after removal of the solvent was chromatographed on a 50g silica Bond Elut column eluted with a solvent gradient of ethyl acetate-20% methanol ethyl acetate to give the title compound as a white solid, yield 1.22g, MF 463.97. NMR(CDC13): 1.2-1.4 (m, 3H), 1.6 (m, 4H), 2.0 (m, 2H), 2.8 (m, 2H), 2.9 (m, 2H), 3.1-3.2 (m 7H), 7.4 (m, 2H), 7.5(m, IH), 7.9 (m, 2H), 8.2 (m, 4H).
Method E
(R)-3-(3,5-Difluoroρhenyl)-3-(4-methanesulfonylphenyl)propionaldehdye
Figure imgf000073_0002
This was prepared from (4S, 5R)-l-(3-[4-methanesulfonylphenyl]acryloyl)-3,4- dimethyl-5-phenyl-imidazolidin-2-one and 3,5-difluorophenylmagnesium bromide using a method similar to that used to prepare (S)-3-phenyl-3-(4-methanesulfonyl- phenyl)proρionaldehyde from phenylmagnesium bromide (Method A); NMR (CDC13): 3.05 (s, 3H), 3.20 (d, 2H), 4.72 (t, IH), 6.75 (m, 3H), 7.35 (d, 2H), 7.88 (d, 2H), 9.75 (s, IH). Method F
(S) N-(3-hydroxy-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]-piperidine
Step 1: (R or S) N-(3-chloro-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]- piperidine
Figure imgf000074_0001
Methanesulphonyl chloride (158 μl) was added to a solution of (S)N-(3-hydroxy-3- phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]-piperidine (600 mg) and triethylamine (417 μl) in dichloromethane (10 ml) maintained at 0°C under an argon atmosphere. The reaction mixture was allowed to warm to room temperature and was stirred for 18 hours. The reaction mixture was diluted with dichloromethane (50 ml) and washed with saturated amonium chloride solution (2x25 ml) and brine (25 ml) and dried. Removal of the solvent gave the title compound which was used without further purification. NMR: (CDC13): 1.18- 2.24 (m, 13H), 2.78 (m, IH), 2.84 (m, IH), 3.04 (IH, m), 4.92 (t, IH), 7.20-7.40 (m, 7H), 7.91 (m, 2H); MS 424 (MH").
Step 2: (S) N-(3-hydroxy-3-phenylpropyl)-4-[2-(4-fluorophenylsulphonyl)ethyl]-piperidine
Figure imgf000074_0002
A solution of (S)-l-phenyl-3-(4-toluenesulphonyl)oxypropan-l-ol (459 mg) in dioxane (10ml) was added to a suspension of 4-[2-(4-fluorophenylsulphonyl)ethyl]piperidine (407 mg) and potassium carbonate (414 mg) and the mixture was heated at 95°C for 17 hours. The reaction mixture was allowed to cool and was partitioned between dichloromethane (100 ml) and water (50 ml). The organic layer was collected and washed with water (50 ml), brine (50 ml) and dried. Removal of the solvent gave the title compound, yield 607 mg. NMR: (CDCI3): 1.18-1.69 (m, 8H), 1.82 (m, 3H), 2.02 (m, IH), 2.48 (m, IH), 2.62 (m, IH), 2.93 (d, IH), 3.05 (m, 3H), 4.89 (m, IH), 7.21-7.40 ( , 7H), 7.92 (m, 2H); MS 406 (MH1). Method G
(R) 3-(l-Methanesulphonylpiperidin-4-yl)-3-[3,5-difluorophenyl]propionaldehyde
Figure imgf000075_0001
Step 1 3-[N-(Benzyloxycarbonylpiperidin-4-yl)]propenoic acid
Figure imgf000075_0002
A mixture of N-benzyloxycarbonyl-4-formylpiperidine (lOg), malonic acid (4.2), pyridine (4 ml) and piperidine (0.4 ml) was heated at 100°C for 2 hours. The reaction mixture was allowed to cool and was diluted with ethyl acetate (100 ml). The solution was washed with 2M HCI (2x100 ml), dried and evaporated to dryness. The residue was triturated with isohexane to give the title compound, yield 13.5g.
NMR (DMSOdό): 1.2 (m, 2H), 1.7 (m, 2H), 2.35 (m, IH), 2.85 (m, 2H), 4 (d, 2H),
5.05 (s, 2H), 5.75 (d, IH), 6.75 (m, IH), 7.35 (m, 5H), 12.25 (broad peak, IH).
Step 2 N-(Benzyloxycarbonylpiperidin-4-yl)propenoic acid isopropyl ester
Figure imgf000075_0003
A solution of N-(benzyloxycarbonylpiperidin-4-yl)propenoic acid (52g) in isopropanol (500 ml) containing concentrated sulphuric acid (20 ml) was heated under reflux for 32 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate (250 ml). The ethyl acetate solution was washed with water (2x250 ml) and saturated aqueous sodium bicarbonate (2x25 ml) and dried. The residue obtained on evaporation of the solvent was chromatographed on a Bond Elut cartridge eluted with a solvent gradient (isohexane - 25% ethyl acetate/isohexane) to give the title compound, yield 54g.
Step 3 Preparation of (R) 3-(N-benzyloxycarbonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propanoic acid isopropyl ester
Figure imgf000076_0001
Dioxane (100 ml) was charged to a 500 ml three necked flask and purged with argon for 10 minutes. Acetylacetonatobis[ethylene]rhodium (I) (620 mg) and R-BINAP were added and the mixture was stirred for 10 minutes. 3,5-Difluorophenylboronic acid (19g) was added and the mixture was purged with argon for 10 minutes. N-(benzyloxycarbonylpiperidin-4- yl)propenoic acid isopropyl ester (8 g) and ethanediol (20 ml) in dioxane (100 ml) were added and the mixture was purged with argon for 10 minutes. The mixture was heated at 100°C for 18 hours, allowed to cool and was passed through activated alumina (200g) washed through with ethyl acetate (3x100 ml). The combined washings were evaporated to dryness and the residue obtained was dissolved in ethyl acetate (100 ml) and washed successively with saturated aqueous sodium bicarbonate (2x100 ml) and 2M HCI (2x100 ml), dried and evaporated to dryness. The product obtained (12g) was shown to be 40% of the required material by NMR and was used without further purification in the subsequent reactions.
Step 4 Preparation of (R) 3-(piperidin-4-yl)-3-(3,5-difluorophenyl)propanoic acid isopropyl ester.
Figure imgf000076_0002
A solution of (R) 3-(N-benzyloxycarbonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propanoic acid isopropyl ester (12g) in ethanol (300 ml) containing 20% palladium hydroxide on charcoal (2g) was hydrogenated under a hydrogen filled balloon. The catalyst was filtered and the filtrate was evaporated to dryness to give the title compound (lOg) which was used without further purification.
Step 5 Preparation of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)- propanoic acid isopropyl ester.
Figure imgf000077_0001
Methanesulphonyl chloride (3.7g) was added to a solution of (R) 3-(piperidin-4-yl)-3- (3,5-difluorophenyl)propanoic acid isopropyl ester (lOg) and triethylamine (3.89g) in dichloromethane (100 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was washed with 2M HCI (2x50 ml) and saturated aqueous sodium bicarbonate (2x50 ml), dried and evaporated to dryness to give the title compound (lOg) which was used without further purification.
Step 6 Preparation of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propanol
Figure imgf000077_0002
Lithium aluminium hydride (25 ml of a IM solution in THF) was added dropwise over 15 minutes to a solution of (R) 3-(N-methanesulphonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propanoic acid isopropyl ester (lOg) in THF (150 ml) at -10°C. The reaction mixture was stirred at -10°C for 30 minutes, 2M NaOH (25 ml) was added, the mixture was filtered and the filtrate evaporated to dryness. The residue obtained was dissolved in ethyl acetate and washed with 2M HCI (2x100 ml) and dried. The residue obtained on removal of the solvent was chromatographed on a Bond Elut column eluting with a solvent gradient (80% ethyl acetate/isohexane - ethyl acetate) to give the title compound, yield 2.2 g.
NMR (DMSO d6): 0.95-1.2 (m, 2H), 1.3 (m, IH), 1.6 (m.2H), 1.9 (m, 2H), 2.6 (m, 2H), 2.8 (s, 3H), 3.1 (m, IH), 3.2 (m, IH), 3.4 (m, IH), 3.5 (m, IH), 6.8-7 (m, 3).
Step 7 Preparation of (R) 3-( -methanesulphonylpiperidin-4-yl)-3-(3,5- difluorophenyl)propionaldehyde.
Figure imgf000078_0001
Dess-Martin periodinane (lg) was added to a solution of (R) 3-(N- methanesulphonylpiperidin-4-yl)-3-(3,5-difluorophenyl)propanol (0.8g) in dichloromethane
(40 ml) and the mixture was stirred for 1.5 hours. The reaction mixture was washed with 2M
NaOH (2x20 ml) and dried. The solution of the title compound in dichloromethane was used in subsequent reactions.
Method H
(R) 3 -(N-Methanesulphonylpiperidin-4-yl)-3 -phenylpropanol
Figure imgf000078_0002
Step 1 Preparation of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid acid chloride.
Figure imgf000079_0001
l-Chloro-N,N,2-trimethylpropenylamine (1.06 ml) was added dropwise over 10 minutes to a suspension of 3-(N-methanesulphonylpiperidin-4-yl)propenoic acid (1.86g, prepared from N-methanesulphonylpiperidine-4-carboxaldehyde [CAS 241134-35-0] according to step 1 of Method E) in THF (20 ml) under an atmosphere of argon and the mixture was stirred for 2 hours and used directly in step 2.
Step 2 Preparation of l-[3-(N-methanesulphonylρiperidin-4-yl)propenyl]-(4S, 5R)-3,4- dimethyl-4-phenyl-imidazolidin-2-one.
Figure imgf000079_0002
Lithium bis(trimethylsilyl)amide (8 ml of a IM solution in THF) was added dropwise to a suspension of (4R,5S)-l,5-dimethyl-4-phenyl-2-imidazolidinone (1.52g) in THF (20 ml) under argon at -10°C. The reaction mixture was stirred at -10°C for 10 minutes, allowed to warm to 0°C and maintained at this temperature for 10 minutes then cooled again to -10°C. The solution of the acid chloride prepared in Step 1 was added dropwise and the reaction mixture was allowed to warm to room temperature and washed with water (100 ml). The aqueous extract was extracted with ethyl acetate (3x50 ml) and the ethyl acetate extracts were dried and the residue passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane - 70% ethyl acetate/isohexane). Yield 1.89g. LC-MS MH+ 406, NMR (CDC13): 0.8 (d, 3H), 1.5-1.6 (m, 3H), 1.9 (m, 2H), 2.3 (m, IH), 2.7 (m, 2H), 2.75 (s, 3H), 2.8 (s, 3H), 3.75 (m, 2H), 3.9 (m, IH), 5.3 (d, IH), 6.85 (d-d, IH), 7.1 (d, IH), 7.2-7.35 (m, 3H), 7.45 (d, IH).
Step 3 Preparation of (R) l-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]- (4S,5R)-3,4-dimethyl-5-phenyl-imidazolidin-2-one.
Figure imgf000080_0001
A mixture of copper(I) iodide (1.78 g) andNNNN'-tetramethylethylenediamine (1.41 ml) in THF (50 ml) was stirred under argon for 1 hour then cooled to -78°C and phenylmagnesium bromide (5.4 ml of a IM solution in THF) was added and the mixture was stirred at -78°C for 30 minutes. A solution of l-[3-(Ν-methanesulphonylpiperidin-4- yl)propenyl]-(4S, 5R)-3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.89g) and dibutylboron triflate (4.67 ml of a IM solution in diethylether) in THF (50 ml) was added over 10 minutes and the reaction mixture was stirred at -78°C for 1 hour then allowed to warm to room temperature. The reaction mixture was concentrated and filtered through a pad of silica (50g) washed with ethyl acetate (2x50 ml) and the ethyl acetate washings were washed with 2M HCI (2x150 ml) and dried. The residue obtained on removal of the solvent was passed through a 90g Biotage column eluting with a solvent gradient (50% ethyl acetate/isohexane- 70% ethyl acetate/isohexane) to give the product as a yellow solid, yield 1.34g, MH*" 484. NMR (CDC13): 0.7 (d, 3H), 1.2 (m, IH), 1.35 (m, IH), 1.5 (m, IH), 1.9 (m, IH), 2.45 (m, IH), 2.55 (m, IH), 2.7 (s, 3H), 2.8 (s, 3H), 3.1 (m, IH), 3.2 (d-d, IH), 3.4 (m, IH), 3.65 (m, IH), 3.75-3.9 (m, 3H), 5.2 (d, IH), 6.7 (d, 2H), 7.05-7.25 (m, 8H).
Step 4 Preparation of the title compound
A solution of (R) l-[3-phenyl-3-(methanesulphonylpiperidin-4-yl)propionyl]-(4S,5R)- 3,4-dimethyl-5-phenyl-imidazolidin-2-one (1.34g) in THF (14 ml) was added to a solution of lithium aluminium hydride (2.77 ml of a IM solution in THF) in THF (10 ml) at 0°C and the mixture was allowed to warm to room temperature over 1 hour. Water (5 ml) was added cautiously, then THF (15 ml) and solid magnesium sulphate. The reaction mixture was filtered and the filtrate was passed through a 40 g Biotage column eluted with a solvent gradient (50% ethyl acetate/isohexane - 70% ethyl acetate/isohexane) to give the title compound as a white solid, yield 338 mg. NMR (CDC13): 1.15-1.25 (m, 2H), 1.3-1.5 (m, 2H), 1.6 (m, IH), 1.75 (m, IH), 1.95-2.10 (m, 2H), 2.5 (m, 2H), 2.6 (m, IH), 2.7 (s, 3H), 3.3-3.4 (m, 2H), 3.45 (m, IH), 3.7 (m, IH), 3.85 (m, IH), 7.05 (m, 2H), 7.15-7.35 (m, 3H). Method I
Preparation of [(piperidin-4-yl)methyl]-(4-methoxyphenylmethyl)sulphone
Figure imgf000081_0001
Step 1 Preparation of [(N-Boc-piperidin-4-yl)methyl]-(4-methoxyphenylmethyl)sulphide
Figure imgf000081_0002
4-Methoxybenzylthiol (0.944 ml) was added to a suspension of sodium hydride (271 mg of a 60% dispersion in mineral oil) in DMF at 0°C and was stirred at this temperature for 15 minutes. 4-Tosyloxymethyl-N-Boc-piperidine (CAS 166815-96-9) was added and the mixture was allowed to warm to room temperature and was stirred for 3 hours. The reaction mixture was evaporated to dryness and the residue was dissolved in dichloromethane (50 ml) and this solution was washed with water (30 ml) and brine (30 ml) and dried. The solvent was evaporated and the residue was chromatographed on a 50g Bond Elut column eluting with a solvent gradient (isohexane-20% ethyl acetate/isohexane). Yield 2g, MH+ 252.14. NMR (CDCI3): 1.0-1.2 (m, 2H), 1.4 (s, 9H), 1.5 (m, IH), 1.7-1.8 (m, 2H), 2.3 (m, 2H), 2.6 (bt, 2H), 3.7 (s, 2H), 3.8 (s, 3H), 4.1 (m, 2H), 6.8 (m, 2H), 7.2 (m, 2H).
Step 2 Preparation of [(N-Boc-piperidin-4-yl)methyl]-(4-methoxyphenylmethyl)sulphone
Figure imgf000081_0003
m-Chloroperbezoic acid (2.81g) was added to a solution of [(N-Boc-piperidin-4- yl)methyl]-(4-methoxyphenylmethyl)sulphide (2g) in dichloromethane (50 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The reaction mixture was washed with 2M NaOH (20 ml), brine (20 ml) and dried. The solvent was evaporated and the residue was purified on a 50g silica Bond Elut eluting with a solvent gradient (isohexane-50% ethyl acetate/isohexane) to give the title compound, yield 1.75g, MH+ (-Boc) 284.11. Step 3 Preparation of [(piρeridin-4-yl)methyl]-(4-methoxyphenylmethyl)sulphone hydrochloride
Figure imgf000082_0001
[(N-Boc-piperidin-4-yl)methyl]-(4-methoxyphenylmethyl)sulphone (1.75g) was stirred with 4M HCI in dioxane (10 ml) for 30 minutes. The reaction mixture was triturated with diethyl ether and the solid obtained was filtered and dried. Yield 1.42g. MH1" 284.
The following compounds were also prepared using a process analogous to Method I
Figure imgf000082_0002
Figure imgf000082_0005
Method J
Preparation of [(piperidin-4-yl)methyl]-(4-methanesulphonylphenylmethyl)sulphone
Figure imgf000082_0003
Step 1 Preparation of [(N-Boc-piperidin-4-yl)methylthioacetate
Figure imgf000082_0004
Potassium thioacetate (1.857 g) was added to a solution of 4-tosyloxymethyl-N-Boc- piperidine (CAS 166815-96-9) (3 g) in DMF (40 ml) and the mixture was heated at 100°C for 4 hours. The reaction mixture was allowed to cool to room temperature and water (5 ml) was added. The reaction mixture was extracted with diethyl ether (3x50 ml). The diethyl ether extracts were washed with saturated aqueous sodium bicarbonate (50 ml), brine (50 ml) and were dried. Removal of the solvent gave an orange oil (2.2 g), MH+ 174, NMR (CDC13) : 1.2 (m, 2H), 1.45 (s, 9H), 1.6 (m, IH), 1.75 (bd, 2H), 2.35 (s, 3H), 2.65 (bt, 2H), 2.8 (d, 2H), 4.1 (m, 2H). This material was used without further purification.
Step 2 Preparation of N-Boc-piperidin-4-yhnethylthiol.
Figure imgf000083_0001
Sodium borohydride (2.2 g) was added in portions over 10 minutes to a solution of (N- Boc-piperidin-4-yl)methylthioacetate (2.2 g) in methanol (40 ml) at 0°C. The mixture was allowed to warm to room temperature and was stirred for 2 hours. The reaction mixture was evaporated and the residue was dissolved in water (10 ml), citric acid (2g) was added and the mixture was extracted with dichloromethane (3x20 ml) and dried. Removal of the solvent gave the product as an orange oil, which by NMR contained ~29% of the starting material. This product was used without further purification.
Step 3 Preparation of [(N-Boc-piperidin-4-yl)methyl]-(4-methanesulphonyl- phenylmethyl)sulphide
Figure imgf000083_0002
N-Boc-piperidin-4-ylmethylthiol (1.155 g) was added to a suspension of sodium hydride (200 mg of a 60% dispersion in mineral oil) in DMF at 0°C and the mixture was stirred for 30 minutes. 4-Methanesulphonylbenzyl chloride (1.023 g) was added, the reaction mixture was allowed to warm to room temperature and was stirred for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in dichloromethane (30 ml) and washed with water (25 ml) and brine (25 ml) and dried. The solvent was evaporated and the residue was purified on a 50g silica Bond Elut eluting with a solvent gradient (isohexane- 50% ethyl acetate/isohexane). Yield lg, MH+ 300. NMR (CDC13) : 1.2 (m, 2H), 1.45 (s, 9H), 1.5 (m, IH), 1.8 (m, 2H), 2.35 (d, 2H), 2.65 (bt, 2H), 3.05 (s, 3H), 3.75 (s, 3H), 4.1 (m, 2H), 7.5 (d, 2H), 7.9 ( d, 2H). Step 4 Preparation of [(N-Boc-piperidin-4-yl)methyl]-(4-methanesulphonyl- phenylmethyl)sulphone.
This was carried out as described in Step 2 of Method I. MH4- 376 (- tert-Butyl): NMR (CDC13) :1.3 (m,2H), 1.4 (s, 9H), 1.9 (m, 2H), 2.2 (m, IH), 2.7- 2.9 (m, 4H), 3.1 (s, 3H), 4.1 (m, 2H), 4.3 (s, 2H), 7.6 (d, 2H), 8.0 (d, 2H).
Step 5 [(piperidin-4-yl)methyl]-(4-methanesulphonylphenylmethyl)sulphone This was carried out as described in Step 3 of Method I, MH+ 332.
The following compounds were also prepared using a process analogous to Method J.
Figure imgf000084_0001
Figure imgf000084_0003
Method K
4-(2-[Piperidin-4-yl]ethylsulphonyl)benzyl methyl sulphone
Figure imgf000084_0002
Step 1 Preparation of 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzyl alcohol
Figure imgf000085_0001
Lithium aluminium hydride (2.823 ml of a IM solution in THF) was added dropwise to a solution of ethyl 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzoate (1.2 g) [prepared according to Method B using ethyl-4-mercaptobenzoate (CAS 28276-32-6) as starting material] in THF (20 ml) at 0°C and the mixture was stirred for 30 minutes. Ethyl acetate (10 ml) was added followed by water (0.1 ml), 2M NaOH (0.1 ml) and water (1 ml) and Celite (2 g). The mixture was stirred for 5 minutes and filtered. The filtrate was evaporated to dryness to give 1.086g, NMR (CDC13) : 1.0-1.1 (m, 2H), 1.4 (s, 9H), 1.55-1.7 (m, 5H), 2.6 (bt, 2H), 3.1 (m, 2H), 4.1 (m, 2H), 4.8 (s, 2H), 7.6 (d, 2H), 7.9 (d, 2H).
Step 2 Preparation of 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzyl alcohol tosylate
Figure imgf000085_0002
p-Toluenesulphonyl chloride (541 mg) was added to a solution of 4-(2-[N-Boc- piperidin-4-yl]ethylsulphonyl)benzyl alcohol (1.086 g) and triethylamine (0.473 ml) in dichloromethane (30 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours. The reaction mixture was washed with water (25 ml), dried and evaporated to dryness. The residue obtained on evaporation of the solvent was passed through a 50g silica Bond Elut column eluting with a solvent gradient (isohexane-50% ethyl acetate/isohexane), yield 765 mg. LC-MS showed this to be a mixture of the required tosylate and the chloro analogue. The mixture was used for the next step.
Step 3 Preparation of 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzyl methyl thioether.
Figure imgf000085_0003
The chloride/tosylate mixture from Step 2 was added to a solution of the sodium salt of methanethiol in DMF at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours then evaporated to dryness. The residue was dissolved in dichloromethane (20 ml) and washed with water (20 ml) and brine (20 ml) and dried. Evaporation of the solvent gave the product, yield 602 mg, MH4- 314.
Step 4 Preparation of 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzyl methyl sulphone.
Figure imgf000086_0001
m-Chloroperbenzoic acid (720 mg) was added to a solution of the thioether (Step 3) in dichloromethane (20 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 16 hours then washed with 2M NaOH (20 ml) and brine (20 ml) and dried. The residue obtained on evaporation of the solvent was passed through a 50g silica Bond Elut column eluting with a solvent gradient (isohexane-50% ethyl acetate/isohexane), yield 416 mg, MH* 390 (- tert-Butyl). NMR (CDC13) : 1.0-1.2 (m, 2H), 1.4 (s, 9H), 1.5 (m, IH), 1.6 (m,2H), 1.7 (m, 2H), 2.6 (bt, 2H), 2.85 (s, 3H), 3.1 (m, 2H), 4.1 (m, 2H), 4.3 (m, 2H), 7.8 (d, 2H), 7.95 (d, 2H).
Step 5 Preparation of the title compound.
4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzyl methyl sulphone (402 mg) was stirred in 4M HCI in dioxane (10 ml) for 1 hour then diethylether was added and the precipitated solid was filtered and dried, yield (HCI salt) 375 mg. MET1" 346.
Method L
4-(2-[Piperidin-4-yl]ethylsulphonyl)benzamide
Figure imgf000086_0002
Step 1 Preparation of 4-(2-[N-Boc- piperidin-4-yl]ethylsulphonyl)benzamide
A mixture of ethyl 4-(2-[N-Boc-piperidin-4-yl]ethylsulphonyl)benzoate (0.8 g) [prepared according to Method B using ethyl-4-mercaptobenzoate (CAS 28276-32-6) as starting material] in methanolic ammonia (10 ml of 7M ammonia in methanol) was heated to 50°C to give a clear solution and was allowed to stand at room temperature for 72 hours. The reaction mixture was evaporated to dryness and the residue obtained on evaporation of the solvent was passed through a 50g silica Bond Elut column eluting with a solvent gradient (isohexane-50% ethyl acetate/isohexane), yield 394 mg, MH1" 297 (-Boc).
Step 2 Preparation of title compound
4-(2-[N-Boc- piperidin-4-yl]ethylsulphonyl)benzamide (394 mg) was stirred in 4M HCI in dioxane (10 ml) for 1 hour then diethylether was added and the precipitated solid was filtered and dried, yield (HCI salt) 428 mg. MH" 297.
Method M
Preparation of {4-[(2-piperidin-4-ylethyl)sulfonyl]phenoxy} acetonitrile
Step 1 tert-Butyl 4-(2- { [4-(cyanomethoxy)ρhenyl] sulfonyl} ethyl)piperidine- 1 -carboxylate
Bromoacetonitrile (320 mg) was added to a solution of N-tert-butoxycarbonyl-4-[2-(4- hydroxyphenylsulphonyl)ethyl]piperidine (1 g) in acetone (20 ml) containing potassium carbonate (037g ) and the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was dissolved in ethyl acetate (50 ml) and the solution was washed with water (2x50 ml), dried and evaporated to dryness, yield 1.4g. NMR (CDC13): 1.1 (m, 2H), 1.42 (s, 9H), 1.6 (m, 5H), 2.6 (t, 3H), 3.1 (m, 2H), 4.1 (m, 2H), 4.9 (s, 2H), 7.1 (d, 2H), 7.9 (d, 2H).
Step 2 4-(2-{[4-(Cyanomethoxy)phenyl]sulfonyl}ethyl)piperidine tert-Butyl 4-(2- { [4-(cy anomethoxy)phenyl] sulfonyl} ethyl)piperidine- 1 -carboxylate (1.4g ) was dissolved in dioxane (5 ml) and HCl/dioxane (20 ml of 4M solution) was added. The mixture was stirred for 1 hour and diethyl ether was added (75 ml) and the oily precpitate obtained was triturated to give {4-[(2-piperidin-4-ylethyl)sulfonyl]phenoxy}acetonitrile hydrochloride, yield 0.9g. M H 309. Method N
Preparation of 4-(2- {[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl} ethyl)piperidine.
Step 1 Benzyl 4-{2-[(4-cyanophenyl)sulfonyl]ethyl}piperidine-l-carboxylate. Benzyl chloroformate (800 mg) was added to a solution of 4-[(2-piperidin-4- ylethyl)sulfonyl]benzonitrile (1.4g, Method B) and triethylamine (1.3g) in dichloromethane (25 ml) at 0°C. The reaction mixture was allowed to warm to room temperature and was stirred for 2 hours, washed with 2M HCI (2x20 ml) and 2M NaOH (2x20 ml) and dried. The residue obtained on removal of the solvent was purified by chromatography on a Bond-Elut column using an eluant gradient of hexane - 50% ethyl acetate/hexane. Yield 1.4g. NMR
(CDC13): 0.9 (m, IH), 1.1 (m, IH), 1.8 (m, 4H), 2.7 (m, 2H), 3.1 (m, 2H), 4.2 (m, 2H), 5.1 (s, 2H), 7.3 (m, 5H), 7.9 (d, 2H), 8.05 (d, 2H).
Step 2 Benzyl 4-(2-{[4-(lH-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine-l-carboxylate. The product from step 1 was mixed with sodium azide (220 mg) and ammonium chloride (182 mg) in DMF (25 ml) and heated at 100 °C for 4 hours. The reaction mixture was allowed to cool and the solvent was evaporated. The residue was dissolved in dichloromethane (50 ml) and washed with 2M NaOH (2x20 ml) and dried. Removal of the solvent gave the product, yield 1.9g, M1H 456, which was used directly in the next stage.
Step 3 Preparation of benzyl 4-(2-{[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)- piperidine-1 -carboxylate and benzyl 4-(2-{[4-(l-methyl-lH-tetrazol-5-yl)phenyl]sulfonyl}- ethyl)piperidine- 1 -carboxylate
Methyl iodide (710 mg) was added to a solution of the product from step 2 (1.9g) in ethanol (25 ml) containing 2M NaOΗ (5 ml) and the mixture was stirred for 16 hours. A second portion of methyl iodide (710 mg) and 2M NaOΗ (5 ml) was added and stirring was continued for 72 hours. The reaction mixture was concentrated and water (30 ml) added. The precipitated solid was collected, dried and dissolved in dichloromethane and passed through a Bond-elut column eluting with 60% ethyl acetate in hexane to give: Benzyl 4-(2-{[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine-l-carboxylate, yield 800 mg, NMR (CDCI3): l.l(m, 2Η), 1.8 (m, 5H), 2.7 (m, 2H), 3.1 (m, 2H), 4.1 (m, 2H), 4.4 (s, 3H), 5.1 (s, 2H), 7.3 (m, 5H), 8.05 (d, 2H), 8.35 (d, 2H). M1H 470. Benzyl 4-(2-{[4-(l-methyl-lH-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine-l-carboxylate, yield 200 mg, NMR (CDC13): l.l(m, 2H), 1.8 (m, 5H), 2.7 (m, 2H)3 3.1 (m, 2H), 4.1 (m, 2H), 4.15 (s, 3H), 5.1 (s, 2H), 7.4 (m, 5H), 7.95 (d, 2H), 8.15 (d, 2H). M1H 470.
Step 4 Preparation of 4-(2-{[4-(2-methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine. 20% Palladium hydroxide on charcoal was added to a solution of benzyl 4-(2-{[4-(2- methyl-2H-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine-l -carboxylate (700 mg) in a mixture of ethyl acetate (50 ml) and ethanol (150 ml) and the mixture was hydrogenated under a hydrogen filled balloon. The catalyst was filtered and the filtrate evaporated to dryness to give the title compound as a white solid, yield 600 mg. NMR (CDC13): 1.1 (m, 2Η), 1.7 (m, 5H), 2.6 (m, 2H), 3.05 (m, 2H), 3.15 (m, 2H), 4.4 (s, 3H), 8.0 (d, 2H), 8.39 (d, 2H).
The corresponding 1 -methyl analogue was prepared in an analogous manner starting with benzyl 4-(2-{[4-(l-methyl-lH-tetrazol-5-yl)phenyl]sulfonyl}ethyl)piperidine-l- carboxylate, yield 120 mg.
Method O
Preparation of 4-[(2-piperidin-4-ylethyl)sulfonyl]aniline.
Figure imgf000089_0001
Step 1 tert-Butyl 4-{2-[(4-aminophenyl)sulfonyl]ethyl}piperidine-l-carboxylate
Nickel (II) acetate tetrahydrate (45 mg) was added to borohydride exchange resin (borohydride on Amberlite® IRA- 140 [available from Aldrich]) (3.61 g) in methanol (35 ml) and after the reaction had subsided was allowed to stand for 1 minute. A solution of tert- butyl 4-{2-[(4-nitroρhenyl)sulfonyl]ethyl}ρiperidine-l-carboxylate (717 mg) [prepared according to Method B] in methanol (5 ml) was added and the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered through Celite® and the resin was washed with methanol (3x10 ml). The combined filtrate and washings were evaporated to dryness and the product was used without further purification. LC/MS, M+H 269 (product -Boc group). Step 2 Preparation of title compound
The product from step 1 (450mg) was dissolved in 4M HCI in dioxane (10 ml) and allowed to stand for 30 minutes. Diethyl ether (20 ml) was added and a solid was obtained on trituration, yield 597 mg, M+H 269.
Method P
Preparation of N- {4-[(2-piperidin-4-ylethyl)sulfonyl]phenyl}methanesulfonamide.
Figure imgf000090_0001
Step 1 Preparation of tert-butyl 4-[2-({4-[(methylsulfonyl)amino]ρhenyl}thio)ethyl]- piperidine- 1 -carboxylate.
Methanesulphonyl chloride (0.63 ml) was added to a solution of tert-butyl 4-{2-[(4- aminophenyl)thio] ethyl} piperidine- 1 -carboxylate (1.61g, Method B) in pyridine (40 ml) at 0°C and allowed to warm to room temperature. The reaction mixture was stirred for 5 hours then evaporated to dryness. The residue was dissolved in dichloromethane (40 ml) washed with water (2x20 ml) and dried. The residue was purified by chromatography on a 50g silica Bond-elut column using an eluant gradient of hexane-50% ethyl acetate/hexane. Yield 320 mg. M+H 413.
Step 2 Preparation of tert-butyl 4-[2-({4-[(methylsulfonyl)amino]phenyl}sulfonyl)ethyl]- piperidine- 1 -carboxylate. m-Chloroperbenzoic acid (375 mg) was added to a solution of the product from step 1
(314 mg) in dichloromethane (30 ml) at 0°C and was stirred for 3 hours. The reaction mixture was washed with aqueous sodium bicarbonate (20 ml), brine (20 ml) and dried.
Removal of the solvent gave tert-butyl 4-[2-({4- [(methylsulfonyl)amino]phenyl}sulfonyl)ethyl]piperidine-l -carboxylate, 330 mg, M+H 347.
Step 3 Preparation of title compound
The tert-butoxycarbonyl group was removed using the procedure described in step 2 of Method O to give the title compound as the hydrochloride salt, M+H 347. Method Q
Preparation of N-phenyl-N-{4-[(2-piperidin-4-ylethyl)sulfonyl]phenyl}urea
Figure imgf000091_0001
Phenylisocyanate (86 μl) was added to a solution of tert-butyl 4-{2-[(4- aminophenyl)sulfonyl]ethyl}piperidine-l-carboxylate (300 mg, Method O) in dichloromethane (10 ml) and the mixture was stirred for 16 hours. A further equivalent of phenylisocyanate was added and stirring continued for 24 hours. The reaction mixture was poured onto a 20g silica Bond-elut column and eluted with a solvent gradient of hexane-70% ethyl acetate/hexane. M1H 388 (M- Boc). The tert-butoxycarbonyl group was removed using the procedure described in step 2 of Method O to give the title compound as the hydrochloride salt, yield 124 mg, M+H 388.
Method R
Preparation of (3i?)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]ρropanoic acid
Figure imgf000091_0002
To a stirred solution of (4S,5i?)-l-{(3R)-3-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]propanoyl}-3,4-dimethyl-5-phenylimidazolidin-2-one (7.5g) (prepared according to Method A, step 1, using 3,5-difluorphenylmagnesium bromide) in THF (300ml) was added a solution of lithium hydroxide monohydrate(2.0g) in water (30ml). After stirring for 16 hours at 20 - 25°C, the solution was evaporated at reduced pressure and the residue partitioned between water (200ml) and dichloromethane (200ml). The aqueous layer was separated and washed again with dichloromethane, then acidified to pH 2 with 2N HCI and the precipitate extracted into ethyl acetate (200ml) which was dried over magnesium sulphate and evaporated to give 4.8 gm pale cream solid (96% yield), NMR: 3.10 (m, 2H), 3.15 (s, 3H), 4.60 (dd, IH), 7.02 (t, IH), 7.18 (d, 2H), 7.67 (d, 2H), 7.82 (d, 2H).
Method S Preparation of (3i?)-3-(3,5-difluorophenyl)-N-methoxy-N-methyl-3-[4-
(methylsulfonyl)phenyl]propanamide
Figure imgf000092_0001
To a stirred mixture of (3i?)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]- propanoic acid (4.8g), Ν,O-dimethyl hydroxylamine hydrochloride (1.5g) andHATU (1.5g) in dichloromethane (200 ml) was added DIPEA (10 ml) and stirring was continued for 16 hours at 20 - 25°C; water (100 ml) was added and the organic layer separated, then washed successively with IM HCI, IM NaOH and water. The solution was dried (MgSO ), evaporated and the residue purified by chromatography on silica, eluting with ethyl acetate to give 4.7g (gum) 87% yield. NMR (CDC13): 3.04 (s, 3H), 3.13 (s, 3H), 3.18 (d, 2H), 3.65 (s, 3H), 4.76 (t, IH), 6.67 (t, IH), 6.78 (d, 2H), 7.44 (d, 2H), 7.89 (d, 2H).
Method T
Preparation of (4R)-4-(3,5-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]butan-2-one
Figure imgf000092_0002
To a stirred solution of (3i?)-3-(3,5-difluorophenyl)-N-methoxy-N-methyl-3-[4-
(methylsulfonyl)phenyl]propanamide (4.7g) in dry THF (50 ml)under argon, cooled to -20°C, was added 12.0ml 3M methyl magnesium bromide (12 ml of a 3M solution in ether). The reaction was stirred for a further 1 hour at 0°C, then 50ml IM HCI was cautiously added and the mixture extracted with ethyl acetate, dried and evaporated to give 4.1gm (gum) 99% yield. NMR (CDC13): 2.16 (s, 3H), 3.043 (s, 3H), 3.21 (d, 2H), 4.69 (t, IH), 6.67 (t, IH), 6.77 (d, 2H), 7.41 (d, 2H), 7.89 (d, 2H).
Method U (S) N-(3-Amino-3-phenylpropyl)-4-[2-(4-methanesulphonylphenylsulphonyl)ethyl]piperidine
Figure imgf000093_0001
Sodium triacetoxyborohydride (1.6g) was added to a mixture of (S) 3-phenyl-3-(tert- butoxycarbonylamino)propionaldehyde (1.23g) and 4-[2-(4-methanesulphonylphenyl- sulphonyl)ethyl]piperidine hydrochloride (1.215g) (Method B) in dichloromethane (50ml) and the mixture was stirred for 16 hours. The reaction mixture was washed successively with 2M sodium hydroxide (15ml), water (15ml) and brine (15ml) and dried. The dichloromethane solution was stirred with PS-NCO (isocyanate resin, 1.5g) for 16 hours and filtered. The filtrate was chromatographed on a 50g silica Bond Elut column eluting with ethyl acetate to give the Boc protected title compound as a white solid, yield 1.595g, MH1" 565.
The Boc protected compound (1.59g) was dissolved in 4M HCl/dioxane (10ml) and allowed to stand at room temperature for 1 hour. The reaction mixture was evaporated to dryness, redissolved in 2M sodium hydroxide (10ml) and extracted with dichloromethane (2x20ml) and dried. Removal of the solvent gave the title compound, yield 0.56g, MH+ 465.
(S) 3 -phenyl-3 -(tert-butoxy carbonvlamino propionaldehyde
Figure imgf000093_0002
Lithium aluminium hydride (19 ml of IM solution in THF) was added to a solution of (S) 3-ρhenyl-3-(tert-butoxycarbonylamino)propionic acid (5.01g) in THF (50ml) at 0°C. The reaction mixture was stirred for 1 hour and ethyl acetate (20ml) was added followed by water (0.5ml), 6M sodium hydroxide (0.5ml) and water (5ml). The mixture was filtered through Celite and evaporated to dryness to give (S) 3-phenyl-3-(tert-butoxycarbonylamino)propanol, yield 2.89g. This material was dissolved in dichloromethane (40ml) and Dess Martin periodinane (2.12g) was added. The reaction mixture was stirred for 1 hour then washed with 2M sodium hydroxide (2x20ml) and brine (10ml) and dried. The dichloromethane solution was concentrated to a volume of about 20ml and used directly in the next stage.
Example 19 The ability of compounds to inhibit the binding of RANTES was assessed by an in vitro radioligand binding assay. Membranes were prepared from Chinese hamster ovary cells . which expressed the recombinant human CCR5 receptor. These membranes were incubated with O.lnM iodinated RANTES, scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated RANTES bound to the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated RANTES was calculated (IC50). Certain compounds of formula (I) have an IC50 of less than 50μM.
Example 20 The ability of compounds to inhibit the binding of MlP-lα was assessed by an in vitro radioligand binding assay. Membranes were prepared from Chinese hamster ovary cells which expressed the recombinant human CCR5 receptor. These membranes were incubated with O.lnM iodinated MlP-lα , scintillation proximity beads and various concentrations of the compounds of the invention in 96-well plates. The amount of iodinated MlP-lα bound to. the receptor was determined by scintillation counting. Competition curves were obtained for compounds and the concentration of compound which displaced 50% of bound iodinated MlP-lα was calculated (IC50). Certain compounds of formula (I) have an IC50 of less than 50μM.
Results from this test for certain compounds of the invention are presented in Table XV. In Table XV the results are presented as Pic50 values. A Pic50 value is the negative log (to base 10) of the IC50 result, so an IC50 of lμM (that is 1 x 10"6M) gives a Pic50 of 6. If a compound was tested more than once then the data below is an average of the probative tests results.
TABLE XV
Figure imgf000095_0001
Scheme 1 To prepare compounds of the invention, for example wherein R1 is aryl or C-linked piperidine.
Figure imgf000096_0001
IV
Figure imgf000096_0002
i Wittig reaction (eg LHDMS, triethylphosphonoacetate) ii Catalytic hydrogenation (eg H2, 10% Pd/C) iii Reduction (eg LAH) iv Oxidation (eg Dess-Martin oxidation)
(<^r x- tR 4 reductive ammination with
Figure imgf000096_0003
(eg using sodium triacetoxyborohydride)
Scheme 2 To prepare compounds of the invention, for example wherein R1 is aryl or C-linked piperidine.
Figure imgf000097_0001
Figure imgf000097_0002
Figure imgf000097_0003
i Base hydrolysis (eg LiOH, MeOH H2O) ii MeMgCl, R3MgBr, Et2O
iii reductive amination
Figure imgf000097_0004
in presence of titanium tetra- isopropoxide (eg using sodium triacetoxyborohydride)
Scheme 3 To prepare compounds of the invention, for example wherein R1 is aryl, heteroaryl, heterocyclyl or NR13C(O)R14.
Figure imgf000098_0001
Figure imgf000098_0002
in which L is an activated group, such as halogen, mesylate, tosylate or triflate.
Scheme 4 To prepare compounds of the invention, for example wherein R1 is aryl, heteroaryl, heterocyclyl or NR13C(O)R14.
Figure imgf000098_0003
in which L1 is a halogen, an activated ester or a complex formed with a carbodiimide. Scheme 5 To prepare compounds of the invention, for example wherein R1 is NR13C(O)R14.
Figure imgf000099_0001
Figure imgf000099_0002
i reductive amination (if R3 is H can use sodium triacetoxyborohydride; if R3 is alkyl can use titanium tetra-isopropoxide and sodium triacetoxyborohydride) ii Deprotection (eg TFA) iii amide bond formation (eg acid chloride, active ester or carbodiimide mediated)
Scheme 5 To prepare compounds of the invention, for example wherein R1 is piperazine.
Figure imgf000100_0001
III
Figure imgf000100_0002
VI
\
N^ f γrtxrtrR4
Figure imgf000100_0004
Figure imgf000100_0003
i Conversion of an OH to a leaving group (eg tosyl chloride (L2 is Tosylate) or mesyl chloride (L2 is Mesylate))
< rtnX- tR4 ii displacement reaction with ^^ (eg in presence of triethylamine) iii Mesyl chloride, DCM 0°C iv Displacement reaction with mono-protected piperazine (P is a protecting group) v Displacement reaction with R substituted piperazine vi Deprotection (TFA for Boc, hydrogenation for Cbz) vii Depending on R, acylation, sulphonylation, alkylation, reductive amination Scheme 6 To prepare compoxmds of the invention, for example wherein R1 is aryl or piperidine.
Figure imgf000101_0001
i activation of acid group and coupling with chiral auxiliary (eg SOCl2 ,
Figure imgf000101_0002
) ii 1,4-addition of organocuprate (eg R2MgBr, Cu(I)I, TMEDA, di-butylboron triflate) iii reduction (eg lithium aluminium hydride) iv Dibal v Oxidation (eg Dess-Martin reagent) vi reductive amination (eg with sodium triacetoxyborohydride) Scheme 7 To prepare compounds of the invention.
Figure imgf000102_0001
Figure imgf000102_0002
i activation via halide, tosylate, mesylate, triflate ii base catalysed displacement

Claims

A compound of formula (I):
Figure imgf000103_0001
wherein:
A is absent or is (CH2) ;
R1 is Cι-8 alkyl, C(O)NR10Rn, C(O)2R12, NR13C(O)R14, NR15C(O)NR16R17,
NR18C(O)2R19, heterocyclyl, aryl or heteroaryl;
R10, R13, R15, R16 and R18 are hydrogen or C1-6 alkyl; Rπ, R12, R14, R17 and R19 are CM alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl (optionally substituted by halo), Cs-6 cycloalkenyl, S(C1-4 alkyl), S(O)(CM alkyl), S(O)2(C1- alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C3- cycloalkyl (optionally substituted by halo or C1-4 alkyl), C4-7 cycloalkyl fused to a phenyl ring, C5. cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, C(O)(d.6 alkyl), S(O) (Cι.6 alkyl), halo or C alkyl); or R11, R12, R14 and R17 can also be hydrogen; or R10 and R11, and/or R16 and R17 may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C1-6 alkyl, S(O)ι.(C1-6 alkyl) or C(O)(Cι-6 alkyl); R2 is C1-6 alkyl, phenyl, heteroaryl or C3- cycloalkyl;
R3 is H or C1-4 alkyl;
R4 is aryl, heteroaryl, C1-6 alkyl or C3. cycloalkyl; X is O or S(O)p; m and n are, independently, 0, 1, 2 or 3, provided m + n is 1 or more; aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR20R21, NR22R23, NR24C(O)R25, NR26C(O)NR27R28, S(O)2NR29R30, NR31S(O)2R32, C(O)NR33R34, CO2R36, NR37CO2R38, S(O)qR39, OS(O)2R49, C1-6 alkyl (optionally mono-substituted by S(O)2R50 or C(O)NR51R52), C2.6 alkenyl, C2.5 alkynyl, C3.10 cycloalkyl, C1-6 haloalkyl, C1-6 alkoxy(C1-6)alkyl, d.6 alkoxy (optionally mono-substituted by CO2R53,
C(O)NR54R55, cyano, heteroaryl or C(O)NHS(O)2R56), NHC(O)NHR57, CM haloalkoxy, phenyl, phenyl(C1- )alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)2, phenyl(C1- )alkoxy, heteroaryl, heteroaryl(C1- )alkyl, heteroaryloxy or heteroaryl(d. 4)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(Cι- alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C alkyl), S(O)2N(C1-4 alkyl)2, cyano, CM alkyl, CM alkoxy, C(O)NH2, C(O)NH(CM alkyl), C(O)N(CM al yl)2, CO2H, CO2(d. 4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(Cι-4 alkyl), CF3 or OCF3; • unless otherwise stated heterocyclyl is optionally substituted by C1-6 alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C1-4 alkyl, C1-4 alkoxy, cyano, nitro, CF3, OCF3, (C1-4 alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio,
S(O)(C1-4 alkyl) or S(O)2(C1-4 alkyl)} or heteroaryl {which itself optionally substituted by halo, CM alkyl, C alkoxy, cyano, nitro, CF3, (CM alkyl)C(O)NH, S(O)2NH2, CM alkylthio, S(O)(C1-4 alkyl) or S(O)2(C1-4 alkyl)}], phenyl {optionally substituted by halo, CM alkyl, CM alkoxy, cyano, nitro, CF3, OCF3, (CM alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(C1-4 alkyl) or S(O)2(C1-4 alkyl)}, heteroaryl {optionally substituted by halo, CM alkyl, CM alkoxy, cyano, nitro, CF3, (C alkyl)C(O)NH, S(O)2NH2, C1-4 alkylthio, S(O)(C1-4 alkyl) or S(O)2(C alkyl)}, S(O)2NR40R41, C(O)R42, C(O)2(C1-6 alkyl) (such as tert-butoxycarbonyl), C(O)2(phenyl(C1-2 alkyl)) (such as benzyloxycarbonyl), C(O)NHR43, S(O)2R44, NHS(O)2NHR45, NHC(O)R46, NHC(O)NHR47 or NHS(O)2R48, provided none of these last four substituents is linked to a ring nitrogen; k, 1, p and q are, independently, 0, 1 or 2;
R20, R22, R24, R26, R27, R29, R31, R33, R37, R40, R51 and R54 are, independently, hydrogen or C1-6 alkyl; R21, R23, R25, R28, R30, R32, R34, R36, R38, R39, R41, R42, R43, R44, R45, R46, R47, R48, R49,
R50, R52, R53, R55, R56 and R57 are, independently, CM alkyl (optionally substituted by halo, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, C5-6 cycloalkenyl, S(C1- alkyl), S(O)(CM alkyl), S(O)2(CM alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C3- cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C1-4 alkyl), S(O)(C1-4 alkyl), S(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(CM alkyl)2, cyano, C1-4 alkyl, C1-4 alkoxy, C(O)NH2, C(O)NH(C1-4 alkyl), C(O)N(CM alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(O)(C1-4 alkyl), NHS(O)2(C1-4 alkyl), C(O)(C1-4 alkyl), CF3 or OCF3;
R21, R23, R25, R28, R30, R34, R35, R36, R41, R42, R43, R45, R46, R47, R52, R53, R55 and R57 may additionally be hydrogen; or a pharmaceutically acceptable salt thereof or a solvate thereof.
2. A compound as claimed in claim 1 wherein R1 is NHC(O)R14, phenyl or heterocyclyl, wherein R14 is as defined in claim 1, and phenyl and heterocyclyl are optionally substituted as described in claim 1.
3. A compound as claimed in claim 1 or 2 wherein R2 is phenyl or heteroaryl, either of which is optionally substituted by halo, C1- alkyl, CM alkoxy, S(O)n(d.4 alkyl), nitro, cyano or CF3; wherein n is 0, 1 or 2.
4. A compound as claimed in claim 1, 2 or 3 wherein R3 is hydrogen.
5. A compound as claimed in claim 1, 2, 3 or 4 wherein R4 is phenyl optionally substituted by one or more of halo, hydroxy, nitro, S(C1-6 alkyl), S(O)(Cι-6 alkyl), S(O)2(C1-6 alkyl), S(O)2NH2, S(O)2NH(C1-6 alkyl), S(O)2N(C1-6 alkyl)2j cyano, C1-6 alkyl, C1-6 alkoxy, CH2S(O)2(Cι.6 alkyl), OS(O)2(C1-6 alkyl), OCH2heteroaryl,
OCH2CO2H, OCH2CO2(Cι-6 alkyl), OCH2C(O)NH2, OCH2C(O)NH(Cι-6 alkyl), OCH2CN, NH2, NH(d.6 alkyl), N(C1-6 alkyl)2, C(O)NH2, C(O)NH(C1-6 alkyl), C(O)N(Cι.6 alkyl)2, CO2H, CO2(C1-6 alkyl), NHC(O)(C1-6 alkyl), NHC(O)O(C1-6 alkyl), NHS(O)2(d.6 alkyl), CF3, CHF2, CH2F, CH2CF3, OCF3, heteroaryl or heteroaryl(C1-4 alkyl); wherein the foregoing heteroaryl groups are optionally substituted by halo, hydroxy, nitro, S(CM alkyl), S(O)(CM alkyl), S(O)2(CM alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl), S(O)2N(CM alkyl)2, cyano, C alkyl, CM alkoxy, C(O)NH2, C(O)NH(Cι-4 alkyl), C(O)N(C1-4 alkyl)2, CO2H, CO2(C1-4 alkyl), NHC(θχC1-4 alkyl), NHS(O)2(CM alkyl), CF3 or OCF3.
A compound as claimed in claim 1, 2, 3, 4 or 5 wherein A is absent.
A compound as claimed in any one of the preceding claims wherein n is 2.
8. A compound as claimed in any one of the preceding claims wherein m is 0.
9. A compound as claimed in any one of the preceding claims wherein X is S(O)2.
10. A process for preparing of a compound as claimed in claim 1 comprising: a. to prepare a compound wherein R3 is hydrogen, coupling a compound of formula (III):
Figure imgf000106_0001
wherein R4, m, n, A and X are as defined in claim 1, with a compound of formula (IV):
Figure imgf000106_0002
wherein R1 and R2 are as defined in claim 1, in the presence of NaBH(OAc)3 (wherein Ac is C(O)CH3) in a suitable solvent at room temperature; b. to prepare a compound wherein R3 is hydrogen, coupling a compound of formula (III):
Figure imgf000106_0003
wherein R4, m, n, A and X are as defined in claim 1, with a compound of formula (V):
Figure imgf000106_0004
wherein R1 and R2 are as defined in claim 1 and L is a leaving group, in the presence of a base, in a suitable solvent at a temperature from 60°C to the boiling point of the solvent.
11. A pharmaceutical composition which comprises a compound as claimed in claiml, or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound as claimed in claiml, or a pharmaceutically acceptable salt thereof or solvate thereof, for use as a medicament.
13. A compound as claimed in claiml, or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in therapy.
14. A method of treating a CCR5 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof.
PCT/SE2003/002008 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5 WO2004056773A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2003288856A AU2003288856B2 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor CCR5
MXPA05006381A MXPA05006381A (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5.
JP2005502630A JP2006514107A (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of the chemokine receptor CCR5
NZ540780A NZ540780A (en) 2002-12-20 2003-12-18 Heterocyclic piperidine derivatives as modulators of chemokine receptor CCR5
EP03781235A EP1572650A1 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5
BR0317459-0A BR0317459A (en) 2002-12-20 2003-12-18 New piperidine derivatives as chemokine ccr5 receptor modulators
US10/539,859 US20060189650A1 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5
CA002508624A CA2508624A1 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5
IS7942A IS7942A (en) 2002-12-20 2005-07-18 New piperidine derivatives that adjust the CCR5 missile receptor
NO20053539A NO20053539L (en) 2002-12-20 2005-07-19 New piperidine derivatives as modulators of chemokine receptor CCR5.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0203821A SE0203821D0 (en) 2002-12-20 2002-12-20 Chemical Compounds
SE0203821-4 2002-12-20
SE0300499-1 2003-02-24
SE0300499A SE0300499D0 (en) 2003-02-24 2003-02-24 Chemical compounds
SE0301425A SE0301425D0 (en) 2003-05-15 2003-05-15 Chemical compounds
SE0301425-5 2003-05-15

Publications (1)

Publication Number Publication Date
WO2004056773A1 true WO2004056773A1 (en) 2004-07-08

Family

ID=32685861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2003/002008 WO2004056773A1 (en) 2002-12-20 2003-12-18 Novel piperidine derivatives as modulators of chemokine receptor ccr5

Country Status (17)

Country Link
US (1) US20060189650A1 (en)
EP (1) EP1572650A1 (en)
JP (1) JP2006514107A (en)
KR (1) KR20050084424A (en)
AR (1) AR042628A1 (en)
AU (1) AU2003288856B2 (en)
BR (1) BR0317459A (en)
CA (1) CA2508624A1 (en)
CL (1) CL2003002678A1 (en)
CO (1) CO5570665A2 (en)
IS (1) IS7942A (en)
MX (1) MXPA05006381A (en)
NZ (1) NZ540780A (en)
PL (1) PL377768A1 (en)
TW (1) TW200505856A (en)
UY (1) UY28139A1 (en)
WO (1) WO2004056773A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005101989A2 (en) * 2004-04-23 2005-11-03 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptor ccr5
WO2006001751A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab Chemical compounds i
WO2006001752A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab Novel piperidine/8-azabicyclo [3.2.1] octan derivatives as moduilators of chemokine receptor ccr5
US7164019B2 (en) 2004-06-09 2007-01-16 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2008019968A1 (en) 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2008039999A1 (en) * 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
WO2011079007A1 (en) 2009-12-23 2011-06-30 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
EP3525790A4 (en) * 2016-10-14 2020-07-01 Merck Sharp & Dohme Corp. Piperidine derivatives as liver x receptor beta agonists, compositions, and their use
WO2021222069A1 (en) 2020-04-27 2021-11-04 Incelldx, Inc. Methods and compositions for treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 interaction

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301369D0 (en) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
SE0302090D0 (en) * 2003-07-16 2003-07-16 Astrazeneca Ab Chemical compounds
JP2007500694A (en) * 2003-07-31 2007-01-18 アストラゼネカ・アクチエボラーグ Piperidine derivatives as CCR5 receptor modulators
CN113444065A (en) * 2021-06-29 2021-09-28 浙江得乐康食品股份有限公司 Shikimic acid sulfonated substance and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002502A1 (en) * 1990-08-06 1992-02-20 Smith Kline & French Laboratories Limited N-hydrocarbyl-4-substituted piperidines, their preparation and use as calcium blocking agents
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
WO2000076514A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2001087839A1 (en) * 2000-05-17 2001-11-22 Astrazeneca Ab Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
WO2001092227A1 (en) * 2000-05-31 2001-12-06 Astrazeneca Ab Chemical compounds
WO2002079156A1 (en) * 2001-03-30 2002-10-10 Astrazeneca Ab Novel piperidine derivatives as modulators of chemokine receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002502A1 (en) * 1990-08-06 1992-02-20 Smith Kline & French Laboratories Limited N-hydrocarbyl-4-substituted piperidines, their preparation and use as calcium blocking agents
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
WO2000076514A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2001087839A1 (en) * 2000-05-17 2001-11-22 Astrazeneca Ab Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
WO2001092227A1 (en) * 2000-05-31 2001-12-06 Astrazeneca Ab Chemical compounds
WO2002079156A1 (en) * 2001-03-30 2002-10-10 Astrazeneca Ab Novel piperidine derivatives as modulators of chemokine receptor

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005101989A3 (en) * 2004-04-23 2006-04-27 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptor ccr5
WO2005101989A2 (en) * 2004-04-23 2005-11-03 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptor ccr5
US7615555B2 (en) 2004-04-23 2009-11-10 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptor CCR5
US7714018B2 (en) 2004-06-09 2010-05-11 Roche Palo Alto Llc Heterocyclic antiviral compounds
US7164019B2 (en) 2004-06-09 2007-01-16 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2006001751A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab Chemical compounds i
WO2006001752A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab Novel piperidine/8-azabicyclo [3.2.1] octan derivatives as moduilators of chemokine receptor ccr5
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2008019968A1 (en) 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2008039999A1 (en) * 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
WO2011079007A1 (en) 2009-12-23 2011-06-30 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
EP3525790A4 (en) * 2016-10-14 2020-07-01 Merck Sharp & Dohme Corp. Piperidine derivatives as liver x receptor beta agonists, compositions, and their use
US10894775B2 (en) 2016-10-14 2021-01-19 Merck Sharp & Dohme Corp. Piperidine derivatives as liver X receptor beta agonists, compositions, and their use
WO2021222069A1 (en) 2020-04-27 2021-11-04 Incelldx, Inc. Methods and compositions for treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 interaction

Also Published As

Publication number Publication date
IS7942A (en) 2005-07-18
UY28139A1 (en) 2004-07-30
CO5570665A2 (en) 2005-10-31
AR042628A1 (en) 2005-06-29
JP2006514107A (en) 2006-04-27
US20060189650A1 (en) 2006-08-24
CA2508624A1 (en) 2004-07-08
AU2003288856A1 (en) 2004-07-14
AU2003288856B2 (en) 2006-11-16
EP1572650A1 (en) 2005-09-14
PL377768A1 (en) 2006-02-20
NZ540780A (en) 2008-04-30
BR0317459A (en) 2005-11-16
MXPA05006381A (en) 2005-08-29
KR20050084424A (en) 2005-08-26
CL2003002678A1 (en) 2005-04-22
TW200505856A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
US20060167048A1 (en) N-4-piperidinyl compounds as ccr5 modulators
AU2003288856B2 (en) Novel piperidine derivatives as modulators of chemokine receptor CCR5
EP1572683B1 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
US20060052413A1 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
EP1625120A1 (en) Chemical compounds
EP1648871B1 (en) Piperidine or 8-aza-bicyclo 3.2.1 oct-3-yl derivatives useful as modulators of chemokine receptor activity
EP1654229B1 (en) Piperidine derivatives as ccr5 receptor modulators
US20080200460A1 (en) Chemical Compounds
ZA200504616B (en) Novel piperidine derivatives as modulators of chemokine receptor CCR5
US20080139612A1 (en) Chemical Compound
US20100093795A1 (en) Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2508624

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005/04616

Country of ref document: ZA

Ref document number: 169015

Country of ref document: IL

Ref document number: 200504616

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003781235

Country of ref document: EP

Ref document number: 2442/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003288856

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 05057099

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006381

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 540780

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006189650

Country of ref document: US

Ref document number: 1020057011450

Country of ref document: KR

Ref document number: 10539859

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 377768

Country of ref document: PL

Ref document number: 2005502630

Country of ref document: JP

Ref document number: 1-2005-501179

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 20038A78338

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005117343

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057011450

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003781235

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0317459

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10539859

Country of ref document: US